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Almost all women are at risk of unintended pregnancy throughout their reproductive
years [1]. In the UK alone, more than 200,000 pregnancies were terminated by induced
abortion in 2010 [2,3]. Additionally, a substantial number of births result from
unintended pregnancy [4],Family planning is achieved through use of contraceptive
methods [5]. Contraceptive prevalence is increasing worldwide, however, some need for
contraception remains unmet. Even in industrialised countries where contraception is
readily available and use is high, many unintended pregnancies occur. The reason for
this is that existing methods are not perfect, and their acceptability is limited by side
effects and inconvenience leading to either non-use or incorrect and inconsistent use [6],
Preventing unintended pregnancy requires the number of successful contraceptive users
to increase. This, at a minimum, requires the availability of safe, acceptable and effective
methods of contraception; access to information, supplies and services; and the
motivation and ability (including recognition of risk) to initiate and use contraceptives
correctly and consistently [7], Currently available methods need to be reviewed and
where necessary adapted to address users' concerns and preferences in an effort to
increase acceptability and hence uptake and adherence. And, most importantly, new
methods need to be developed which do not cause the systemic side-effects linked to
existing methods and offer additional non-contraceptive health benefits.
Methodology
Using a variety of methodologies we explored three areas. Firstly we sought to establish
via a questionnaire survey how many pregnancies ending in either childbirth or abortion
are unintended, and what proportion of women use emergency contraception (EC) to try
to prevent pregnancy.
Secondly we explored the issue of acceptability of adapted methods of contraception
(Implanon® and Depo-provera®) via questionnaire survey. And thirdly we further
developed a novel contraceptive, mifepristone by exploring both its effectiveness and its
16
potential non-contraceptive health benefits (amenorrhoea and protection against STI's
including HIV).
Results
Ninety percent of pregnancies which end in induced abortion were clearly unintended,
however, of these women only 12% recognised their risk and used EC to try and prevent
a pregnancy. Additionally one third of pregnancies which resulted in a birth were not
clearly intended.
Both Implanon®, in practice, and subcutaneous depo-provera®, in theory, were found to
be acceptable methods of contraception to women. Approximately half (47%) of those
who used Implanon® continued to use it for the full duration (>2years 9/12) and one
third of all users chose to have another implant when the first one expired. Regarding
subcutaneous depo-provera® 67% of current users, 26% of never users and 40% of ex-
users said they would seriously consider self-administration of depo-provera® if it were
to be licensed.
In investigating mifepristone it was found that there were no pregnancies in 356 months
of exposure to mifepristone and more women were amenorrhoic whilst taking
mifepristone than POP (49% vs 0% p<0.001) and no mifepristone users discontinued for
reasons related to bleeding profiles. Additionally no significant changes were found in
vaginal thickness or content with use ofmifepristone.
Discussion
Unintended pregnancy is common, even among women who choose to continue
pregnancy. EC use is low indicating that women are often not aware of their risk. Thus
EC is unlikely to reduce unintended pregnancy. Rather, we need to encourage improved
use of regular contraception.
Long acting reversible contraceptives are particularly beneficial as they do not require
daily intake and hence can be 'forgotten'. Our findings suggest that the long acting
reversible methods of contraception (LARC) Implanon® is acceptable to women and its
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continuation rates justify its widespread provision. Similarly, the advent of subcutaneous
self-administrable Depo-provera® would likely be beneficial and popular with women.
Alongside adapting existing methods of contraception there is a need to develop novel
methods of contraception such as antigestogens. Our studies ofmifepristone show that
mifepristone is an effective oral contraceptive pill with a better pattern of menstrual
bleeding than an existing POP (levenorgestrel). We also found that in contrast to other
oestrogen-free contraceptives, mifepristone is unlikely to be associated with an increased
risk of transmission ofHIV and other sexually transmitted infections.
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Chapter 1: Background
Family planning is one of the twelve pillars of reproductive health as defined by the
World Health Organisation (WHO) (Appendix 1) [8]. It allows people to attain their
desired number of children and determines the spacing of pregnancies. It is achieved
through use of contraceptive methods and the treatment of infertility [5]
Definitions of Reproductive Health and Reproductive Health Care
"Reproductive health (RH) is defined as a state of physical, mental, and social well-
being in all matters relating to the reproductive system and its functions and processes,
and not merely the absence of disease or infirmity. Reproductive health, therefore,
implies that people are able to have a satisfying and safe sex life and that they have the
capability to reproduce and the freedom to decide if, when, and how often to do so.
Implicit in this last condition is the right ofmen and women to be informed and to have
access to safe, effective, affordable, and acceptable methods of family planning of their
choice, as well as other methods of their choice for regulation of fertility that are not
against the law. They also need to have the right of access to appropriate health-care
services that will enable women to go safely through pregnancy and childbirth and
provide couples with the best chance of having a healthy infant." [9]
Accordingly, "reproductive health care is defined as the constellation ofmethods,
techniques, and services that contribute to reproductive health and well-being by
preventing and solving reproductive health problems. It also includes sexual health, the
purpose ofwhich is the enhancement of life and personal relations, and not merely
counselling and care related to reproduction and sexually transmitted infections" [9],
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The above definitions of 'reproductive health' and 'reproductive health care' were the
result of the 1994 United Nations International Conference on Population and
Development. At this conference the majority of participating nations agreed that
without the most basic rights for women within the family and society - most of all
reproductive rights (including the right to decide, jointly or alone if necessary, on the
number of children they were prepared to bear) - meaningful strides in public health,
education, the protection of the environment and economic development would lag at
best and be impossible at worst [10,11], This resulted in a decisive shift of national
population policies from the demographic, where the central justification for programs
was the reduction of environmental, economic and societal pressures, to the quality of
life imperative [11,12] and the foundations for the global reproductive health agenda
were laid. Whilst there remained much debate as to where the boundaries lay, it seemed
that no longer was RH solely about preventing and treating disease, but also about
supporting normal functions such as pregnancy and childbirth. Above all, the definition
of RH assumed responsibility within it to enhance life-processes and how to nurture
them in the face of adversity [13].
Political endorsement
To improve any country's socio-economic welfare, its government has to look to meet
and improve its health requirements. In 2000, 189 countries made a promise to free
people from extreme poverty and multiple deprivation. This pledge became the eighth
Millenium Development Goal (MDG) to be achieved by 2015 (Appendix 2). However,
reproductive health was not specifically included as an independent goal or a measurable
target. This was despite experts providing evidence for years that investing in
reproductive health is integral to directly meeting those MDGs related to health
[14,15,16,17,18,19,20,21,22]. It took until September 2005, after much intense advocacy
by both non-governmental organisations (NGO's) and leaders in the field of
reproductive health, for a specific commitment to be made by World leaders, to integrate
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the target of 'achieving universal access to reproductive health by 2015' together with
indicators for measuring its progress (Appendix 3), into strategies to attain
internationally agreed development goals, including those contained in the Millennium
declaration (MDGs) [23], Examples of goals where it was felt increased attention to
sexual and reproductive health would contribute significantly were: MDG1 - to reduce
poverty and hunger; MDG 3 - to promote gender equality and empowerment ofwomen
and MDG 6 - combating HIV and other diseases [23].
Subsequently most countries now have population policies in place. However, there
remains a real need for these to be legitimised and for encouragement from development
agencies to implement these policies with conviction and commitment [24]
The importance of Reproductive Health and Health Care
The benefits of helping women and couples access and effectively use contraception
include the prevention of negative outcomes such as infant death, low birth weight
babies, lower breast feeding rates, and depression associated with unintended
pregnancies [25,26,27,28] and on a broader scale can lead to improving women's
education and employment opportunities and their participation in social and political
domains [26,29], Couples with the means to control their fertility are usually able to
invest more resources in each child. This ultimately raises the standard of health,
education and wealth in a population [30], Thus reproductive health has been identified
as both a fundamental human right and also a social and economic imperative [8],
The need for contraceptive research and development
Most countries in the world have some national family planning program and allow
NGO's to provide such services. Whilst over time the specific objectives of such
programmes have been debated, there is no doubt that they have been successful with a
resultant decline in fertility rate throughout much of the world. Between 1950-1955 and
2005-2010, the median level of total fertility in the world (constituted by 196 countries
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for whom data was available) fell by half, from 4.95 to 2.52 children per woman and the
reduction of fertility was even more marked in some countries or regions [31 ] (figure 1).
However, the world population continues to grow.
Figure 1: World Fertility Rate 1950-2050
Source: UN Population Division
It is known that in 1000AD, just over 1000 years ago, the world population did not
exceed 300 million people. It took about 800 years to reach the first billion in 1804, and
123 years to reach the second in 1927 [31]. Succeeding increments of one billion have
taken less and less time - 33, 14, 13 and 12 years and the world population is predicted to
reach seven billion on the 31st ofOctober, 2011. This is despite the population growth
rate having declined from 1.82 in 1950-55 to 1.22 in 2000-2005, and continuing to
decline, being 1.15 in 2011 [31,32]. One possible reason for this is that the decline in
crude death rate (18.7 in 1950-55 to 8.4 in 2005-2010) and hence the increase in life
expectancy (47.7 years for both sexes combined in 1950-55 to 67.9 in 2005-2010) are
greater than the decline in the total fertility rate (4.95 in 1950-55 to 2.52 in 2005-2010)
[32].
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Fertility rates are dropping throughout the world (current [2011] world fertility rate is
2.45 [32]) and women are now spending the majority of their reproductive lives trying
to avoid pregnancy [33], The average reproductive lifespan of a woman is 35.9 years
[33]. A woman in a first world country will spend 90% of her reproductive life
postponing or avoiding further births. A woman in a developing country will spend
slightly less time avoiding pregnancy [34], This therefore leads to increased potential for
unintended pregnancy and hence a greater need for effective fertility control.
The decline in both crude death rates and fertility rates can be attributed to advances in
technology and thus, the lesser decline in fertility rates could be said to reflect the
inadequate attention and resources afforded to the contraceptive research and
development field, as well as possibly a shift in focus of effort from discovery to
adaptation [35]. Most governments, including those ofpoorer developing countries,
already have population and family planning policies but are receiving too little
encouragement and funding to implement them [24,36],
'Unmet need for contraception' or 'at risk of unintended pregnancy'?
The concept of 'Unmet need' for contraception
The general concept of unmet need was first introduced in the 1960's, when researchers
began to demonstrate and measure the discordance between women's desires to limit
their births and their actual use of contraception in much of the developing world [37]. In
1988, Westhoff (1995) developed an algorithm for measuring unmet need using data
from the Demographic and Health surveys (DHS) [38]. This definition took into account
unmet need for contraception to space births and is now considered the standard measure
of the level of unmet need for contraception [39,40,41],
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Definition of unmet need for contraception
• Is in a marital or consensual union
• Is fecund (i.e. not pregnant, amenorrhoeic or otherwise infecund, according to her
own report)
• Does not want to have a child in the next two years, and
• Is not using any contraceptive method, either modern or traditional
In addition, pregnant or amenorrhoeic women in union are considered to have an unmet
need if they report that their current or most recent pregnancy was unplanned.
The concept of 'Unintended pregnancy'
Unintended pregnancy is a core concept in understanding, and accurate measurement of,
the fertility of populations, fertility-related behaviours and the unmet need for
contraception [42],
Definition of unintended pregnancy
An unintended pregnancy is one which occurs among couples who had wanted to delay
having a child (mistimed) or who did not want to become pregnant at all (unwanted).
Separate research, from that of measuring unmet need, has been undertaken to estimate
the numbers and characteristics ofwomen at risk of unintended pregnancy and in need of
contraceptive services and supplies[43,44]. This research has surmised that the definition
of 'women at risk of unintended pregnancy' as used in the industrialised world and the
definition of 'women with an unmet need for contraception' used in developing
countries are essentially fairly similar. The main differentiating factor is related to the
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level of contraceptive use. In countries where contraceptive prevalence is low (mostly
developing countries) it is more common to measure 'unmet need' and in countries
where contraceptive prevalence is high 'unintended pregnancy' is more likely to be used
as this includes those pregnancies which occur whilst using a method of contraception.
However, critics have pointed out two shortcomings of using the term 'unmet need'
nowadays. The first is that data for 'unmet need' often exclude sexually active unmarried
women who represent a large and growing segment of the population. The second
criticism is that the term 'unmet need' excludes those who are using a method of
contraception but are using it incorrectly or inconsistently [45], Thus I would propose
that the concept of being at risk of unintended pregnancy is a much broader one. It
encompasses both married and unmarried sexually active women and includes those
women who are using a method of contraception but are using it incorrectly or
inconsistently. As such it is the preferred measure to use in research undertaken where
contraceptive use is high such as the UK and subsequently the reason why I chose to
measure unintended pregnancy rather than unmet need in my research [46],
The global prevalence of unintended pregnancy
Almost all women are at risk of unintended pregnancy throughout their reproductive
years [1], hence, unintended pregnancy is common. The scale of sexual activity,
reproduction and their potential risk at the population level is difficult to visualise.
Tsui et al (2010) surmise that with a majority of the 1.74 billion reproductive age
females being sexually active and a probability of conception during unprotected coitus
being 3 in 100 [47], each year as many as 720 million conceptions may occur [48]. The
majority of conceptions (60-70%) will be spontaneously miscarried, leaving
approximately 239 million identified pregnancies, of which 136.2 million will progress
to livebirths, 33 million being unwanted [48]. They deduce that another 46 million will
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be electively terminated [48]. If their modelling is correct then the conclusion is that
33% of all identified pregnancies are unintended globally.
Prevalence in the developing world
Levels of unintended pregnancy are declining in the developing world but are still very
high. In developing countries, the rate of unintended pregnancy declined by 20%
between 1995 and 2008 (from 71 to 57 per 1,000 women aged 15-44) [29], The
Guttmacher institute estimated that in 2008, in the developing world, the pregnancy rate
was 137 per 1,000 women aged 15-44 and the unintended pregnancy rate was 57 per
1,000, or 82.3 million unintended pregnancies per year [29],
In 2008, annual rates of unintended pregnancy were highest in Africa, at 86/1,000
women aged 15-44. The rate varied from 56 in North Africa to 72 in Southern Africa to
118 in Eastern Africa. Unintended pregnancy were also high in Latin America and the
Caribbean (72/1,000) and lower still in Asia (49/1,000).
Prevalence in the United States
The Guttmacher institute has also calculated state-level estimates of unintended
pregnancy, in 2001 and 2006, for the United States [49,50]. Finer et al (2011) reported
that nearly half (49%) of all pregnancies were unintended in 2006. This was slightly
higher than in 2001 (48%). The unintended pregnancy rate rose from 50 per 1,000
women, aged 15-44, in 2001 to 52 per 1,000 women in 2006 [49,50], The investigators
also found that in 2006, in 29 states more than half of pregnancies were unintended and
in nine, a consistent upward trend in unintended pregnancy rates, between 2001 and
2006, was apparent. No state had a consistent decline [49],
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Prevalence in the United Kingdom
A questionnaire survey of 2000 mothers, randomly selected from birth registrations in
1989 and interviewed six months post childbirth indicated that almost one third of
pregnancies which progressed to birth were "unplanned" [4], Additionally, almost
200,000 pregnancies are tenninated every year. However, there have been no estimates
of pregnancy intendedness in women in the United Kingdom (UK) since 1989 [4], and
consequently one of the aims of this thesis was to quantify pregnancy intention among
women who presented over the course of eight months to a large teaching hospital in
Edinburgh, UK, for antenatal care or for termination ofpregnancy in 2005. The results
of this can be found in chapter two.
Consequences of unintended pregnancies
Unintended pregnancies result in either unplanned child-bearing or induced abortion (or
miscarriage). Both can have far reaching social, psychological and economic
consequences. A reduction in unintended pregnancies reduces the number of events
exposed to poor pregnancy outcomes and can make planned events healthier [48]. This is
due to there being opportunity for preconceptual care (e.g. folic acid supplementation,
smoking cessation advice) and increased likelihood of attending for antenatal care early
on [51]. Additionally pregnancies which are planned generally tend to have longer birth
intervals and evidence shows a statistical link between longer birth intervals (greater
than 30 months) and decreased risk of neonatal, infant and child mortality and of child
malnutrition [52]
Unintended childbearing can lead to child health and development issues, relationship
instability, and compromises in education and employment that may exacerbate ongoing
poverty [26,27,28,48,53], A study by Schwarz et al (2008) attempted to measure the
effects of unintended pregnancy on women's quality of life in the United States (US) in
2008. They surveyed 192 sexually active non-pregnant women and found that 94% of
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women felt that an unintended pregnancy would adversely impact on their quality of life
[54].
Worldwide, 22% of pregnancies, or about 42 million, are electively aborted, ofwhich 20
million induced abortions happen under unsafe conditions, mostly in the developing
world [29]. One quarter of the world's population lives in countries where abortion is
prohibited by law (unless to save the mother's life). However, such legislation does not
reduce total abortion rates [55], it merely causes women to seek and undergo unsafe
abortions. Approximately 67,000 women die every year from unsafe abortions, and
thousands more have physical and emotional sequelae [56],
Reducing unintended pregnancy and elective abortions
To attempt to reduce the number of unintended pregnancies we firstly need to
understand why they happen, especially, when there are a large number of highly
effective contraceptive methods known to us.
As discussed, family planning programmes throughout the world have had undeniable
success in utilising a variety of methods of contraception, both hormonal and non-
hormonal to reduce fertility rates. Evidence shows that contraception plays a key role in
reducing induced abortions [57,58] and can avert as many as 32% of all maternal deaths
and nearly 10% of childhood deaths [24], Women who use any contraceptive method
have a lower risk of unintended pregnancy than do sexually active women who use no
method [7], For example, in the United States, women who do not use contraceptives are
6.7 times more likely to have an abortion than women who do [57,59], In addition, it has
been surmised that the number of abortions in Armenia, Kazakhstan, Kyrgizstan, and
Uzbekistan could be halved ifwomen who do not use contraceptives or who use
traditional methods were to use modern methods [60],
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However, using a method of contraception is not sufficient in itself. Three US - state
based studies [61,62,63] demonstrated that some contraceptive use or knowledge is
advantageous in comparison to non-use in reducing the incidence of unintended
pregnancy, but the measured protection was not as high as one might have expected. For
example, in one study the adjusted (for age and race/ethnicity) odds ratio, of unintended
pregnancy, for women having unprotected sex, compared with those using
contraception, was 1.67 (95% CI 1.11- 2.52) [63]. The magnitude of the adjusted odds
ratio, whilst statistically significant, is not substantial considering the high efficacy of
modern methods of contraception. The reason for this is that the term 'contraceptive
prevalence' does not presume correct and consistent use. For example, reported
prevalence of condoms does not take into account the often sporadic nature of condom
use [48].
Thus, whilst contraceptive methods have the potential to reduce the numbers of
unintended pregnancy and elective abortions, to achieve a substantial reduction they
must be used both correctly and consistently.
Understanding non-use and poor use of contraceptive methods
Developing World
Of the 82.3 million unintended pregnancies estimated to occur annually in the
developing world [29], 82% are due to an unmet need for modem contraception i.e. no
method of contraception is being used. The remaining 18% of unintended pregnancies
are due to either inconsistent or incorrect use of contraception or to true contraceptive
method failure [7,29],
Every year, one in four sexually active women, in the developing world, who want to
avoid becoming pregnant has an unmet need for modem contraception. The reasons for
this unmet need include lack of access, lack of knowledge, partner opposition, being
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postpartum or breastfeeding and method related reasons (fear of side-effects or health
risks) to use of modern contraceptive methods [7,39,64]. In Bangladesh, women with
good access to high quality family planning services have an abortion rate of 2.3 per
1000 compared with 6.8 for women with poor access [65]. It is estimated that 70% of
unmet need could be rectified if appropriate contraceptive methods were made available
and that unintended pregnancy could be reduced by as much as 59% if method-related
reasons for non-use ofmodern contraceptives could be overcome [7],
The Industrialised world
In industrialised countries, as opposed to developing countries, prevalence of use of
contraception is high. Despite this widespread use of contraception unintended
pregnancy is also high and there are 26 million abortions per year [66].
In the USA, modern contraceptives are used by 72% of married women [67], however,
49% ofpregnancies are unintended and 54% ofwomen who have an elective abortion
were using contraception when they became pregnant [68], In France, although 97% of
women wishing to avoid pregnancy use modem contraceptives, 33% of pregnancies are
unintended and of these 50% end in elective abortion [66], A Swiss study whose aim
was to attempt to understand why contraceptive measures are abandoned or not used at
all demonstrated that of 103 women attending for elective abortion 98% (101 of the 103
women) had used a modem method of contraception at some point in the past [69]. A
Scottish study by Schunmann et al (2006) found that 84% ofwomen requesting an
abortion were using contraception about the time they conceived, and only 16% reported
non-use [70], Repeat abortions are also a significant problem [71] and in Scotland
between 20 and 25% of women undergoing abortion will have another abortion at some
time during their reproductive lives [72], A UK questionnaire study of 133 women
attending for elective abortion revealed that 98% of those having a repeat abortion and
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83% of those undergoing a first time abortion were using a recommended method of
contraception [73].
Efficacy ofmodem contraceptive methods is high (table 2: figures for perfect use [74]).
Data suggest that true method failure accounts for only 5% of unintended pregnancies
occurring when contraception is correctly and consistently being used [74,75,76]. The
remaining 95% arise because of non-use or less effective use of modem methods of
contraception. This very high failure rate of non-permanent modem methods primarily
reflects the difficulty of using them consistently and correctly [77].
Schunmann et al (2006), in their study of 316 women undergoing abortion in Edinburgh,
in 2001/2 found that whilst 84% ofwomen were using contraception at the time when
pregnancy occurred, 44% admitted , when asked directly, to using their chosen method
inconsistently or incorrectly and only 39% claimed perfect use [70].
There are plenty of factors which contribute to why contraception was used
inconsistently or incorrectly or was not used at all. These include: lack of awareness,
knowledge, access, counselling, support and motivation. These factors have been cited
above for the developing world but apply equally, though in different ways, to the
industrialised world. For example the studies detailed above demonstrate that lack of
awareness and knowledge are not just about knowing of the existence of services and
methods but also knowing how to use contraceptives appropriately, knowing one's
individual suitability to various methods and being aware of one's need for
contraception.
Thus the larger percentage of the problem in industrialised countries lies with
compliance and motivation followed by lack of appropriate counselling and support
[65,66,68,78,79], Compliance with a method is heavily reliant on how easy a method is
to use and how easy a method is to use is very dependent on the woman's life-style,
socioeconomic status, age, and other factors [80]. Consequently compliance is not
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always easy and hence the relatively high user-failure rates associated with existing
contraceptive methods (apart from a few exceptions, such as sterilisation, implants and
intrauterine devices (Appendix 4: figures for typical use [74,81]). One American study
found that virtually all pill users (98%) reported having a reminder or routine to help
them take their pill every day and yet, 38% reported having missed at least one active
pill in the prior three months: eight percent had missed one, 11% two and 19% three or
more. Some 71% of those who had missed a pill had simply forgotten to take it [77]. On
bivariate analysis inconsistent use was more common amongst those who had had two or
more partners in the past year than of those who had only one (58% versus 35%);
amongst women who had no children as opposed to those who had two children or more
(43% versus 28%); and amongst those who were not completely satisfied with their
chosen method as opposed to those who were (48% versus 35%) [77],
Another American study, by Hou et al (2010), used a randomised controlled trial design
to estimate whether women receiving daily text-message reminders have increased
adherence compared with women not receiving reminders [82]. Pill-taking was tracked
for three months by an electronic monitoring device with wireless data collection. The
investigators found that the mean number of missed pills per cycle did not differ
significantly between the text-message reminder group and control group (4.9±3.0 vs
4.6±3.5 respectively), and that the number of missed pills per cycle increased over the
course of the study (P=0.02), but that this pattern did not increase differentially between
the groups (P=0.58). The authors concluded that whilst the lack of benefit of the text-
message reminders might be due to the frequent use of alternative reminder systems in
the control group, the rate ofmissed pills when measured objectively was still very high
in both groups [82],
Similarly of those who report using condoms as their primary method of contraception
61% of users, overall, had not used the method every time they had sex or had put it on
after beginning sex at least once in the prior three months [77]. The most common
reason for not using a condom consistently was not having one available or not
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expecting to have sex (25%). In addition inconsistent use was more common amongst
those who were ambivalent about avoiding a pregnancy as opposed to those who thought
it was very important (78% versus 58%) [77], and among those who were not
completely satisfied with the method than among those who were (66% versus 55%).
Contraceptive choices are very much determined by presumed advantages and
disadvantages of the various methods available to each individual user. Ifwomen and
men are dissatisfied with their method of contraception, their chance of adhering to the
behaviours required to use it successfully are reduced [77,83,84],
Whilst reliability and safety are important to women, so are side-effect profiles, be they
real or perceived/assumed. The fear of or actual experience of troublesome side-effects
(for example: bleeding problems, acne, weight gain) or risks (for example: breast cancer
or venous thrombo-embolism with the combined oral contraceptive pill) can lead to a
fear to start contraceptive use or early discontinuation. Other reasons include partner
influences, cultural values and norms; and problems in the contraceptive care system
[85,86],
With discontinuation there is the risk that disillusionment with one method may lead to
either use of no method or use of a less effective method. A study by Rosenberg et al
(1998) found that six months after a new contraceptive prescription, of those who
discontinued (32% of new starts and 16% of switchers) more than four fifths of those
who remained at risk of pregnancy either failed to adopt another method or adopted a
less effective method [86], Additionally discontinuation of a method can lead to gaps in
use of contraception and this heightens many women's risk of unintended pregnancy. A
survey by the Guttmacher Institute found that almost four in ten women for whom
avoiding pregnancy was of little or no importance had had at least one month long gap in
use of contraception or failed to use any method for a year, compared with fewer than
two in ten of those who deemed it very important [85].
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The data presented suggests that, both in the developing and industrialised world,
increasing uptake of modern methods of contraception requires improving the
accessibility and quality of contraception information and services [24,87,88]. However,
non-use and ineffective use does not only reflect difficulties in access but also indicates
dissatisfaction with available methods. A variety of new methods and administration
schedules are needed that address user's concerns and preferences, fit different stages of
women's reproductive lives and are compatible with their particular life contexts [7],
Reducing unintended pregnancy
Preventing unintended pregnancy, meeting the standards set in Cairo in 1994 [13,89,90]
and achieving the MDGs, requires for the number of successful contraceptive users
(implying correct and consistent use) to increase. This, at a minimum, requires the
availability of safe, acceptable and effective methods of contraception; access to
information, supplies and services; and the motivation and ability to use contraceptives
correctly and consistently [7].
For it to be used contraception has to be viewed as an attractive and plausible option. For
this methods need to offer a number of things: efficacy, ease of use, safety, convenience,
minimal side-effects and easy reversibility. As mentioned earlier, contraceptive choices
are very much determined by presumed advantages and disadvantages of the various
methods available to each individual user. Non-contraceptive health benefits (e.g
amenorrhoea, protection from sexually transmitted infections) can influence continuation
rates of contraception.
One study in the USA demonstrated that women who experienced troublesome
dysmenorrhoea prior to using the combined oral contraceptive pill (COC) were eight
times more likely to continue using the pill than women who did not report
dysmenorrhoea [91].
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Recent studies have suggested that many women prefer to bleed less often than once a
month or not to bleed at all (amenorrhoea) [92,93,94,95,96], The impact of monthly
menstruation may range from a minor inconvenience for some women to a major health
concern for those who suffer from menstrual disorders and health conditions that are
aggravated during their menstrual cycle [97], Gynecologists have advocated use of COC
in an extended and continuous manner since the 1960's and 70's to treat menstrual
disorders, such as menorrhagia and dysmenorrhoea, and gynaecologic disorders such as
endometriosis [98], Being able to offer the choice of amenorrhoea would be
advantageous for many women, improving quality of life for those who suffer from
menstrual-related disorders and provide greater convenience for women with busy and
active lifestyle [97] and thus would likely increase uptake and continuation rates.
Strategy for improving contraceptive choice and use
There is a need for a three tiered strategy, as proposed by Darroch et al (2011), to
improve uptake and adherence of contraceptive methods [58],
Women and couples need to receive accurate information about their risk of unintended
pregnancy, have access to quality services that offer a range of contraceptive methods,
and receive counselling and care that helps them initiate and sustain correct and
consistent method use.
Currently available methods need to be reviewed and where necessary adapted to
address users' concerns and preferences, fit different stages ofwomen's reproductive
lives and be compatible with their particular life contexts in an effort to increase
acceptability and hence uptake and adherence.
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New methods of contraception need to be discovered and developed which do not cause
the systemic side-effects linked to existing methods and offer additional non-
contraceptive health benefits.
In the context of this background this thesis aims to
• Quantify the incidence of unintended pregnancy in Lothian, Scotland and the
outcome of such pregnancies.
• Explore uptake of emergency contraception uptake in women with unintended
pregnancy and thus assess awareness of risk of unintended pregnancy.
• Explore continuation rates of a long-acting gestagen implant (Implanon®).
• Assess whether adapting the injectable contraceptive, Depo-Provera® to a form
where self-administration is feasible would increase acceptability and improve
uptake.
• Compare a novel oestrogen free contraceptive daily pill (mifepristone) with an
existing gestagen only daily pill (levonorgestrel) with the aim to further develop
mifepristone by assessing efficacy, side-effects and the potential non-contraceptive
benefit amenorrhoea.
• Explore a novel oestrogen free contraceptive daily pill's (mifepristone) safety and its
potential to protect against sexually transmitted diseases and HIV by studying its
effects on ovarian function, endometrium, and vagina.
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Appendix 1: Twelve pillars of reproductive health [8]
The status ofwomen
Family planning
Maternal care and safe motherhood
Abortion
Reproductive tract infections and HIV/AIDS
Infertility
Nutrition
Infant and child health
Adolescent reproductive health and sexuality
Sexual behaviour and harmful sexual practices
Environmental and occupational reproductive health
Appendix 2: The Millennium Development Goals
Eradicate extreme poverty and hunger
Achieve universal primary education
Promote gender equality and empower women
Reduce child mortality
Improve maternal health
Combat HIV/AIDS, malaria and other diseases
Ensure environmental sustainability
Develop a global partnership for development
Appendix 3: Millenium Development Goal 5 - Improve maternal health
Target 5A. Reduce by three quarters, between 1990 and 2015, the maternal mortality
ratio
Indicators for measuring progress:
5.1 Maternal mortality ratio (UNICEF-WHO)
5.2 Proportion of births attended by skilled health personnel (UNICEF-WHO)
Target 5B. Achieve, by 2015, universal access to reproductive health
Indicators for measuring progress:
5.3 Contraceptive prevalence rate
5.4 Adolescent birth rate
5.5 Antenatal care coverage (at least one visit and at least four visits)
5.6 Unmet need for family planning
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Appendix 4: Summary table of contraceptive effectiveness (typical use
failure rates) and efficacy (perfect use) plus continuation rates at one year
Percentage of women experiencing an unintended pregnancy during the first year of typical use and the
first year of perfect use of contraception and the percentage continuing use at the end of the first year.
United States. [74]
- % ofWomen Experiencing an Unintended










No method d 85 85 -
Spermicides e 29 18 42




Standard Days methodf - 5 -
TwoDay method f - 4 -
Ovulation methodf - 3 -
Sponge - - -
Parous women 32 20 46
Nulliparous women 16 9 57
Diaphragm 8 16 6 57
Condom h - - -
Female (Reality) 21 5 49
Male 15 2 53
Combined pill and progestin-
only pill
8 0.3 68
Evra Patch 8 0.3 68
NuvaRing 8 0.3 68
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Depo-Provera 3 0.3 56
IUD - - -
ParaGard (copper T) 0.8 0.6 78
Mirena (LNG-1US) 0.2 0.2 80
Implanon 0.05 0.05 84
Female Sterilization 0.5 0.5 100
Male Sterilization 0.15 0.10 100
Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces
the risk of pregnancy by at least 75% 1.
Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception
Explanation of table:
a. Among typical couples who initiate use of a method (not necessarily for the first time), the percentage
who experience an accidental pregnancy during the first year if they do not stop use for any other reason.
Estimates of the probability of pregnancy during the first year of typical use for spermicides, withdrawal,
periodic abstinence, the diaphragm, the male condom, the pill, and Depo-Provera are taken from the 1995
National Survey of Family Growth corrected for underreporting of abortion; see the text for the derivation
of estimates for the other methods.
b. Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly
(both consistently and correctly), the percentage who experience an accidental pregnancy during the first
year if they do not stop use for any other reason. See the text for the derivation of the estimate for each
method.
c. Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year.
d. The percentages becoming pregnant in columns (2) and (3) are based on data from populations where
contraception is not used and from women who cease using contraception in order to become pregnant.
Among such populations, about 89% become pregnant within 1 year. This estimate was lowered slightly
(to 85%) to represent the percentage who would become pregnant within 1 year among women now
relying on reversible methods of contraception if they abandoned contraception altogether.
e. Foams, creams, gels, vaginal suppositories, and vaginal film.
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f. The Ovulation and TwoDay methods are based on evaluation of cervical mucus. The Standard Days
method avoids intercourse on cycle days 8 through 19.
g. With spermicidal cream or jelly.
h. Without spermicides.
i. The treatment schedule is one dose within 120 hours after unprotected intercourse, and a second dose 12
hours after the first dose. Both doses of Plan B can be taken at the same time. Plan B (1 dose is 1 white
pill) is the only dedicated product specifically marketed for emergency contraception. The Food and Drug
Administration has in addition declared the following 22 brands of oral contraceptives to be safe and
effective for emergency contraception: Ogestrel or Ovral (1 dose is 2 white pills), Levlen or Nordette (1
dose is 4 light-orange pills), Cryselle, Levora, Low-Ogestrel, Lo/Ovral or Quasence (1 dose is 4 white
pills), Tri-Levlen or Triphasil (1 dose is 4 yellow pills), Jolessa, Portia, Seasonale or Trivora (1 dose is 4
pink pills), Seasonique (1 dose is 4 light-blue-green pills), Empresse (1 dose is 4 orange pills), Alesse,
Lessina or Levlite (1 dose is 5 pink pills), Aviane (1 dose is 5 orange pills), and Lutera (1 dose is 5 white
pills).
j However, to maintain effective protection against pregnancy, another method of contraception must be
used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are
introduced, or the baby reaches 6 months of age.
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Chapter 2: Quantifying incidence of unintended
pregnancy and its outcome, uptake of emergency
contraception and assessing awareness of risk of
unintended pregnancy among a large cohort of women
attending for antenatal care or abortion in Scotland
Background
Unintended pregnancy is common. In the UK, almost 200,000 pregnancies are
terminated every year [3,99]. In a questionnaire survey of 2000 mothers who were
randomly selected from birth registrations in 1989 and interviewed 6 months after
childbirth, almost a third of women said their pregnancies (31-3%) were "unplanned"
[4].
Quantifying the level of unintended pregnancy
There have been numerous efforts to measure intendedness of a pregnancy [1,4,49,100],
They varied from studies in which the concept of unintendedness is considered self-
evident to studies where sophisticated measurement strategies with multi-dimensional
probing questions have been used [101,102], Large surveys have generally adopted the
latter method and the one most widely adopted, for many years, has been the US
National Survey of Family Growth which was originally devised in 1973 [102],
However, over time, though items have been added to ensure validity, many of its
questions have become outdated and a need was identified for a measure of pregnancy
intendedness which accurately reflected the needs and priorities of women in the 21st
century [103,104], This is in keeping with changes in both cultural and social norms
such as deferring childbearing to pursue opportunities in education or employment or
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having a child outwith marriage. In response to this identified need, and the fact that no
new estimates for unintended pregnancy have been produced in the UK since the study
by Fleissig et al (1991) detailed above in 1989 [4], Barrett et al (2004) developed and
psychometrically evaluated the 'London Measure of unplanned pregnancy' (LMUP)
[105]. This is a six item measure of unplanned/unintended pregnancy and psychometric
testing (table 1). It demonstrated high internal consistency, high stability and excellent
validity. The measure has a number of advantages: it makes no assumptions about the
nature of women's relationships; it does not rely on women having fully formed
childbearing plans; it does not assume a particular form of family structure; and it is
suitable to use regardless of pregnancy outcome. Additionally it does not assume that
women have clearly defined intentions and/or behaviours consistent with intentions.
Results are on a scale of 0-12 and hence provide more information than previous
dichotomous measures [105]. As the authors explain the LMUP's greatest advantage is
that it provides a more complex and realistic portrayal of human fertility behaviour than
existing measures have to date [105],
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Table 1: London Measure of Unplanned Pregnancy (LMUP)
Question Answer Score
Ql. At the time of conception Always used contraception 0
Inconsistent use 1
Not using contraception 2
Q2. In terms of becoming a mother Wrong time 0
OK but not quite right 1
Right time 2
Q3. Just before conception Did not intend to become pregnant 0
Changing intentions 1
Intended to get pregnant 2
Q4- just before conception Did not want a baby 0
Mixed feelings about hawing a baby 1
Wanted a baby 2
Q5. Before conception Had never discussed children 0
Discussed but no firm agreement 1
Agreed pregnancywith partner 2
Q6. Before conception No actions 0
Health preparations (1 action*) 1
Health preparations (s2 actions*) 2
Health preparations included; taking folic acid supplements; stopping or reduction of smoking; stopping or reduction
of drinking alcohol; healthy eating; seeking medical advice before conception.
Table 1: Pregnancy Intendedness Instrument'
Understanding unintended pregnancy
Up to a quarter of pregnancies that end in induced abortion in the UK arise from
unprotected sexual intercourse; most of the rest are the result of inconsistent or incorrect
use of contraceptives (eg, missed pills) or accidental damage of barrier contraceptives
(eg, a burst condom) [70,106].
Once an episode of unprotected sexual intercourse has occurred be it due to non-use,
incorrect use or inconsistent use the methods of contraception which can be used are
grouped as emergency contraception.
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Emergency contraception
The World Health Organisation (WHO) defines 'emergency contraception' (EC) as
'those backup methods for contraceptive emergencies which women can use within the
first few days after unprotected intercourse, or in the event of potential contraceptive
failure to prevent an unwanted pregnancy' [107].
Methods of EC explored have, to date, included stilbestrol, ethinyl estradiol combined
with levonorgestrel LNG (the Yuzpe regimen), danazol, LNG alone, mifepristone,
insertion of a copper intrauterine device (IUD) and most recently ulipristal acetate
[108,109,110,111,112,113]. Of these methods, levonorgestrel (LNG) EC is the most
widely used EC method worldwide today [114].
Levonorgestrel emergency contraception
Pharmacology and metabolism
LNG-EC comprises a 1.5mg tablet. It is rapidly and completely absorbed after oral
administration. Bioavailability is approximately 100%. The maximum concentration
achieved is 19.1ng/ml and the time to reach this is 1.7 hours [115]. Its half-life is
28hours and it is extensively metabolised to a large number of inactive metabolites
[115].
Mode of action
There is much political and ethical controversy surrounding EC regarding its
mechanisms of action. It has been demonstrated that LNG-EC acts through an effect on
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follicular development to delay or inhibit ovulation [116,117] but appears to have no
effect once luteinising hormone has started to increase as the pre-ovulatory surge
[118,119], Thereafter, LNG-EC cannot prevent ovulation and it does not prevent
fertilisation or affect the human fallopian tube [114,120], LNG-EC has no active effect
on human sperm function [121,122,123,124] however, in being a progestin, it does alter
the cervical mucus, so that it mimics the non-fertile thick, tacky, non-distensible mucus
found during the second half of the menstrual cycle, and makes it impenetrable to sperm.
LNG-EC has no effect on endometrial development or function [125], In in-vitro models
[126,127], and work in monkeys [128], it has been demonstrated that LNG does not
interfere with blastocyst function or implantation.
Safety
LNG-EC is safe for use by all women, including adolescents [129], Levonorgestrel, the
active ingredient in LNG-EC, has been widely used in various formulations for over 30
years and has been extensively studied in women of reproductive age [129], LNG-EC
poses no risk of overdose and no major drug interactions or contraindications exist for
LNG-EC [130], While the WHO recommends a single dose of 1.5mg of levonorgestrel,
repeat use doses do not pose any known health risks and no serious adverse outcomes
have been reported in this eventuality [131,132],
Risk of Cancer
Current research shows no association with increased risk of cancer [ 129],
Effect on future fertility
The use of LNG-EC has no effect on future fertility [133,134], LNG-EC is cleared
within a few days and women who have used LNG-EC are at risk of pregnancy from any
subsequent acts of unprotected sexual intercourse (UPSI) [129],
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Ectopic pregnancy
LNG-EC does not increase the risk of ectopic pregnancy, a potentially dangerous
condition in which a fertilised egg implants outside the uterus [135]. A systematic
review including data from 136 studies, which followed a defined population of women
treated one time with emergency contraceptive pills (either levonorgestrel or
mifepristone) and in which the number and location of pregnancies were ascertained
found that the rate of ectopic pregnancy when treatment with EC fails does not exceed
the rate observed in the general population [136]. The authors concluded that because
EC is effective in lowering the risk of pregnancy, their use will reduce the chance that an
act of intercourse will result in ectopic pregnancy.
Effect on pregnancy outcomes
LNG-EC does not harm a developing fetus if taken mistakenly early in pregnancy [129].
A study by Zhang et al (2009) found no association between the use of LNG-EC and the
risk of major congenital malformations, pregnancy complications or any other adverse
pregnancy outcomes [137].
Administration
The World Health Organisation recommends a single dose of 1.5mg LNG-EC orally as
soon as possible within 72 hours after unprotected intercourse or known or suspected
contraceptive failure [107],
Studies have been undertaken to assess the optimum dosing regimen. Johansson et al
(2002) investigated three dosing regimes 0.75mg LNG twice with a 12 hour intervals
(regime A), 0.75mg twice with a 24 hour interval (regime B) and 1.5mg in a single dose
(regime C) [138], Maximum LNG concentrations were approximately 27nmol/l for
regimens A and B, and close to 40nmol/l for treatment C. The area under the curve was
significantly higher for treatment C during the first 12 hours and significantly lower for
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treatment B. However, after 48 hours and up to 9 days from onset of treatment, serum
LNG levels were similar in all three regimens. They concluded that pharmacologically
the regimen A and C were sufficiently similar to justify a clinical comparison. Cheng et
al (2008) have undertaken a Cochrane systematic review of interventions for emergency
contraception and found that single dose administration has similar clinical effectiveness
as the split dose regimen [139], In view of it being easier to take a single dose this is the
administration schedule now recommended.
Piaggio et al (2011) have explored how long after UPSI LNG-EC can be administered
and still be effective [140]. Data were analysed from 6794 women participating in four
WHO randomised trials receiving 1.5mg LNG-EC in a single dose or split into two
doses twelve hours apart. For the four trials combined, odds ratios for pregnancy in the
second, third and fourth day with respect to the first day were not significantly different
from 1 at the 5% level of significance. On the fifth day, the odds ratio of pregnancy
compared to day 1 administration was almost 6. The authors concluded that LNG-EC
should be administered as soon as possible after UPSI and that it is uncertain whether
administration on day five post UPSI offers any protection [140],
Efficacy
The efficacy of emergency contraception is described in terms of potential pregnancies
prevented based on calculating the risk of pregnancy for the day of the cycle on which
intercourse occurred [141]. This is difficult to calculate because often it is not known
how fertile the user is and information on cycle length, last menstrual period and time of
UPSI is unreliable [142], Additionally, it is difficult to know precisely when in relation
to ovulation EC has been given [142].
The WHO fact sheet states that based on reports from four studies including almost
5000 women, LNG-EC used within 5 days after UPSI is thought to reduce a woman's
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chance of pregnancy by 60-90% [107], A randomised controlled trial of LNG-EC versus
the Yuzpe regimen of combined oral contraceptives for EC estimated that the proportion
of pregnancies prevented was 85% (95%CI 74-93%) [143]. It has to be emphasised that
these figures are only estimates and as mentioned above there are problems with the
methods used to calculate them hence Raymond et al (2004) used data from two
published randomised trials of the levonorgestrel and Yuzpe regimens to calculate
minimum effectiveness of the LNG-EC regimen [144], They conservatively assumed
that the Yuzpe regimen was entirely ineffective in these trials and thus estimated that
LNG-EC prevented at least 49% of expected pregnancies (95%CI: 17%-69%). The
authors concluded that considering physiologic data suggests that the Yuzpe method
does, in fact, have some efficacy, the effectiveness of the levonorgestrel regimen is
likely to be higher than their minimum estimate [144].
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Side-effects
Changes in bleeding pattern have been reported following the use of LNG-EC. A
prospective observational study of 544 women who took 1.5mg LNG-EC found that
early or timely menses occurred in 69% of women and was late by more than a week in
21%. Normal vaginal bleeding occurred in 57% of women whilst others had
intermenstrual bleeding/spotting, premenstrual bleeding/spotting or menorrhagia [145].
Other side-effects that have been reported include nausea and vomiting [145,146] and
headache [147].
Economics
EC cost-effectiveness studies weigh the costs of using EC, the likelihood that EC will
prevent pregnancy, and the costs of an unintended pregnancy [148,149,150,151]. In
addition to payment method, costs can be based on whether a woman obtains EC after
unprotected sex versus in advance of need [149,150], and whether she obtains EC from a
doctor or clinic versus directly from a pharmacist [148,151,152]. Costs do not, however,
include those factors to which a monetary value cannot easily be assigned, such as the
psychological consequences of experiencing an unintended pregnancy [153],
A number of studies have compared the costs of EC with an unintended pregnancy and
have universally concluded that EC is cost-effective [148,149,150,152,153,154].
Preventing unintended pregnancy in developing countries is particularly imperative as
discussed in chapter 1. An analysis comparing the public sector cost of EC with the
average medical costs of unintended pregnancy (related to birth, miscarriage, ectopic
pregnancy and abortion) found that assuming 85% efficacy, EC is cost-effective in a
number of developing countries [151,153],
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Access to EC1
EC is available in many countries but not all [155], Ease of access is variable. Although
use of a combination of oral contraceptive pills as a substitute for EC has always been
possible, in many countries a dedicated product has only recently become available. For
example at the time of our study EC was not available in Russia but now LNG-EC is
available (labelled Escinor 1.5 and Escapelle) [155], However, in many countries, such
as much of the Middle East and sub-Saharan Africa, a dedicated product remains
unavailable [155]. Use of oral contraceptive pills taken in a number to match (roughly)
the dose in the yuzpe regimen is common. Where EC is available efforts are being made
to improve access. In some countries, such as the UK and the US, it is available over-
the-counter, in others women have to see a pharmacist and in others attend a health
clinic.
Use of EC 1
Regardless of improving access, use of EC remains low. In a 2001 survey of 880 female
undergraduates in Nigeria, of whom 34% had had an abortion in the past, 58% knew
about EC, but only 2% had used it [156]. In a group of 623 women who sought
contraception or abortion in India - where an estimated 5-6 million abortions are
undertaken every year, most of them illegal - only 6% knew about emergency
contraception and none had ever used it [157],
In more developed countries knowledge is greater and whilst more women use it,
amongst those undergoing induced abortion use remains low. Among women
undergoing abortion, the proportion who said they used emergency contraception to try
to prevent the pregnancy was 1.3% in the USA in 2000 [158], 2.9% in Sweden in 2000
' excludes IUD's inserted for purpose of emergency contraception
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[159], 6.6% in Denmark in 2002 (though 24.1% had used it previously) [160], and 9.2%
in France in 2002 [161]. In the UK, use of EC has increased since it was first licensed in
1984 but not proportionately to knowledge. In a questionnaire study of women
presenting for abortion in Dundee in 1984, 1% of women had tried to prevent pregnancy
with EC [162], The study was repeated in 1996 and it was found that 7% of women had
used EC to try and prevent unintended pregnancy [163], This was in comparison to the
increase from 12% having knowledge of EC in 1984 to 73% in 1996. In 2000, a small
study undertaken in Newcastle found that 11% of women presenting for induced
abortion had used EC [106]. There are no data available on use of EC among those
women who continue with their pregnancy.
Reasons for non-use/ poor use
Lack of knowledge
In many countries, both developing and industrialised, lack of knowledge remains a
significant barrier to use. Results from a cross-sectional survey of first year female
students in Uganda in 2005 showed that less than half (45.1%) had ever heard about EC
[164], In Nepal, a cross-sectional survey of college students, in 2006, showed that only
two thirds had heard of EC [165], A cross-sectional survey of 14-19 year olds (n=100) in
the US found that only 56% had heard of emergency contraception [166], Even where
knowledge of existence of EC is high, knowledge regarding its use is often poor. One
study of female college students (n=609) in the US found that whilst 98% had heard of
EC, 60% did not believe they could obtain it and 71% had misconceptions regarding the
side-effects associated with EC [167].
Poor access
This is not the case in the UK any longer where EC is readily available over-the counter,
from pharmacists and health clinics and can be obtained in advance of need. However, in
countries where EC is not available at all or can only be accessed by prescription, this
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does pose a barrier to use. An online survey of 531 women from 49 states in the United
States, aged 14-19 who had engaged in UPSI at a time when they were aware of EC
found that only 48% had ever used EC. Those who were able to access EC without a
prescription were more likely to use EC within 24 hours (OR2.17; 95% CI 1.06-4.44)
[168],
Failure to recognise risk of unintended pregnancy
Several studies have shown that failure to recognise the need to use emergency
contraception is common. Even in settings where women have been supplied with EC in
advance of need have shown that three out of four women who put themselves at risk of
pregnancy did not use EC because they did not recognise - or did not acknowledge - the
risk [169,170,171],
We have attempted to quantify pregnancy intention in a study looking at unintended
pregnancy and use of emergency contraception amongst a large cohort of women in
Scotland (see study below) [172],
Objectives for survey
• Quantify the incidence of unintended pregnancy in Lothian, Scotland and the
outcome of such pregnancies
• Explore the uptake of emergency contraception in women with unintended
pregnancy and thus assess awareness of risk of unintended pregnancy
Since 1989 there have been no estimates of pregnancy intendedness in the UK [4].
Additionally whilst knowledge of EC has risen dramatically, since being made available
in 1984 (12% in 1984 to 73% in 1996) [163], this has not been the case for use of EC
(1% in 1984 to 7% in 1996) [162,163] and the most recent data on use appears to be
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from 2000 (11%) [106], Additionally, whilst studies have investigated use of EC in the
general population or among women requesting induced abortion, there is no data
available on use of EC by women who are continuing with their pregnancy.
In 2004, we undertook a questionnaire survey designed to quantify pregnancy intention
and use of emergency contraception among women who presented to a large teaching
hospital in Edinburgh, UK, for antenatal care, or to attend the pregnancy support centre
(women who have a history or high likelihood of miscarriage), or for termination of
pregnancy [172],
Methods
From July 5, 2004, until Feb 28, 2005, all women booking for antenatal care or abortion
in the New Royal Infirmary of Edinburgh, were invited to complete a self-administered
questionnaire asking about pregnancy intention and use of emergency contraception. We
excluded women whose foetus was shown to have died, by ultrasonography, and those
who were unable to read or write English well enough to understand or complete the
questionnaire. Women who were judged by the nursing staff to be distressed about the
clinical consultation were not offered the questionnaire. This judgement applied mainly
to women presenting at the abortion clinic.
Before seeking ethics approval for the study, we asked 207 women to read and comment
on a draft information sheet and questionnaire. The final questionnaire consisted of 15
questions about age, pregnancy gestation, contraceptive use (including emergency
contraception) in the month of conception, and pregnancy intention. Intendedness was
measured by using Barrett and colleagues' (2004) instrument (table 1) [105]. For the
intendedness score, the answer to each of the six questions was scored from 0 to 2, so the
total scores ranged from 0 (least intended) to 12 (most intended). Although Barrett and
colleagues (2004) emphasised that there were no cutoff points on the range of scores
obtained, they suggested that three score groups were identifiable: 10-12 (planned), 4-9
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(ambivalent), and 0-3 (unplanned) [105]. These three groups were used for the purposes
of analysis and discussion. Ethics approval for the survey was obtained from the local
research ethics committee.
On the basis of an estimated proportion of emergency contraceptive use of at least 10%
[106] among women presenting for abortion and our estimate of 2% for women
continuing their pregnancies, a sample size of 1000 women undergoing abortion and
4500 booking for antenatal care was needed to ensure that the upper confidence limit for
proportion of emergency contraceptive use was only 50% higher than the lower limit.
The study was powered to 90% and the confidence intervals set to 95%. Quality control
checks were done on 5% of all data entries. Data were analysed by use of Excel (2003)
and SPSS (version 12).
Groups were compared by %2 tests for binary data, Mann-Whitney tests for intendedness
scores, and two-sample t-tests for age and gestation. Ages in different intendedness
groups were comparer by one-way ANOVA.
Results
5686 pregnant women attended the hospital during the study period, 5630 of whom were
eligible to participate (figure 1).
1285 (78%) of 1645 women attending for abortion were given the questionnaire and it
was returned by 1006 (78%). 2905 (93%) of women attending the antenatal clinic and
810 (92%) of those attending pregnancy support centre were given the questionnaire; of
those women, 2496 (86%) and 643 (79%), returned the questionnaire, respectively
(figure 1). Women attending for abortion were younger than those planning to continue
their pregnancies and women seeking abortion or attending the pregnancy support clinic
attended hospital at an earlier gestation than those women attending an antenatal clinic
(table 2). 3815 women answered all six questions in the intendedness measure, 2908 of
them continuing their pregnancy and 907 who requested abortion. 814 (89-7%) of
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women who requested abortion had a total score of 3 or less, which suggests that their
pregnancies were unintended (table 2). Only two women who wanted an abortion scored
10 or more (intended) and 91 (10-0%) were ambivalent about the intendedness of the
pregnancy (score 4-9), (figure 2). Of the women who planned to continue their
pregnancies, 250 (8-6%) scored less than 3 (unintended), 1909 (65-6%) scored 10 or
more (intended) and 749 (25-8%) had some ambivalence about their intention to
conceive (score 4-9) (table 2, figure 2). Intendedness was associated with age in women
who chose to continue with their pregnancies; women who had intended to become
pregnant were significantly older than those who were ambivalent or had unintended
pregnancy. There was no significant association between age and intendedness in women
presenting for abortions (table 3). 113 (11-8%) women presenting for abortion used
emergency contraception to try to prevent pregnancy whereas only 40 (1-4%) of those
continuing with their pregnancies had done so (table 2). Of the women who used
emergency contraception, 74 (65%) of those attending for abortion and 20 (50%) of
those continuing with their pregnancy said they had used it after every episode of
unprotected intercourse during the menstrual cycle in which they got pregnant. Women
who used emergency contraception were significantly more likely to score low rather
than high on the intendedness scale, both in the abortion group and in those continuing
their pregnancies (table 4). In women continuing with their pregnancies, young age was
significantly associated with
emergency contraception use (p<0-0001). Age was not related to emergency
contraception use in women seeking abortion, but in this group, women who presented
before 39 days of gestation were significantly more likely to have used emergency
contraception than those presenting later.
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Figure 1: Study profile
Figure 1: Study profile
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Mean (SD) 25 0 (6-7) 30-3 (62) 29-6(5-8) 29-7 (5-9) <0-0001 0-002
Range 10-45 14-44 15-44 14-44
Gestation (days)
Mean (SD) 56(19) 58(15) 92(17) 87(21) <0-0001 <0-0001
Range 7-181 16-129 44-270 16-270
Total intendedness score, n (%)
10-12 (intended) 2 (0 2%) 402 (65-4%) 1507(65-7%) 1909(65-6%) <0-0001 042
4-9 (ambivalent) 91(100%) 140 (22-8%) 609(26-6%) 749(25-8%)
0-3 (unintended) 814(89-7%) 73 (119%) 177(7 7%) 250(8-6%)
EC used in conception cycle
Yes 113 (11-8%) 17 (2-7%) 23 (1-0%) 40 (1-4%) <0-0001 0002




74(65%) 7 (41%) 13(56%) 20(50%) 0-12 042
EC=emergency contraception. 'Seeking abortion versus total continuing with their pregnancy. tAttending
miscarriage clinic versus those attending the antenatal clinic tPercentage is of those answeri ng "Yes* to use of
emergency contraception in conception cycle.
Table 2; Characteristics ofwomen, use of emergency contraception, and intendedness score
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Figure 2: Spread of intendedness scores for women undergoing induced abortion and for
all women continuing their pregnancies (including thoe seen in the miscarriage clinic)
0=least intended pregnancies, 12 = most intended.



















figure 2: Spread of Intendedness scores forwomen undergoing induced
abortion and for all women continuing their pregnancies (including those
seen In the miscarriage clinic).
0=least intended pregnancies, 12=most intended.
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Intended 31-0 31-9 31-0 31-2
Ambivalent 24-9 28-3 27-3 27-5
Unintended 248 25-8 25-6 25-7
P 028 *0-0001 *00001 *0-0001
p values are from one-wayANOVA.
Table 3:Association between mean age (years) and intendedness
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Table 4: Trends in maternal age, gestational stage, and pregnancy intendedness among






0-19 19(9-3%) 1 (3-7%) 6G-6%) 7 (3-6%)
20-24 35(11-1%) 8 (7-8%) 7 (2-3%) 15(3-7%)
25-29 34(17-4%) 2 (1-6%) 5 (0-9%) 7(1-0%)
30-34 10 (8-8%) 4 (2-1%) 2 (0-2%) 6 (0-6%)
*35 11(10-4%) 2 (12%) 3(0-7%) 5 (0-8%)
P* 0-64 0-011 0-0001 ■:0-0001
Gestation (days)
0-39 21 (22-8%) 2 (5-0%) 0 2 <5-0%)
40-79 74 (10-6%) 9 (2-5%) 2 (0 9%) 11 (1-8%)
80-119 6(8-7%) 1(2-5%) 17 (1-0%) 18 (1-0%)
is120 2 (14-3%) 0 3(3-8%) 3 (3-8%)
P* 0-015 0-48 0-13 0-19
Intendedness
Intended 0 6 (1-6%) 1 (0-1%) 7(0-4%)
Ambivalent 4(4-7%) 7(5-0%) 14(2-4%) 21 (2-9%)
Unintended 96 (12 3%) 3(4-1%) 6 (3-5%) 9 (3-7%)
P* 0-031 0-054 cO-OOOl ■-0-0001
Percentages a re the proportion ofwomen in that age, gestational stage, or
intendedness groupwho used emergency contraception. Information is not
available for alt participants. * x'test for trend.
ToWe 4-' Trends in maternal age, gestational stage, and pregnancy
intendedness amongwomen using emergency contraception
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Discussion
In Edinburgh in 2005, only two-thirds of pregnancies destined to end in childbirth were
clearly intended, one in ten was unintended, and around a quarter of women were
somewhat ambivalent about their intention to become pregnant. When Barrett and
colleagues (2004) developed their instrument, they took care to describe the differences
in the meaning of the words "planned and unplanned", "intended and unintended", and
"wanted and unwanted" [105]. In 1989, Fleissig used the word "unplanned" and the
questionnaire was completed by women six months postpartum [4]. Despite the
difference in timing of the survey, and differences in wording of the questionnaires, the
proportion of pregnancies that are "planned" or "intended" has not changed since
Fleissig's study. This finding is perhaps surprising given the demographic changes
(falling birth rates, later age of first childbirth) [173], changes in sexual behaviour [174],
and the increase in contraceptive choice in the past 25 years [6].
The relation between age and intendedness among women continuing their pregnancies
is unsurprising. The findings that over 90% of pregnancies ending in abortion were
unintended and that only 10% ofwomen requesting abortion were ambivalent about their
pregnancies is consistent with the findings of a smaller study of 300 women in
Edinburgh undergoing abortion, in which a similar proportion claimed to have used
emergency contraception [70]. In that study a modified version of the intendedness
measure was used in a face-to-face interview rather than in a self-administered
questionnaire. Despite the methodological differences, both studies show that most
women who requested abortion had no intention to conceive.
One in ten women undergoing abortion and a quarter of women continuing with their
pregnancies seemed to have some ambivalence about pregnancy intention. Since the
number ofwomen who were ineligible for the study or deemed to be too distressed to be
given the questionnaire was small we do not believe that inclusion of these women
would have altered the findings.
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The observation of a relation between intendedness and emergency contraception use
adds weight to the validity of Barrett and colleagues' scoring system. The results also
suggest that, women who are ambivalent about their pregnancies are more likely to
continue than to have them terminated. The association between use of emergency
contraception and earlier gestational stage at presentation among women requesting
abortion is probably related to heightened awareness of the risk of pregnancy since they
recognised that they were at risk of pregnancy before missing a menstrual period. Use of
emergency contraception was related to age only for women who were continuing with
their pregnancy, perhaps because younger women are more ambivalent about avoiding
pregnancy than older women.
The availability and use of emergency contraception varies around the world. Although
use of a combination of oral contraceptive pills as a substitute for emergency
contraception has always been possible, in many countries a dedicated product has only
recently become available. Generally, use does not start to increase until such a product
becomes available (eg, in Nigeria and the USA in 1998, in France in 1999, and in India
in 2002). In much of sub-Saharan Africa, the former Soviet Union, and the Middle East,
a dedicated product is not available. In a 2001 survey of 880 female undergraduates in
Nigeria, of whom 34% had had an abortion in the past, 58% knew about emergency
contraception, but only 2% had ever used it [156]. In a group of 623 women who sought
contraception or abortion in India—where an estimated 5-6 million abortions occur each
year, most of them illegal—only 6% knew about emergency contraception and none had
ever used it [157]. In more developed countries, knowledge of emergency contraception
is greater and more women use it. Among women undergoing abortion, the proportion
who said they had used emergency contraception to try to prevent the pregnancy was
1-3% in the USA in 2000 [158], 2-9% in Sweden in 2000 [159], and 9-2% in France in
2002 [161]. Use of emergency contraception has increased in the UK since it was first
licensed in 1984. In a questionnaire study of women presenting for abortion in Dundee
in 1984, 1% of women had tried to prevent the pregnancy with emergency contraception
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[162]. When the study was repeated in 1996, 7% of women had used emergency
contraception [163], Nevertheless, emergency contraception is unlikely to prevent many
pregnancies if, as in our survey of women who became pregnant, only one in ten women
who definitely did not want to become pregnant use it in cycles when they have put
themselves at risk of pregnancy, and not much more than half of those use it with every
act of unprotected intercourse. The availability of emergency contraception over the
counter in UK pharmacies does not seem to have resulted in increased use [175].
Other studies have shown that failure to recognise the need to use emergency
contraception is common. In a questionnaire study of 1365 women who had induced
abortions in France, 90% had heard of emergency contraception but only a third had ever
used it and only 9% had used it in the cycle in which they became pregnant [161]. 38%
of the women were aware that they had put themselves at risk of pregnancy in the cycle
in which they conceived—most of these were either not using contraception or were
relying on condoms or withdrawal. Nine out of ten of them knew about emergency
contraception but only one in four of them used it. More than half the women did not
realise that they were at risk of pregnancy, and only 2-8% used emergency
contraception. Lack of knowledge of how and when to use emergency contraception,
difficulties with getting hold of it, and reservations about using it are all commonly cited
barriers to its use [176], However, without these barriers, most women who have become
pregnant and could have used emergency contraception to prevent an unwanted
pregnancy failed to do so. Several studies, from various settings, in which women were
given a supply of emergency contraception in advance of need have shown that three out
of four women who put themselves at risk ofpregnancy, even when they had a supply at
home, did not use emergency contraception because they did not recognise—or did not
acknowledge—the risk [169,170,171].
Although 98% of women who wish to avoid pregnancy use contraception in the UK
[177], abortion rates continue to rise [3,99]. Unintended pregnancies that end in
childbirth, unless they occur in teenagers, are of less concern to policymakers than those
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that end in abortion, but they do affect the lives of the women involved. Understanding
of sexual behaviour and patterns of contraceptive use is crucial for development of
interventions to reduce unintended pregnancy. This survey needs to be repeated in other
settings, and if the findings are similar elsewhere, a strategy will need to be developed to
improve contraceptive use. We need to find ways to raise awareness of the real risks of
pregnancy associated with lack of use of contraception or with incorrect or inconsistent
use. Emergency contraception is unlikely to make a substantial difference to pregnancy
rates. Condoms and oral contraceptive pills are the most commonly used reversible
methods of contraception in the UK and both rely on consistent use for their
effectiveness. Condom use is commonly inconsistent, and compliance with oral
contraception is not easy. In one US study, 47% ofwomen reported missing one or more
pills per cycle and 22% reported missing two or more [178]. In a study that used
electronic diaries to record compliance, 63% of women missed one or more pills in the
first cycle of use, and 74% did so in the second cycle [179]. We need to encourage
women who clearly want to avoid pregnancy and are taking risks to use long-acting
contraceptive methods (implants and intrauterine devices) that do not depend on
compliance for their effectiveness [180].
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Chapter 3: Determining acceptability of long-acting
reversible methods of contraception - The case of
Implanon®
Background
Long-acting reversible methods of contraception
These are methods of contraception which have a long duration of action and do not
require any active adherence once initiated. They are sometimes, aptly, termed
'forgettable contraception' [181]. They are characterised by low failure rates [74]
earning them a position at the top tier of contraceptive methods, side by side with
sterilisation2 [181]. A recent guideline from the National Institute of Health and
Clinical Excellence (NICE) in the UK suggested that increased uptake of long-acting
reversible methods of contraception (LARC) would reduce unintended pregnancy
[180],
The current etonogestrel implant (Implanon®) is one of an array of LARC.
Implanon®
Implanon® is a long-acting reversible contraceptive method providing contraceptive
protection for three years [182], Implanon® was first marketed in Indonesia in 1998
[183], It was licensed in the UK in 1999 and became available in the United States in
2006 [183,184], It is currently available in more than 30 countries [183], A new version
of the etonogestrel implant, with an improved inserter and radio-opaque device for easier
detection is currently undergoing assessment [185],
2




Implanon* consists of a single rod that is 4cm long and 2mm in diameter. It contains
68mg of etonogestrel (a progestogen that is derived from 19-nortestosterone and is the
biologically active metabolite of desogestrel) (Figure 1) in an ethinyl vinyl acetate
(EVA) copolymer core, surrounded by an EVA membrane. The rod is inserted
subdermally and releases etonogestrel at a rate of 67 micrograms/day initially, gradually
decreasing, reaching 30 micrograms/day by the end of the three years [186], The dose of
30 micrograms/day is sufficient to inhibit ovulation throughout almost the entire three
years of use [187,188,189,190].
Figure 1: Chemical compound information of implanon; MW: 324.45g/mol, MF: C22H28O2
Mode of action
Concentrations of etonogestrel are sufficient to inhibit ovulation within eight hours of
insertion of Implanon® and maximum concentrations are attained within four days of
inserting the implant, thus ensuring rapid and sustained ovulation inhibition [189],
Additionally, etonogestrel changes the quality of the cervical mucus and thus impairs or
suppresses the access of fertile spermatozoa to the site of fertilisation [187], Etonogestrel
also suppresses endometrial development [187], However, these additional mechanisms
are (for the vast majority of users) superfluous as there is no egg to fertilise or implant.
Implanon® has the advantage of being independent of compliance for its efficacy [191].
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Safety
The safety profile of Implanon® has been shown to be acceptable and not essentially
different from other low dose progestogen only methods [182,183], Implanon® is
assigned a category ' 1' classification for healthy women from menarche to before the
menopause (18 to >40) (World Health Organisation Medical Eligibility Criteria (WHO
MEC)) and there are very few contraindications in contrast to combined hormonal
contraception [192,193] (appendix 1). Etonogestrel does not accumulate in the body
[194] and ovulation is resumed within three weeks of removal in more than 90% of users
[190,195],
Cancer risk
Toxicology studies have addressed both the progestogens and the polymers that make up
the implant. Carcinogenicity studies reviewing the polyethylene-co-vinyl acetate (the
polymer used in Implanon®) indicated that this material is safe for use [196], Much of
the data on etonogestrel is derived from its prodrug, desogestrel. The data from
toxicology, genotoxicity, carcinogenicity and fetal development studies have
demonstrated overall safety [197], In a 24 month carcinogenicity study in rats with
subdermal implants releasing 10 and 20 micrograms etonogestrel per day (equal to about
1.8-3.6 times the systemic steady state exposure of women using Implanon®), no drug
related carcinogenic potential was observed [186]. An integrated safety analysis
including 11 international studies concerning Implanon® of which 10 had a duration of
at least two years found no link to cancer risk [198].
Cardiovascular disease
Epidemiological studies on the cardiovascular risk of progestagen-only contraceptives
are rare. A review of the safety of implantable contraceptives by Curtis (2002) in 2002
concluded that cardiovascular events among Norplant users were rare, although there
was no evidence to assess whether rates differed from those of non-hormonal controls
[199], Whilst this review was of the implant, Norplant both implant types are low-dose
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progestogen-only implants and hence it seems reasonable to extrapolate from Norplant
to Implanon®. Since 2002 I am aware of only two studies on this topic, One small study
of 36 healthy, non-smoking women has explored the effect of Implanon® on
cardiovascular risk factors, including markers of inflammation and found there to be no
increase in risk in healthy young women [200], A second non-comparative study (n=60)
in Spain reported no clinically significant changes in blood pressures, blood cholesterol
or glucose concentrations among Implanon® users at one year [201]. These data are
reassuring.
Bone mineral density
The evidence available on this topic is limited. The American College of Obstetricians
and Gynecologists states in its 2011 practice bulletin that the evidence, whilst limited, is
reassuring that implants do not have a major effect on bone mineral density (BMD), a
surrogate marker for fracture risk [202], When extrapolating from pharmacokinetic
studies of the etonogestrel implant and data on BMD assessment in women aged 18
years and older, they state that the implant should not affect ovarian estrodiol production
or BMD in adolescents [202], To my knowledge there are only three studies to date
exploring the relationship between Implanon® and BMD [203,204,205,206], The study
by Beerhuizen et al [204] found no effect of Implanon® on BMD whereas the other two
studies found a loss of BMD at the ultra-distal radius in one [203,205] and the distal
radius and ulna [206] in the other. However, whilst these findings could indicate that
BMD changes through the time of use evaluations at forearm sites are less predictive and
accurate than those at the hip and vertebra. Further limitations of the studies include
small study numbers; of short duration (two year and three year follow up of one study)
and a cross-sectional survey in the case of the other, and hence the results must be
treated with caution. No studies have evaluated fracture risk in current or past implant
users, change in BMD after discontinuation of the implant, or the BMD in women
younger than 18 years [202]. In summary more research with larger sample sizes is
needed but based on the available evidence an update on hormonal contraception and
bone density by Islay and Kaunitz (2011) states that skeletal health concerns should not
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restrict the use of hormonal contraception, including DMPA® and in this case,
Implanon® [207]
Administration
Contraceptive implants are inserted subdermally in the upper arm by a trained health
professional. This requires attendance to a health facility for both insertion and removal
as the implant is non-biodegradable. This has a cost-benefit implication. The benefit is
that it allows for appropriate counselling and for an alternative method to be initiated if
and when Implanon® is removed. It also guarantees compliance for the duration of use.
The cost incurred is in the training of health professionals and upfront resource
utilisation in terms of appointment time used in counselling, insertion and removal and
will depend on the duration of time the implant is retained for.
Efficacy
Recent data have shown that Implanon® is one of the most effective reversible
contraceptives with a 'perfect use failure rate' of 0.01 per 100 implants fitted [208] and a
'typical use' failure rate of 0.049 per 100 implants fitted [208]. This has led to some
health insurance schemes fully reimbursing the cost of implant provision in a number of





The WHO has defined bleeding pattern indices. These indicate the extent of deviation
from a normal pattern as observed in a normal menstrual cycle [210]. Bleeding patterns
include amenorrhoea, infrequent bleeding, frequent bleeding, prolonged bleeding and
normal bleeding [211] (Appendix 2).
This is the most common side effect of Implanon®. An integrated analysis of data from
11 international trials comprising 942 women and 24,679 cycles found Implanon use to
be associated with an altered bleeding pattern [212]. These altered patterns comprised
amenorrhoea (22.2%); infrequent bleeding (33.6%); frequent bleeding (6.7%) and
prolonged bleeding (17.7%). In 75% of reference periods (RP) bleeding/spotting days
were fewer than or comparable to those observed during the natural cycle, but they
occurred at unpredictable intervals. On average, the number of days of bleeding per 90
day RP was 17.5. A positive finding of this analysis was that the group of women with
favourable bleeding patterns (amenorrhoea or infrequent bleeding) during the first three
months tended to continue with this pattern throughout the first two years of use,
whereas the group with unfavourable initial patterns (frequent or prolonged bleeding)
had at least a 50% chance that the pattern would improve [212]. However, this finding
must be treated with some degree of caution because as the authors themselves surmised
the prognosis of bleeding patterns based on the first RP is hampered by the fact that
those discontinuing early did not contribute any further RP data to the analysis, which
then leads to a more favourable pattern with time [212],
The NICE guidance published in 2005 recommends that women should be informed that
bleeding patterns are likely to change while using Implanon® and that whilst 20% of




Weight gain is a major concern for contraceptive users. Although commonly reported in
contraceptive studies it is difficult to ascertain whether weight gain is caused by the
contraceptive itself because most studies lack a control group [202], Weight gain is
reported by 12% of Implanon® users in contraceptive studies but few (2.3%) discontinue
because of this weight change [183]. It is unlikely to be associated with Implanon®
given the low dose of Progestogen in Implanon®.
Dermatological reactions
Acne is a commonly reported adverse effect of progesterone-only contraceptives.
Overall, most women (86-90%) using the implant have either no change or an
improvement in reports of acne and 10-14% of users experience a worsening of
symptoms [202],
Provider-dependence for insertion and removal
Both insertion and removal of Implanon® require attendance at a health facility. It also
requires adequately trained providers as well as aseptic techniques. Furthermore, since
initiation and discontinuation of use is provider-dependent and not controlled by the
user, there may be a risk of coercion of use on the one hand or, on the other hand,
difficulty in access to initiating use, if trained providers are not readily available [213],
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Benefits
Implanon® is a safe, efficacious long-acting reversible 'forgettable' contraceptive. It is
free from daily user compliance and thus its typical and perfect use failure rates are
closely aligned.
Oestrogen-free
Similarly to other methods of contraception discussed in this thesis, Implanon® contains
no oestrogen. This makes it ideal for women who are either intolerant of or who have
contraindications to oestrogen-containing methods - such as focal migraine.
Return to fertility
After removal of Implanon®, serum concentrations of etonogestrel decline to below the
limit of detection of the assay (20pg/ml) within one week [189] and ovulation is resumed
within three weeks of removal in more than 90% of users [187,190,195,214],
Pain syndromes
Current studies, though limited in number, are encouraging that Implanon® may provide
another option for pain syndromes such as dysmenorrhoea and endometriosis [181].
Examples of such studies include: A study by Funk et al (2005) of 315 patients found
that rates of dysmenorrhoea decreased from 59% at baseline to 21% with Implanon®
treatment [215]. Of the 187 patients with dysmenorrhoea at baseline, 81% reported
improvement and only 10% reported an increase in symptoms; Mansour et al (2008)
undertook an integrated analysis of 11 clinical trials and found that 77% of women who
had baseline dysmenorrhoea experienced complete resolution of symptoms [212], A
pilot study by Walch et al (2009) compared Implanon® with Depot
medroxyprogesterone acetate (DMPA) in women with laparoscopically proven
endometriosis. It reported that both methods were associated with decreased pain scores.
In the etonogestrel implant group, pain intensity scores decreased by 68% compared
73
with 53% in the DMPA group [216]; A case series, by Yisa et al (2005), of five women
with severe endometriosis reported that four of the five (80%) had excellent relief of
symptoms with the implant [217]; and a recent randomised trial, by Shokeir et al (2009),
of 23 women with pelvic pain and pelvic congestion syndrome compared Implanon®
treatment with no treatment. Women with Implanon® had significantly lower pain
scores at one year, decreased severity of dysmenorrhoea, less monthly blood loss, and
fewer days of pain than untreated controls [218], This was a small pilot study however
and larger randomised controlled trials are necessary to confirm these findings.
Amenorrhoea
Studies have shown that many women would prefer a contraceptive option that is
associated with less frequent or no bleeding. The integrated analyses of 11 clinical trials
(942 women) reported that 22.2% (209/942) of women experienced amenorrhoea [212],
It also revealed that only 0.7% (7/942) discontinued for this reason. From these
observations it would appear that users of Implanon® in all the cultures that were
studied found amenorrhoea and infrequent bleeding to be highly acceptable [212]
Economics
Implant costs include not only the price of the device, but the equipment and supplies
necessary for insertion and removal, training costs, time spent with clients for
counselling and procedures, follow-up visits for management of side-effects and
unintended pregnancies, and the time, personnel and supplies for infection prevention
[191]. Cost data in 2005 found that first year cost of Implanon® was £175 and total three
year cost was £230 (table 1) [180].
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Cost component and basic assumptions
Component Cost
Ingredient cost (Implanon®) £90.00 per device
[219]
First year cost £175 Initial GP consultation, 20 min £44.80
Total 3 year cost £230 Consultation for insertion, 16 min £35.84
Sterile pack for insertion £4.40
Consultation for removal, 22 min £49.28
Sterile pack for removal £5.50
Resource use and cost of sterile pack based on GDG
consensus; GP unit cost = £2.24 per surgery/clinic
minute [220]
It has been suggested that this high upfront cost of Implanon® limits its availability in
parts of the UK [ 180] and perhaps in other countries.
To date three cost-effective analyses of Implanon® have been undertaken in the United
Kingdom (UK) [180,221,222],
Phillips (2000) examined Implanon® compared with Norplant, Levonorgestrel releasing
Intrauterine system (IUS), Depo-Provera (DMPA) and the combined oral contraceptive
pill (COC) [221]. Data for Implanon® was taken from clinical trials and data for other
methods was from reports in the literature. They found that reversible long-term
approaches to contraception provided an effective and efficient use of healthcare return
on public investment. Phillips (2000) concluded that Implanon® produces better rates of
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return than both Norplant and IUS, and is more cost-effective in terms of cost per
pregnancy avoided and cost per protected year than Norplant, IUS, DMPA and COC. A
limitation of this study was that the analysis was based partly on data obtained from
clinical trials and which may not reflect everyday clinical practice, especially in relation
to continuation rates [221],
A second modelling study by Varney and Guest (2004), performed from the perspective
of the UK, NHS using data on contraceptive service use from a General Practice
Research database, found Implanon® to be more cost-effective than DMPA but less
cost-effective than the IUS [222], One significant limitation of this study undertaken
between 1997 and 2002 was that data on Implanon® use was limited (n=277) as
compared to that for IUS (n=6080) and DMPA (n=10,478). The most likely reason for
this is that Implanon® only became available in the UK in late 1999 and initially the
majority of implants would have been inserted and removed in the family planning clinic
environment rather than in general practice due to health professionals having to be
trained in insertion and removal techniques.
More recently NICE (2005) developed an economic model to examine the cost-
effectiveness of LARC methods based on the clinical effectiveness data they presented
in their guideline on the effective and appropriate use of LARC [180]. Data on
continuation rates were from real life studies in the UK and Europe, including data from
the study presented below. The guideline development group found that all LARC
methods are more cost-effective - even if only used for one year - than either the COC
or condoms and that among the four LARC methods DMPA is less cost-effective than
the IUD, IUS and implant, with the latter becoming more cost-effective with longer
duration of use [ 180].
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This suggests that:
• Cost-effectiveness of all methods of contraception depends on their continuation
rates, but this is particularly true for the very long-acting methods (implants and
intrauterine devices) and
• High initiation costs should not be a barrier to use of LARC methods [ 180],
Use worldwide
The etonogestrel implant (Implanon®) is a relatively new method of contraception. It's
use is relatively low though it is becoming an increasingly popular choice of
contraception and approximately six million women use this method worldwide [209]. In
2007, 3.7% of married women were using injectables/implants as their chosen method of
contraception, worldwide [223]. This can be separated into use in more developed
regions (1.3%) and less developed regions (4.2%). Admittedly the majority of this figure
comprises injectable users and that component which is implants includes Jadelle and
Norplant as well as Implanon®.
In the UK in 2008/9 the Office of National Statistics estimated current Implanon use
amongst women aged 16-49 to be 1 %. This was a third of that for Depo-Provera (3%)
[224],
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Reasons for discounting/discontinuing Implanon®
Discontinuation of Implanon® particularly occurs during the first six months of use and
then levels off [198]. This is possibly due to one of two factors: either because side-
effects such as menstrual irregularity improve over time or because those women that
experience side-effects will discontinue within the first six months.
Menstrual irregularity is the most frequently cited reason for discontinuation. Mansour et
al (2008) found in an integrated analysis of 11 clinical trials that 11.3% of women
discontinued Implanon® prematurely due to bleeding abnormalities [212]. Blumenthal et
al (2008) undertook an integrated safety analysis of Implanon® and found that 10.4%
(98/942) of women discontinued Implanon® use due to bleeding irregularities [198].
Other reasons for discontinuation other than planning a pregnancy (4.1%) identified in
the study by Blumenthal et al (2008) included emotional lability (2.3%), weight increase
(2.3%), acne (1.3%), headache (1.6%) and depression (1.0%) [198].
Determining acceptability by investigating continuation rates
Although no single contraceptive method is perfect or appealing to all, contraceptive
implants are safe and fulfil a very important need among fertility regulation methods
thus increasing choice of method. To increase use of any method it must appeal and be
considered acceptable to the user. There is evidence to demonstrate that the acceptability
of a contraceptive method (and continuation rate) is increased when users are well
informed about the side effects and risks [225,226]. Acceptability of the chosen method
is likely to be fundamental to correct and consistent use and to continuation.
Thus, continuation rates are one objective measure of acceptability. This is not to say
continuation rates equate to level of acceptability. That would be simplistic. There are
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many factors which determine acceptability and continuation of a method may only
reflect that it is the most acceptable of those methods available.
Continuation in international clinical trials of Implanon® has been shown to be high,
between 90 and 95% at 6 months and 80 and 88% at 12 months [182]. However,
participants in prospective clinical trials often have relatively high continuation rates
because the inclusion criteria for trials are rigid and tend to bias toward a
willingness/likelihood to continue the method. Regular study related follow-up serves as
a positive reinforcement and in countries where women have to pay for contraception
and healthcare is expensive, provision of free supplies and services through clinical trials
ensures good compliance [227],
"Real life" data are much harder to come by and loss to follow up is common. Moreover
much of the data for Implanon®1 comes from developing countries where the availability
of and access to other methods of contraception is usually limited and where
continuation rates are often high.
In a review of evidence from European settings the NICE guideline (2005) concluded
that 20-25% of women will discontinue Implanon®1 within one year of insertion, and up
to 44% will stop using the method within three years [180].
To date, three small studies have investigated continuation rates in the clinic setting in
the UK.
The first study by Smith et al (2002) set out to assess continuation rates and also factors
associated with early removal in three community services [228]. An audit was carried
out by use of a retrospective review of service users who had undergone an Implanon®
procedure between the date when Implanon® was introduced into each service and 31st
December 2000 inclusive. Client records were reviewed after June 2001 ensuring a
minimum of six months' data for each user. Kaplan Meier survival analysis techniques
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were utilised to enable as much information as possible to be used from previous follow-
up appointments from those subjects where it was not known whether or not they had
continued with Implanon®. A total of 190 subjects were identified between the three
sites. At six months, 97 had definitely continued with their implant, 22 had had it
removed and 71 were lost to follow-up. It was assumed that no-one would have had their
implant removed elsewhere and continuation rate was calculated at 88% or by survival
analysis 84%. By the end of the study, 95 subjects had had their implant fitted at least 12
months previously. Similar analysis revealed 78% continuation and by survival analysis
67%. Whilst this study did utilise real life data, and perhaps because of this, there were a
number of weaknesses; there was a high default rate to follow-up and hence estimates of
continuation would be considered unreliable. Also, it was assumed that no-one had had
their implant removed elsewhere. The authors themselves felt that repeat analysis of the
cohort after three years when all 190 subjects should have had their implants removed
would give more accurate continuation rates and hopefully the number of defaulters
would have been lower as most women would hopefully have attended one of the three
sites for the removal of their implant[228].
Similarly the second study, by Rai et al (2004), a retrospective case note review which
followed up 147 women who had had Implanon® inserted three years previously found
there was a high loss to follow up (24%). The study found that the probability that
Implanon® was still being used at three years was 75% (58-85%) by Kaplan Meier
survival analysis and 53% (28-73%) by confirmed analysis [229],
The third study, by Agrawal and Robinson (2005), assessed the first three years' use of
Implanon® in a family planning and reproductive health care centre in Luton. Case notes
were reviewed for the first 106 women who had Implanon® inserted since introduction
of the implant in September 1999. Again, loss to follow up was high (19%).
Continuation rates were 69.8% at one year, 44.1% at two years and 30.2% at three years
[230],
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The above studies would indicate that continuation rates in "real life" situations are not
as high as in trial situations. However, consideration must be given to the fact that loss to
follow up was high in these studies. For this reason the results must be viewed with a
degree of caution.
Objective for survey:
• Explore continuation rates of a long-acting gestogen implant (Implanon®)
At the time of undertaking this research there was a need for reliable data on 'real life'
continuation rates. With so many contraceptive methods on the market any new method,
especially one that has a high upfront cost such as Implanon®, has to prove itself as an
effective and efficient use of healthcare resources. Cost-effectiveness of all methods of
contraception depends on their continuation rates, but this is particularly relevant as
detailed earlier for the very long-acting methods (implants and intrauterine devices).
• (S) • • •
To determine continuation rates of Implanon in clinical practice in Scotland, a
retrospective case note review combined with a questionnaire survey three years after
insertion of Implanon* in a cohort of 326 new users attending a large family planning
clinic in Edinburgh, Scotland was undertaken [231],
Materials and methods
Case notes for all women attending the clinic for Implanon® insertion between
January 1 and December 31, 2001, were reviewed at the end of 2004. If the implant
had been removed in the clinic, data were obtained from the case records. Women who
had not returned to the clinic for Implanon® removal (and who had consented to being
contacted when first attending the clinic) were contacted to remind them about the need
for removal of their implant before 3 years of use was completed. These women were
also asked to complete a brief questionnaire to determine whether Implanon® had been
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removed and, if so, the date and reason for removal of the implant, where the procedure
was done, and the method of contraception used for the first 3 months after
discontinuation of Implanon®. Three attempts at contact were made: twice by mail and
once by telephone. An interval of 2 weeks was maintained between each attempt at
contact.
Data were analyzed using Excel 2003 (Microsoft Corporation) and SPSS version 12
(SPSS, Inc., Chicago, IL, USA). Ages of women continuing for more or less than 2
years were compared using a two-sample t test. Cumulative discontinuation rates
were computed using descriptive statistics. Many women returned to the clinic slightly
before 3 years after Implanon® insertion to ensure that replacement contraception was
available for use. Women returning for implant removal more than 2 years and 9
months after insertion were deemed to have used the implant for its full duration.
Results
Three hundred twenty-four women had Implanon® inserted in 2001. Median age at
insertion was 26 years (range, 15- 49). Information about implant removal was
available for a total of 277 women (85%). Two hundred thirty-six of these women had
their implant removed in the clinic, and data were collected from their case records.
Letters were sent to 87 women who had not returned to the clinic for implant removal; 1
woman chose not to disclose her home address. Forty-one women responded and
returned the questionnaire. All 46 women who failed to respond to the request for
information were no longer residing at the address recorded in their case records.
For the 277 women in whom information was available, continuation rates of
Implanon® were 89% (CI 84-91) at 6 months, 75% (CI 69-79) at 1 year, 59% (CI
52- 63) at 2 years and 47% (CI 40 -52) at 2 years and 9 months. Thirty-three
women did not return for implant removal until at least 1 month after 3 years of
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use; the longest duration of use was 4 years and 8 days. Continuation rates were
independent of age.
Sixty-eight women discontinued Implanon® within 1 year; 62 of them (91%) did so
because of unwanted side effects. The most common documented reason for implant
removal was frequent and/or unpredictable bleeding (n - 42, 62%). Weight gain
accounted for 21% of removals (« = 14) and mood change accounted for 16% (n =11).
Of the six women who discontinued within 1 year for reasons other than side effects,
five did so because they wished to become pregnant and one because she was no
longer in a relationship.
Data on the contraceptive chosen for use following Implanon® removal were collected
(table 2). Twenty-three women (8%) were actively trying to conceive. Thirty-nine
percent of women had a second implant inserted, while another 14% chose an
alternative long-acting method or sterilization. More than 47% of the women elected
to use a less effective method of contraception.
Table 2: Contraceptive method used following removal of Implanon®
Method N (%)











Continuation rates of all methods of contraception are generally disappointing. In an
international review of discontinuation rates after 1 year of use of hormonal
contraception, rates varied from 19% (for Norplant) to 62% (the combined pill)
[232], Discontinuation rates are higher for methods that do not require removal by
a health professional [233]. In this study of women in Edinburgh, continuation rates
among women in whom data could be obtained might best be described as
reasonable with just under 60% continuing for 2 years and just under half
continuing for 3 years. The fact that nearly 40% continued to use Implanon® for
contraception after 3 years is encouraging.
The present study involved a cohort of women attending a clinic that offers all
currently licensed methods of contraception free of charge. Routine follow-up
consisted of at most one visit to the clinic 6-12 weeks after insertion of the implant.
Women were free to attend the clinic for review at any time, and Implanon® was
removed on request at no cost. Follow-up rates in our study were quite good at 85%. In
a postal survey of UK women followed up after Implanon® insertion in the East
Midlands, the response rate was only 44% [234], Although clinical trials have more
frequent data collection and higher rates of follow-up, continuation rates in this cohort
of Scottish women should be generally representative of UK women attending a
community family planning clinic.
We have no idea as to how long those women lost to follow-up continued to use their
Implanon®, and it does not seem worthwhile to guess. Only a dozen general practices
(family doctors) in the area offer Implanon® removal and only to women who are
registered with them. It is likely that most of these women continued to use Implanon®
until they moved away from Edinburgh.
Robust data on patterns of contraceptive use in the UK are lacking. However, in the
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United States, 40% of married women and 61% of unmarried women using a reversible
method of contraception change it over the course of 2 years [235]. Many — especially
those with less years of education — change from a more-effective method to a less-
effective method. This study similarly demonstrates that almost half of the women,
despite wishing to avoid pregnancy, chose a less-effective method of contraception
when they stopped using Implanon®. This is unfortunate since data from the United
States and the UK suggest that using condoms or oral contraceptives is much more likely
to risk unintended pregnancy [70,158]. In contrast, there are data to show that
contraceptive implants are associated with lower rates of unintended pregnancy than
either condoms or contraceptive pills [236].
Using preliminary data from this study, the NICE guideline on LARC concluded that
Implanon® is a cost- effective method of contraception and more cost-effective— even
if used only for 1 year — than either the combined oral contraceptive pill or condoms
[180]. Concerns that the high up-front costs of this method are unjustified because
discontinuation rates are high are unfounded as this study has shown that continuation
rates for Implanon® in real life in the UK are not unreasonable when compared with
those of clinical trials and with data for other contraceptives. This should reassure health
care providers and commissioners that increasing the uptake of this long-acting
method as recommended in the NICE guideline [ 180] is worth the effort and the cost.
The fact that more than one third ofwomen chose to continue to use the implant when
their first one had expired reflects a strong level of satisfaction on the part of the users.
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Appendix 1: World Health Organisation Medical eligibility criteria (WHO-
MEC) [193]
1= Yes: Use the method in any circumstance
2= Yes: Generally use the method
3= No: Use of the method is not usually recommended unless other more appropriate
methods are not available or acceptable
4= No: Method NOT to be used
Categories 1 and 4 are clearly defined recommendations. For categories 2 or 3, greater
clinical judgement will be needed and careful follow-up may be required. If clinical
judgement is limited, categories 1 and 2 both mean the method can be used, and
categories 3 and 4 both mean the method should not be used.
Appendix 2: WHO defined 'clinically important' bleeding patterns [211]
1. Amenorrhoea: no bleeding during the reference period
2. Infrequent bleeding: fewer than 2 bleeding episodes per 90 day period
3. Frequent bleeding: more than 4 episodes in a 90 day period
4. Irregular bleeding: between three and 5 episodes with a range of lengths of bleeding-
free intervals exceeding 17 days
5. Prolonged bleeding: 1 or more bleeding episodes lasting 10 days or more
6. None of the above: a 'normal' bleeding pattern
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Chapter 4: Adapting currently existing methods of
contraception - The case of Depo-Provera®
Background
Depo-Provera®
Depo-Provera® (depot medroxyprogesterone acetate or DMPA®) is a long-acting,
progestogen-only, injectable contraceptive licensed for use in over 106 countries [237].
DMPA was licensed as a contraceptive in the UK in the early 1960's. However, a
number of countries (including the United States of America) were reluctant to approve
it for many years. This reluctance revolved around the results of testing done on beagle
dogs. The dogs were given large doses of the progestogen over a long period of time and
developed tumours [238], It was not until 1992, after the World Health Organisation
(WHO) [239] published the results of a nine year study showing that users of this
injectable method of contraception had no appreciable increase in the risk of breast and




DMPA comprises one millilitre of sterile acqueous microcrystalline suspension
containing 150mg of medroxyprogesterone acetate. Medroxyprogesterone is a synthetic
progestin which is more potent than progesterone.
The long duration of action of DMPA (11-13 weeks) results from its slow absorption
from the injection site. Immediately after injection of 150mg/ml, plasma levels have
been found to be 1.7 +/- 0.3 nmol/1. Two weeks after injection, concentrations are 6.8 +/-
0.8 nmol/1 but by 12 weeks concentrations have fallen to initial levels again. At lower
doses, plasma levels ofmedroxyprogesterone acetate (MPA) appear to be directly related
to the dose administered. Serum accumulation over time has not been demonstrated.
Medroxyprogesterone acetate (MPA) is eliminated via urinary and faecal excretion. At
least 11 metabolites have been reported and all have been found to be excreted in the
urine and some but not all are conjugated [243].
Mode of action
DMPA prevents pregnancy by two methods. Progestins diffuse freely into target cells in
the female reproductive tract, mammary gland, and the pituitary and bind to the
progesterone receptor. The primary mechanism of action is to prevent ovulation by
acting at the level of the pituitary and hypothalamus. Once bound to the progesterone
receptor, progestins decrease the pulse frequency of gonadatropin releasing hormone
(GnRH) release from the hypothalamus. This decreases the release of follicle stimulating
hormone (FSH) and luteinising hormone (LH) by the anterior pituitary. Decreased levels
of FSH inhibit follicular development, preventing an increase in oestradiol levels.
Progestogen negative feedback and the lack of oestrogen positive feedback on LH
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release prevent an LH surge. The inhibition of follicular development and the absence of
an LH surge suppress ovulation [244].
As with other progestin-only methods, DMPA also has an effect on the cervical mucus.
The mucus becomes scanty and thick which makes it unfavourable for sperm penetration
[245],
Soon after the first injection of DMPA, the endometrium starts to become thin and
atrophic. Under these circumstances, DMPA could, theoretically, inhibit implantation.
However, DMPA is highly effective in preventing ovulation and sperm penetration, as
described above, and thus the role for inhibiting implantation is negligible. There are no
data available to support prevention of implantation as a contraceptive action of DMPA
[246],
Safety
The use of DMPA has been dogged by controversy about its safety from its start.
Cancer risks
Initial concerns were regarding gynaecologic malignancies. Evidence has shown
concerns over ovarian, cervical and liver cancer to be unfounded as discussed previously
and a large body of data exists to support that DMPA does not increase the overall risk
of breast cancer either [247,248].
Bone mineral density
Skeletal impact in adult premenopausal women
More recently discussion has centred on the effect of DMPA on bone mineral density.
In the early 1990's Cundy et al (1991) reported that bone mineral density (BMD) was
lower in current users of DMPA than in pre-menopausal non-users [249]. Since then,
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many reports, most based on cross-sectional data, have assessed BMD with DMPA use.
They have similarly observed reduced BMD in DMPA users [250,251,252,253], This
has led to concerns that this hormone-induced bone loss might translate into long-term
increased fracture risk [207]. The Food and drugs administration (FDA) were
sufficiently concerned as to add a black box label warning to DMPA packaging, in 2004,
warning of the risk of significant bone loss and cautioning against long tenn use (>2yrs)
[207],
Studies, of duration longer than one year, investigated the relationship between bone loss
with time. Tang et al (2000) found that there was a suggestion that there was a
retardation in bone loss with time [250] and Berenson et al (2004) found that in their two
year study the bone loss was linear [253]. No study, to my knowledge, has found an
acceleration in bone loss with time which is reassuring.
In 1994, Cundy et al (1994) went on to assess BMD during and after use of DMPA, and
noted that declines in BMD with current use of DMPA were reversible on
discontinuation [254]. Other studies have confirmed Cundy's 1994 observations
[255,256,257,258,259] and a systematic review of ten observational studies conducted
between 1996 and 2006 which examined BMD trends during and after use of DMPA
concluded that declines in BMD associated with current use of DMPA are reversible
[260],
Skeletal impact on adolescents
This is of particular interest as adolescence is the time of accumulation of peak bone
mass [207].
A 2005 cohort study by Scholes et al (2005) following 170 adolescents (including 80
who used DMPA at baseline) found that recovery of BMD was complete within 12
months following DMPA discontinuation [261], It was noted that the adjusted mean
BMD values for discontinuers were at least as high as those of non-users for all anatomic
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sites at 12 months and at all subsequent follow-up intervals. Of special note, BMD was
ultimately observed to be higher in former than in never users of DMPA. Duration of
DMPA use was not observed to impact the speed of BMD recovery following DMPA
discontinuation.
A more recent study by Harel et al (2010) enrolled and prospectively followed 89
adolescent DMPA users aged 12-18 years. Subjects provided data for up to 240 weeks
whilst receiving DMPA and for up to 300 weeks after DMPA cessation [262], Bone
mineral density was assessed at three sites using duel-energy X-ray absorptiometry
(DEXA): lumber spine (LS), total hip (TH) and femoral neck (FN). At the time of their
final DMPA injection (240 weeks) study participants had BMD declines from baseline
of 2.7% (LS), 4.1% (TH) and 3.9% (FN) (p<0.01 at all three sites). Within 60 weeks of
discontinuation LS BMD had returned to baseline, and 240 weeks after DMPA
discontinuation, the mean LS BMD was 4.7% above baseline. Mean TH and FN BMD
values recovered more slowly:240 weeks and 180 weeks, respectively, after the final
DMPA injection [262], This study substantiated the results of Scholes et al (2005) [261]
that BMD loss in female adolescents is substantially or fully reversible in most girls after
discontinuing DMPA.
In summary the evidence, to date, indicates that the decrease in BMD associated with
current use of DMPA is reversible after discontinuation of DMPA with recovery to
baseline BMD levels within one to two years [207,261,262], This is reassuring given that
peak bone mass is attained during adolescence and early adulthood and there has been
much debate regarding use ofDMPA in young women [261].
Skeletal impact on postmenopausal women
Concerns have been raised that long-term DMPA use may be a risk factor for
postmenopausal osteoporosis and fractures. A second related concern has been that use
up to menopause, without any time to let oestrogen levels to normalise may increase this
risk [207]. A number of studies have been undertaken to explore this and findings to date
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suggest that older reproductive age women do not appear to suffer a negative impact on
their skeletal health [207,250,263,264,265,266,267],
Impact on risk of fractures
The data is very limited. A few studies have addressed fracture risk associated with
DMPA use [207], Case reports [268,269] have suggested an association between DMPA
use and fractures in adult women, as have four published observational studies.
The first, by Lappe et al (2001) studied the impact of lifestyle factors on stress fractures
in female army recruits [270], Bone density was measured at baseline using quantitative
ultrasound of the heel and reported as speed of sound (SOS) through bone. Women were
followed for the eight weeks of basic training for occurrence of stress fractures. DMPA
use at baseline was associated with higher risk of stress fracture during follow-up only
among non-Hispanic Caucasian women (relative risk (RR) 1.71 95% CI 1.01-2.90).
However the investigators reported that this association became non-significant when
adjustment was made for SOS at baseline. They did not give the RR and 95% CI.
The second observational study, by Watson et al (2006), investigated the association
between fracture incidence and DMPA use in women with developmental disabilities
(DD) using a cross-sectional population based observational study [271], They found a
significant association. A considerable limitation to this study is that the investigators
were not able to control for severity of disability. This is very likely to have been a
confounder because women with more severe disabilities and therefore more risk factors
for low bone mineral density, and hence increased risk of fracture, are also more likely
to be given DMPA for menstrual suppression and/or contraception.
Vestergaard et al (2008) conducted a large national case-control study in Denmark
(64,548 fracture cases: 193,641 controls) [272]. They assessed both use of DMPA and
IUD. The authors found an increased risk of fractures in women who had ever used
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DMPA (adjusted OR 1.44 95% CI 1.01-2.06) while IUD use appeared to be associated
with a reduced fracture risk (OR 0.75 95% CI 0.64-0.87). However, the authors pointed
out a number of limitations. Firstly, use of DMPA is very rare in Denmark so the
numbers were very small (n=163) and hence the study will have been underpowered.
Secondly, there was a lack of baseline data on BMI and smoking thus adequate control
for confounding factors was not possible and hence causal inferences were not possible
with respect to DMPA use. Similarly with regard to the finding that IUDs were
protective against fracture. There was insufficient data on lifestyle factors and the results
are more likely to have been due to the effect of residual confounding from lifestyle
factors which had not been included in the study than to any real protective effect.
The most recent published observational study, another large population based British
case-control study, by Meier et al (2010) (17,527 fracture cases: 70,130 controls and
11% vs 8% use ofDMPA respectively) found current use to be associated with increased
risk of fracture and that the risk increased with increasing DMPA exposure (OR 1.36,
95% CI 1.15-1.60 with 3-9 prescriptions; OR 1.54, 95% CI 1.33 - 1.78 with >10
prescriptions) [273]. Past DMPA use was also associated with significantly increased
risk, again increasing with increased DMPA exposure (OR ranged from 1.17 to 1.30).
However, Isley and Kaunitz (2011) [207] have commented on their unpublished data
using a retrospective cohort design to assess use of DMPA and risk of fracture in the
same UK database. The results were presented at the Association of Reproductive Health
Professionals annual meeting in Atlanta in 2010. Using the retrospective study design
the investigators were able to take into consideration the timing of DMPA use and the
timing of the fracture to compare fracture rates between DMPA users and users of other
hormonal contraceptives (predominantly COCs). An increased risk of fracture was noted
in DMPA users, even after just one DMPA injection. This led the authors to compare
risk between women who were destined to become DMPA users to those who went on to
use COC. They found that future DMPA users had an incident rate ratio of 1.28 (95% CI
1.07-1.53) for any type of fracture. They also compared fracture type and found that
93
DMPA users were more likely to have trauma-related appendicular fractures(OR 1.38,
95% CI 1.31 - 1.46) and less likely to have an axial fracture (OR 0.95 95% CI 0.74-
1.23). The study also found that risk did not increase with increasing number of
injections. These results, as Islay and Kaunitz (2011) [273] pointed out, are consistent
with those of Vestergaard's Danish study [272], suggesting that DMPA users appear
behaviourally different from those who use other methods of contraception. This
unpublished study provides important evidence to support that the observed increase in
fracture rate observed in DMPA users in some studies does not appear to be due to
DMPA use and, accordingly, is not related to low BMD [273],
In summary, current understanding is that short-term skeletal changes observed during
use of injections do not predict long-term impact on skeletal health [274], The WHO
recommends that women in the age range of 18 through 45 years can use DMPA without
restriction (WHO MEC category 1). For women who are less than 18 or more than 45,
the benefits of using DMPA generally outweigh the known or theoretical risks (WHO
MEC category 2) [275,276] (Appendix 1 chapter 3).
Risk of Sexually transmitted infection and HIV-1 transmission
A key question for clinicians is whether an aetiological association exists between
contraceptive methods and HIV [277], Increased risk related to hormonal contraceptive
users would be of importance to global public health because of the large numbers of
women using such methods [278]. The WHO has called for high quality studies to assess
the potential role of hormonal contraception in increased HIV-1 risk [279,280],
Morrison et al (2009) conducted a systematic review (studies published 1966 to 2008).
They focussed on COC, DMPA and IUD. For DMPA users the data demonstrated no
increase in HIV risk among women in the general public and was equivocal for women
in high risk groups (e.g. sex workers) [277],
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Earlier this year Heffron et al (2011) presented findings of their prospective cohort study
of 3,790 heterosexual HIV-1 sero-discordant couples participating in two longitudinal
studies of HIV-1 incidence in seven African countries at the meeting of the International
AIDS society [278], They found that use of hormonal contraception might increase the
risk of acquiring HIV infection two-fold. Additionally they reported that HIV-infected
women were two times more likely to transmit infection to their uninfected partner
compared with those who did not use hormonal contraception. The contraceptive
methods used by women in this analysis were primarily DMPA, with a smaller number
using COC [278]. Whilst this study adds to the existing body of evidence the findings,
similarly to previous studies are from observational studies, which may be biased by
self-selection. Users of hormonal contraception may differ in important ways from non-
users (for example, with regards to sexual behaviour and condom use). Additionally
information on contraceptive use was collected by self-report, and overall, few women
actually reported using hormonal contraception during the study period (at enrolment
10.8% of uninfected women and 13.5% of infected women were using DMPA). Another
limitation of the study was that few new HIV infections were reported amongst
contraceptive users [281 ].
As a result of the Heffron study findings and the public health concerns it raises, WHO
is convening a Technical Consultation on 31st January -1st February to re-examine the
totality of evidence on potential effects of hormonal contraception on HIV acquisition,
disease progression, and infectivity/transmission to sexual partners [281]. In the
meantime the consensus from systematic reviews is that the weight of evidence does not
indicate that use of hormonal contraception increases the risk of HIV acquisition,
transmission or disease progression among the general public, but may have an impact
on women at high risk of HIV-infection, such as sex workers.
Abscess formation
As with any intramuscular injection, especially if not administered correctly there is a




The suspension must be given by deep intramuscular injection every 11 to 13 weeks
[283]. This dosing schedule requires routine attendance at a health facility four times
each year.
Efficacy
DMPA requires less user participation and as a consequence is highly efficacious [284],
Its failure rate is similar to that of the levenorgestrel releasing intra-uterine system
(LNG-IUS, Mirena®) when used perfectly and it is the most effective method of
reversible hormonal contraception that does not require an invasive procedure. Even
with typical use it has a low rate of failure (0.3-3%) as compared to the oral
contraceptive pill (0.3-8%) [74],
Side-effects
Menstrual irregularity
Most women who use DMPA experience menstrual changes. Some have prolonged or
heavy bleeding, others have irregular bleeding and spotting throughout the cycle, but
most become amenorrhoiec.
After the first DMPA injection over 40% of users experience irregular bleeding, spotting
and prolonged episodes of bleeding (>10days) (figure 1) [285,286,287], Following
subsequent injections these bleeding changes become less common and after 12 months
(4 injections) are relatively uncommon.
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In contrast amenorrhoea and infrequent bleeding become more common with time
(figure 1). By 12 months 50% of users are amenorrhoeic and by 24 months 80% are
amenorrhoeic [285,286,287], Opinions have been changing over time and whilst
irregular bleeding, spotting and heavy bleeding are considered a side-effect
amenorrhoea is more and more being considered a benefit [93],
Weight gain
As mentioned in the previous chapter weight gain is a major concern for contraceptive
users. Concern can keep women from using contraception or can cause them to
discontinue methods prematurely, which can lead to unintended pregnancy.
Weight fluctuation in women of reproductive age is common, regardless of hormonal
contraception use and hence it is difficult to ascertain if the cause of weight gain is the
contraceptive itself. Studies on weight gain during DMPA use report conflicting results
[180],
Observational studies have reported variable effects of DMPA on body weight. Among
adolescents and older women who used DMPA for up to one year, several studies
reported non-significant changes in weight [288,289,290,291] while other studies, such
as that by Clark et al (2005) [292], have found significant gains of 3-6kg
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[292,293,294,295,296,297]. The study by Clark et al (2005) was the first large
prospective study with a control comparison group evaluating long-term (30 months)
weight change in women using DMPA. It compared longitudinal changes in weight,
body fat, and ratio of central to peripheral fat mass among first-time DMPA users
(n=178) to women using no hormonal contraception (n=145) [292]. The study
demonstrated a change in body composition towards greater fatness and toward a central
distribution of fat among DMPA users as compared to controls. It also demonstrated that
higher levels of physical activity offered some protection against gains in fat mass.
The NICE guideline team when developing their guideline on LARC reported two
studies on the effect of weight gain and DMPA [180], Both reported weight gain in
DMPA users. One multinational randomised controlled trial (1983) reported a mean
weight gain of approximately 3kg in both DMPA (n=1587) and Norethisterone-
enanthate (n=789) users at two years [298], The second study by Mangan et al (2002)
reported a significantly greater weight gain among overweight DMPA users (~6.2kg)
compared with both 'normal' weight DMPA users (3.1kg) and overweight COC users
(3.4kg) at one year [299],
A Cochrane database systematic review (2011) evaluating the potential association
between progestin-only contraceptive use and changes in body weight has been
published this year (2011). It identified 15 studies (those meeting their inclusion criteria)
examining the effect of progestin-only contraceptives (POC) on weight [300]. Eleven of
the studies examined DMPA. The review found that only two of the eleven studies
showed differences in weight or body composition change for DMPA compared to no
hormonal method. One small study (n=33) by Bonny et al (2009) found that adolescents
using DMPA had a greater increase in body fat (%) versus a group using no hormonal
method (mean difference 11.00; 95%CI 2.65-19.36). The DMPA group also had a
greater decrease in lean body mass (%) (mean difference -4.00; 95%CI -6.93 to -1.07)
[301]. In the second study by Pantoja et al (2010) (n=758) [302,303] comparing DMPA
to copper intrauterine device (IUD), there was a small but significant difference in mean
weight change (kg) for all three years of the study (mean difference 2.28, 2.71, 3.17
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respectively). The remaining nine studies identified showed no significant weight change
with use of DMPA. Unfortunately the authors were unable to conduct a meta-analysis
due to the range of contraceptive methods examined and different reporting for weight
change.
The data, therefore, remains inconclusive. It suggests that responses are individualised,
and while weight gain is observed in a portion of patients, patients may also lose or
maintain weight.
Several factors are thought to influence the differences in weight change observed in
studies of hormonal contraceptives. These include demographics of the treatment
population (e.g. certain racial or ethnic groups such as African Americans are more
susceptible to weight gain), baseline BMI, metabolic differences between patients and
the normal gains associated with aging [304],
Considering the conflicting data, the current recommendation, by NICE, is to inform
women that DMPA may be associated with an increase of 2-3kg in weight over one year
and counsel appropriately [180],
Delayed return to fertility
Re-establishment of ovulation and menstruation after injection of DMPA is delayed and
difficult to predict. The delay is due to persistence of MPA in the circulation, because
microcrystals in the injected depot may sometimes dissolve very slowly. In a large US
study of women who discontinued DMPA use to try for pregnancy (response rate 61%),
68% of women who became pregnant conceived within twelve months, 83% within 15
months and 93% within 18 months of the last injection [282], This final pregnancy rate
at 18 months is within the normal reference range. The median time to conception for
those who do conceive is ten months after the last injection [282], There is no evidence
that DMPA causes permanent impairment of fertility [283].
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Benefits
Depo-Provera ® is an efficacious, safe and convenient method of contraception.
Additionally a number of non-contraceptive health benefits have been observed among
women who use DMPA.
Depo-Provera ® has demonstrated an 80% risk reduction for endometrial cancer, and
this may extend to beyond its duration of use [305],
A multi-centre hospital based case control study of 3619 women (910 cases and 2709
controls) found that DMPA use has a strong duration dependent protective effect against
uterine leiomyomas [306] and reduced the need for hysterectomy in women with uterine
leiomyomas [307], Cases were all newly diagnosed patients with pathologically proven
diagnoses of uterine leiomyomas, admitted to one of eight hospitals in three regions of
Thailand from January 1991 to June 1993. Each case was matched to three controls by
sex, age within five years and date of admission within three months [306],
The decreased frequency of menstrual cycles may in itself be protective against some
gynaecological malignancies such as ovarian cancer where the evidence base suggests
that frequent, repetitive ovulatory cycles may be associated with an increased risk
[95,308,309,310],
Case reports have described a reduction or total absence in painful crises in patients with
Sickle cell anaemia during treatment with DMPA [311,312] and also a reduction in
seizures in epileptic patients using DMPA [313], Data exists to indicate that DMPA has
intrinsic anticonvulsant activity [307,314,315],
Women with endometriosis have found DMPA to effectively relieve pelvic pain [316],
as have women post hysterectomy who have suffered pelvic pain and dyspareunia of
ovarian origin [307],
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The amenorrhea experienced by the majority of users is often seen as a benefit because it
improves conditions such as menorrhagia, dysmenorrhea and iron deficiency anaemia
[308,317,318,319]. This particular effect is particularly beneficial to those with
menstrual cycle related disorders, such as premenstrual syndrome or migraine headaches
[320,321], Amenorrheoa is also advantageous for mentally and physically handicapped
women who have difficulties with menstrual hygiene [322].
Additionally, progestogen-only contraceptives such as DMPA have been recommended




The actual cost of the injection itself is low (£5 per dose in the UK). On top of this
however is the cost of running the service that the woman attends to receive her
injection. The dosing schedule as mentioned requires attendance quarterly at a health
facility. In contrast, the WHO recommends that women using oral contraception need to
be seen by a health professional only once each year [324]. Cost data in 2005 found that
first year cost of DMPA® was £144 and subsequent years were £99/year (table 1). Thus,
although an inexpensive method of contraception per se, Depo-Provera® involves
increased costs to health services when compared with all other available methods
[222,325], It also creates greater cost and inconvenience for the user.









First year £144 Ingredient cost (DMPA®) £5.01 per dose
[219]
Following years £99 Initial GP consultation (first year), 20
mins
£44.80
3 year cost £342 Consultation for injection every 12
weeks, 8 min
£17.92
5 year cost £540
8 year cost £837 Resource use based on GDG consensus; GP unit cost =
£2.24 per surgery/clinic minute [220]
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Use worldwide
With time Depo Provera® has become an increasingly popular option for hormonal
contraception among women. In 2007, worldwide, 3.7% of married women surveyed
were using injectables3/implant as their chosen method of contraception [223]. This is
projected to reach nearly 40 million by 2015 - more than double that in 1995 [237,326],
The use of DMPA® varies globally. In developing countries the prevalence of
injectable/implant use in 2007 was 4.2% [223]. Data from Demographic and Health
Surveys undertaken in 46 developing countries were reviewed, in 2009, by Family
Health International. Levels of contraceptive use varied substantially among countries
with the vast majority documenting relatively low levels of injectable use among married
women of reproductive age (MWRA) [327]. 24 countries reported prevalence rates of
injectable use among MWRA to be less than 5%. Despite these low usage rates, in ten of
these countries injectable use accounts for between 23% and 46% of modern method
use. Three of the 46 countries, Indonesia, Namibia and South Africa supported much
higher use with more than one in five MWRA using injectable contraception in each
country (28%, 22% and 28% respectively). In these countries, injectable use accounted
for between 41 and 49% of modern method use. In the remaining 19 countries, the
prevalence of injectable use ranged from 18% in Malawi to 5% in Ghana [327]. In Sub-
saharan Africa, injectables are the most popular contraceptive method chosen by more
than one out of every three women using modern contraception [328].
Recent data often refers to injectables. Injectables comprise DMPA, Norethisterone enanthat (NET-EN) and Lunelle. The first two
are progestin-only contraceptives and the latter is a combined oestrogen/progesterone contraceptive. DMPA is the most widely used
injectable. Thus where data refers to injectables it includes use ofall three methods. Where data is available for DMPA alone 1 have
noted that. Additionally data tends to combine results for injectable use and implant use hence the use of injectable/implant..
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In contrast, DMPA is used by only a small minority of women in more developed
countries (1.3%) [223]. According to the National Survey of Family Life and Growth
(2010), only 3% of women in the United States in 2006-8 were using DMPA [329].
Even in the United Kingdom where use is the highest among the more developed
countries [223], whilst 9% of 25-29 year olds were using DMPA in 2008/9, for women
aged 16-49 the figures were identical to the US with only 3% using DMPA [224].
Reasons for discounting/discontinuing DMPA
The percentage of women who have discontinued injectable use by the end of the first
year has been estimated by Trussed et al (1999) to be 30% [330], While consideration of
long-term safety may be a part of the reason why DMPA is not as popular with women
as other methods, women are often more concerned about the relatively immediate
effects of contraceptives such as potential changes in menstrual cycle, body weight and
mood. These concerns can lead to a reluctance to start treatment or to discontinue it
prematurely [331,332] and may partly explain why uptake is low in some countries of
the world.
Menstrual irregularity
Menstrual disturbances are the major reason for discontinuation of DMPA
[331,333,334,335,336,337], A telephone survey by Skeggs et al (1997), of 1,864 New
Zealand women, that included 252 DMPA users, found that menstrual disturbances were
cited by 20% as the reason for discontinuation. These changes were equally distributed
between irregular bleeding (6.8%), heavy bleeding (6.8%) and amenorrhea (6.8%) [336].
In a one year American study of 402, new DMPA users, by Davidson et al (1997), those
who continued and those who discontinued reported similar menstrual changes [337],
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However, perception of what menstrual changes constitute a side effect are changing and
a number of more recent surveys have found that many women would prefer a
contraceptive option associated with less frequent or no menses [338,339,340].
Weight gain
Another frequently given reason for discontinuation is weight gain. The telephone
survey of 252 DMPA users, mentioned above, found that 12% (n=37) of women cited
weight gain as their reason for discontinuation [336].
Women of all ages are concerned with weight gain. This is with good reason. Thirty
years ago international nutritionists were focussed on childhood malnutrition. Today the
WHO finds itself needing to deal with the new pandemic of obesity and its
accompanying non-communicable diseases (NCDs) while the challenge of childhood
malnutrition has far from disappeared [341], Thus it is not surprising that weight gain is
often cited by women as the reason for discontinuing hormonal contraception. However,
as discussed earlier, the evidence is conflicting as to whether DMPA causes weight gain
when compared to non-hormonal contraceptives.
Mood changes
Another common concern reported by many women is the effect on mood. The majority
of published reports indicate that DMPA does not cause depressive symptoms
[342,343,344,345,346], Only one population based study, Civic et al (2000), of women
enrolled in a health maintenance organisation (HMO) reported an association between
DMPA and depressive symptoms but could not establish a causal relationship [347],
Needle phobia
A potential deterrent specific to DMPA is that it is administered via an injection. Needle
phobia affects at least 10% of the population [348]. While no research exists on uptake
of DMPA by needle phobics, research has shown that a fear of injections can interfere
105
with uptake of travel vaccines and also initiation of insulin therapy in diabetics
[349,350,351]. Parallel conclusions could therefore be drawn for DMPA.
Improving choice and use of DMPA
Depo-Provera ® is an efficacious, safe and convenient method of contraception. The
reasons for its appeal are multiple as described above. However, as stated, the use of
DMPA has been dogged by controversy about its safety from its start.
Originally the concerns were about cancer and then effects on bone mineral density
which led to black box labelling by the FDA in 2004 in the States [274], Research into
these areas has been reassuring with regard to its safety [247,248,274,276].
More recently the reasons for, not choosing to use or, discontinuing DMPA have been
concerns surrounding weight gain and menstrual disturbance. The concerns surrounding
weight gain appear to be unfounded [300] though meta-analysis of studies is still
outstanding and menstrual irregularity, though troublesome is often temporary and can
often be improved by short courses of oestrogen or shorter injection intervals [352] or
tolerated in the short term if appropriately counselled [79],
Currently concerns surround the potential effects of hormonal contraception on HIV-1
acquisition, progression and transmission, and the WHO are convening a Technical
Consultation in January 2012 to re-examine the evidence [281].
To improve use of DMPA, as discussed previously in chapter 1, three strategies have
been identified: improve counselling; develop methods which require a low level of
compliant behaviour by the user and improve the quality of life of users by minimising
the negative side-effects and maximising non contraceptive benefits [79].
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Counselling
As surmised by Bigrigg et al (1999), perhaps the most important issue surrounding the
use of DMPA is that of patient information [352], The method has had a particularly bad
image, which naturally makes potential users anxious and subject to misinformation
from poorly informed or biased sources [352,353]. A study by Glasier et al (2007), in the
UK, exploring the changes in prescribing by health professionals in response to the black
box labelling of DMPA, revealed that there is a need to provide clear, balanced
information on new findings about adverse effects of contraceptives as otherwise it risks
increasing rates of unintended pregnancy [353], Additionally it has been found that
users are more tolerant of side-effects and specifically menstrual irregularity if
counselled appropriately prior to commencing DMPA [354],
Develop methods which require low user compliance
DMPA is instantly effective and only requires to be administered every three months. It
is considered a long-term reversible contraceptive and as such fits the criteria for being a
method requiring low compliance. If it were possible to attend less frequently for
administration then this would likely further increase continuation rates.
Minimise side-effects and maximise benefits
The need to visit a health professional four times a year is considered by some as an
inconvenience and hence a side-effect. It has also been found that decreasing the need to
attend a health professional is linked to reducing unintended pregnancy [355], A study
by Foster et al (2011) explored how the number of packages of oral contraceptive pills
dispensed related to subsequent pregnancies. They found that women who received a
one-year supply of pills were less likely to have an unintended pregnancy (1.2% vs 3.3%
of women receiving only three packets of OCP and 2.9% of women receiving only one
packet of OCP). They also found a 46% reduction in the odds of an abortion (95% CI
0.32 - 0.93), controlling for age, race, and previous pill use. They concluded that making
OCP more accessible may reduce the incidence of unintended pregnancy [355], Thus in
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keeping with this if it were possible for DMPA users to attend health services less
frequently then it is likely that DMPA would potentially be more attractive to
prospective users as well as current users.
In response to this a new delivery system with a new formulation of DMPA has been
developed. Subcutaneous DMPA has the potential for self-administration and thus the
potential for reducing visits to a health professional to annually.
Subcutaneous Depo-Provera® (DMPA-SC)
Formulation and administration
With hormonal contraception, the goal is to provide high contraceptive efficacy while
using the lowest possible steroidal dose. This has resulted in progressive lowering of the
standard content of oral contraceptives since they became available. A new micronised
preparation of DMPA has recently been developed [356] and is now licensed for use in
the UK. It is pharmacologically unique. A dose of 104 mg in 0.65ml of aqueous
microcrystalline suspension (16% weight/volume) [357] is administered subcutaneously
into the anterior thigh or abdomen every twelve weeks. The slower rate of absorption
observed with DMPA-SC relative to the IM formulation allows for a lower peak serum
medroxyprogesterone (MPA) concentration and a long duration of effect [357]
Efficacy and safety
DMPA-SC provides efficacy, safety and immediacy of onset equivalent to Depo-Provera
® intramuscular (IM) injection. Two large, open-label, Phase 3 studies assessed the one
year contraceptive efficacy and safety with DMPA-SC administered every three months
[356]. No pregnancies were reported in either study, which included a total of 16,023
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woman-cycles of exposure to DMPA-SC and substantial numbers of overweight or
obese women. The safety profile was found to be similar to that reported with Depo-
Provera [356]. Because the 104 mg dose was chosen on the basis of studies in Caucasian
women [357], there was concern that this dose may have variable efficacy in women of
other racial groups, particularly Asian women (WHO). A single-centre, single-dose
open-label study was performed, by Toh et al (2004), in Singapore in Asian women aged
between 16 and 40 years. DMPA-SC was found to provide effective suppression of
ovulation for at least 91 days in Asian women providing reassurance that ethnicity has
no effect on the medroxyprogesterone acetate profile [358].
Side-effects
Two large phase 3 open label non-comparator multi-centre contraceptive trials have
detailed that the majority of women experienced a change in menstrual pattern with
DMPA-SC such as irregular spotting or bleeding, prolonged spotting or bleeding, and
heavy bleeding during the first month following the first injection [356], As women
continued to use DMPA-SC, fewer experienced irregular bleeding and more experienced
amenorrhea. By month six 38% ofwomen were amenorrhoeic and this increased to 55%
by month 12 [356], Analysis of data from three studies by Arias et al (2006) found rates
of amenorrhoea to be (52-64% across studies) at month 12 and 71% at 24 months [359].
These rates are comparable to those originally reported for DMPA-IM. Changes in
bleeding pattern showed no consistent difference according to age or BMI but did
indicate that incidence of amenorrhoea increases over time [359,360],
Similar to DMPA intramuscular the median time to ovulation was thirty weeks after the
last injection and the cumulative rate of return to ovulation at 12 months was 97.4%
[361],
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A side effect encountered with the new preparation was that of injection site reactions. In
five clinical studies carried out by Pfizer Inc. involving 2,325 women (282 treated for up
to six months, 1,780 treated for up to one year and 263 treated for up to two years), 5%
of women reported injection site reactions, and 1% had persistent skin changes,
described as small areas of induration or atrophy [357].
The remainder of the side-effect profile is identical to that of the intramuscular
formulation [356,362],
Additional benefits
DMPA-SC is licensed for management of endometriosis-associated pain. A multi-centre,
evaluator-blinded, comparator-controlled trial, by Crosignani et al (2006), has
demonstrated a reduction in endometriosis-associated pain in women with signs and
symptoms of endometriosis [363]. The study randomised 300 women with
laparoscopically diagnosed endometriosis to one of three treatment options; three
monthly DMPA-SC, monthly leupromide (3.75mg) or three monthly leupromide
(11.25mg). Each study assessed reduction in endometriosis-associated pain over six
months of treatment and recurrence of symptoms for 12 months post-treatment. It also
assessed changes in bone mineral density and productivity at six and 18 months. DMPA-
SC was found to reduce endometriosis-associated pain as effectively as leupromide and
improved productivity while causing significantly less decline in BMD [363,364],
Another benefit of DMPA-SC is that it can be self-administered, thus enabling DMPA-
SC to be more competitively aligned with Implanon® and Mirena® in terms of cost-
effectiveness. Self-administration also allows for greater convenience to the user.
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Economics
As mentioned just above subcutaneous depo-provera can be self-administered.
The cost of the injection is low. If women are happy to self-administer then once trained
at delivering her own injection a woman need only attend a health professional once a
year rather than the four episodes of contact required with DMPA-IM. This then allows
for DMPA-SC to be more cost-effective than DMPA-IM users and to be more
competitively aligned with Implanon® and Mirena® in terms of cost-effectiveness.
Objective
• Assess whether adapting the injectable contraceptive, Depo-Provera® to a form
where self-administration is feasible would increase acceptability and improve
uptake
In anticipation of DMPA-SC becoming available in the UK, we undertook two
questionnaire surveys (Appendices 1 and 2) to determine whether women currently
using Depo-Provera® would want to self-administer, and whether the opportunity to do
so would make DMPA a more attractive method to women who are not currently using
it.
The surveys also allowed us to investigate reasons for not choosing to use DMPA or for
discontinuing DMPA. It also gave an opportunity to ask discontinuers of the
intramuscular method whether they would be interested in the subcutaneous formulation
and to then research this further.
Subjects and methods
During December 2003, a self-administered questionnaire (Appendix A/Questionnaire 1)
was offered to women attending a large family planning clinic in Edinburgh for repeat
DMPA injection. The questionnaire was attached to every packet of DMPA, thus
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ensuring that it was offered to everyone. Women were asked if, after appropriate
instruction, they would be interested in giving themselves the 3 monthly injections. If
they responded positively, they were asked whether, and how, they would prefer to be
reminded of the date when their injection was due. Women who were not interested in
self-administering Depo-Provera® were asked to choose one or more reason, from a list
of possible reasons, why they would not want to self-administer.
For 2 weeks during the spring of 2004, a second self-administered questionnaire was
offered to every woman attending the same Edinburgh family planning clinic (Appendix
B/Questionnaire 2). Women were asked about current and ever use of all available
methods of contraception. Those who had used but discontinued DMPA in the past were
asked to choose from a list their reasons for discontinuation. Women who had never
used it, but had considered it, were also asked to choose from a similar list what had
deterred them from trying it.
All women were asked whether the opportunity to self-administer Depo-Provera®, and
thereby to attend clinics only once a year, would make them reconsider using the
method.
Data from the two questionnaires were entered into a SPSS dataset and descriptive
analysis was carried out.
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Results
One-hundred seventy-six women currently using Depo-Provera® completed
Questionnaire 1. The response rate was 100%. Sixty-seven percent of women (118) said
they would like to self-administer DMPA. Of these, 89% felt that they would need
reminding of the date of injection. Thirty-three percent of women felt that being told the
dates for the next three injections at the time of their annual review would suffice; 30%
of them preferred to receive a reminder letter, and 25% a text message, just prior to the
date of the next injection.
Of the 58 women (33%) who did not wish to self-administer DMPA, the most common
reason was a dislike or fear of needles (62%), 43% were concerned that they would
administer the contraceptive incorrectly, while 33% felt it was important to see a doctor
every 3 months. Twelve percent of women were disinclined to self-administer because
they were worried that they might forget.
Three-hundred seventy copies of Questionnaire 2 were distributed and 323 were returned
completed (87%). The main method of contraception being used by the women who
completed Questionnaire 2 is shown in Table 2. Ten women were using Depo-Provera®
and seven of them (70%) expressed an interest in self-administration. Two hundred
sixty-five women had never used Depo-Provera®; their reasons for not choosing the
method are shown in Table 3. One hundred sixty-five of them answered the question
about self-administration. Sixty-one percent said they would prefer to attend the clinic
less often for supplies of contraception. Twenty-six percent (43 women) said they would
seriously consider using Depo-Provera® if self-administration was possible.
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Table 2: Primary contraceptive method used by women at time of completing
Questionnaire 2
Primary method of contraception Number of respondents %
(n=323) Respondents
Combined oral contraceptive pill 142a 44
Barrier methods 63 20
Intrauterine system/ intrauterine 34 11
device
Progesterone-only pill 24b 7
Contraceptive implant 20 6
Depo-Provera® (DMPA) 10 3
No method 8 2
Withdrawal 7C 2
Natural family planning 5d 1
Vasectomy/sterilisation 3 1
Other 4 1
No response 3 1
a. 20 of the 142 women were using barrier protection as well
b. 2 of the 24 women were using barrier protection as well
c. 3 of the 7 women were using barrier protection as well intermittently
d. 2 of the 5 women were using barrier protection as well intermittently
Note: 27 women in total used barrier protection as well as another method of contraception.
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Change in bleeding pattern:
Irregular 40 26
Amenorrhoea 19 30
Weight gain 35 41
Mood swings 27 QNA*
Headaches 10 QNA*
12 weekly visits 10 11
Painful injection/ fear of needles 6 20
Wish for return of fertility/ not
wanting a delay in resumption of
fertility
6 20
Not being able to stop the
contraception immediately
QNA* 23
Adverse opinions from friends/ family QNA* 19
* QNA = question not asked
Forty-eight women (15%) had used DMPA in the past but had discontinued the method
for reasons shown in Table 2. Thirty-four of 44 women (77%) who answered were
interested in a method which allowed them to reduce the number of times they attended
a clinic for contraception. Eighteen of 45 women (40%) who answered the relevant




Depo-Provera® is an important method of contraception. Anecdote suggests that in the
United Kingdom it is increasingly popular among young women and among women of
all ages who like the convenience of amenorrhea. In the United States, the fall in teenage
pregnancy rates has been attributed to increased use of Depo-Provera® [100], The need
to attend a health professional every 3 months simply for a single injection is a clear
disadvantage of the method.
In our survey, two out of three women currently using Depo-Provera® expressed a
theoretical interest in self-administration. It is, of course, very likely that a number of
them, when offered the real option of self-administration would not take up the offer,
and that more would find that they were unable or unwilling to give themselves an
injection when the time came for it. Self-injected medication is the norm for diabetics
and for some people with migraine or arthritis or undergoing infertility treatment. In
most cases, the injections are self-administered daily or at least twice weekly. It is
possible that women would never gain sufficient practice to become confident in self-
administering an injection only four times each year. In a trial of self-administration of
the once/monthly combined injectable contraceptive undertaken in Brazil, 14% refused
to participate at the onset and another 31% declined after being trained to self-administer
using oranges [365], At the end of the study (three injections in total), more than 80% of
women had been successful in giving their own injections and only 50% expressed a
preference to continue self-administration. Just how many women, who in our survey
said they would like to self-administer Depo-Provera®, would do so in reality is the
subject of a future study.
It is highly likely that many health care professionals would be skeptical about women's
ability to self-administer Depo-Provera® and, particularly, to do so at the correct time.
Presently, if an injection is more than 2 weeks late, it is recommended that the next
injection is withheld until pregnancy can be reasonably excluded [324], If women were
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given their own injections, it is possible that there would be a greater chance that an
injection would be given late and possibly given when conception had already occurred.
In our clinic, we do not currently send reminders to women using DMPA but simply
inform them when they attend for their injection, when the next one is due. All are
clearly informed when they start to use the method, that the injection interval is 12
weeks. Since we do not presently remind them to attend the clinic for their injection,
only the desire to avoid late injection when pregnancy had already occurred should
stimulate us to have a system in place to remind them to self-inject. In a randomized trial
designed to test whether an intensive reminder system would improve compliance
among 250 women using Depo-Provera® in the United States [366], intensive reminders
did not improve continuation rates. Women receiving either mailed or telephone
reminders were no less likely to return to the clinic on time than women given an
appointment at the time of the first injection. One could argue that the need to make
arrangements (including travel, and possibly taking time off work) to attend a clinic for
injections would, in fact, be more likely to lead to mistimed injections compared with the
ease of having the drug at home.
We were somewhat surprised that the ability to self-administer the injection, and thereby
enable women to reduce the number of clinic visits, might increase the acceptability of
Depo-Provera®, both to women who have never used it and to those who have tried but
discontinued the method. It is likely, however, that this is an overestimate since the
reasons for discontinuation of DMPA generally related to the side effects (Table 3) and
not to the need to attend a health professional four times each year.
In conclusion, the advent of a form of Depo-Provera® which would allow women to
self-administer is likely to be a benefit to perhaps as many as half of the women
choosing this method. Our survey also suggests that use of injectable contraception may
increase were self-administration possible. We have discussed the concept in our clinic
and suggest that women who express a wish to self-administer Depo-Provera® should be
given the appropriate training allowing an annual clinic visit with three injections
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supplied for home use. The success of such a scheme, and the health economics
involved, will need to be tested scientifically.
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Appendix A. Questionnaire 1
The jag at home!!!
Imagine — no more visits to the doctors every 11 weeks for your jag! Just once a year!!
Interested? Keep on reading.
Soon the Depo-Provera injection will be available for you to give to yourself.
It is safe, easy and less painful.
Unlike today when it has to go deep into your muscle, the new way will be to inject it just
under the skin (similarly to what diabetics do 3 times every day). We would supervise
you the first time and if you were happy, you could take 3 injections home with you.
Your next routine appointment would be a year later—just like women on the pill!!
Please answer the following 2 questions.
Your answers are strictly confidential and anonymous.
1. Would you want to give yourself your injection?
Yes (please go to question 2)
No (please go to question 3)
2. How would you want to be reminded that it was time for your next injection? (Please
pick ONE only)
Do not want any reminders Letter
Told the next 3 dates in advance when I attended Phonecall
Text message Email
3. Why not?
Worried about giving it correctly
Prefer to see the doctor every 11 weeks
Would forget
Just do not want to give it to myself
Other reason— please tell us
Thank you for completing the questionnaire. Please hand it back to reception.
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Appendix B. Questionnaire 2
Depo-provera contraception
- your views on a new version that can be administered at home
Depo-provera ('the jag') is a form of hormonal contraception that presently is administered 3-monthly by
intra-muacular injection. This has to be given by a doctor or nurse, and so requires a visit to the health
centre or family planning clinic.
It is hoped that in the near future, a new form of depo-provera injection will be available that involves an
injection just under the skin (similar to the injection that diabetics give themselves) instead of the current
form which is injected into the thigh muscle The first injection would be supervised, and if you were happy
about it you would take the next 3 injections home with you
We are carrying out this survey to find out what women who are not currently using depo-provera think
of this development, Your answers are strictly confidential and it would be appreciated if you would answer
the questions below by ticking the boxes beside the most appropriate answers. Many thanks
Q1. What method of contraception are you currently using?
I 1 combined oral contraceptive pill jZ) progesterone only pill
1 I condoms(male/female) Q contraceptive implant (e g Implanon)
I IIUD / IUS (coil) Q natural family planning / rtiyihmn method
□ diaphragm / cap □ withdrawal
[ |other (please specify)
Q2. Have you ever used the 3-monthly depot injections?
yesQ [3 no
please go to Q3 ^ ^ please go to Q4
Q3. What was/were you reason/s for stopping
f | painful injection
11 having to visit doctor/clinic every 3 months
1 1 weight gain
1 1 mood swings
f~lheadaches
1 1 wishing to return to fertility/ get pregnant
I I irregular bleeding
I 1 absent periods
I 1 other (please specify)
Q6 Would you regard it an advantage if you
could reduce the number of visits to your
doctor/ clinic for contraception?
yesO Ono
Q7. Would you consider depo-provera if you
were able to give the injection to yourself?
yesD 00
it? Q4. Have you ever considered using depot as a
contraceptive method?
yeSd (please go to OS and Q7)
please go to Q5 4*
QS What was/were you reason/s for not using it?
□ fear of noodles/ injections
□ fear ofweight gain
ZD having to attend the doctor/clinic every
3 months for the injection
ZD fear of irregular bleeding
!_J prefer to have a period every month
Z delay in return to fertility
1 1 not being able to stop the contraception
straight away (it is with you for 3 months)
□ fnends/relatives have put me off the idea
Q other (please specify
Please seal your completed questionnaire in
the envelope provideo and hano it inat
reception. Thank you.
»Tiiiy Planning and Well Woman Services. Dean Terrace. Edirouron. EH4 1NL
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Chapter 5: Development of novel methods of
contraception - The case of mifepristone
Background
Investment in longer term work is needed to discover and develop new methods of
contraception that do not cause systemic side-effects, can be used on demand, and do not
require partner participation or knowledge [7,81]. Fifty years have passed since the first
clinical trials in Puerto Rico demonstrated that a daily pill containing ethinyl estradiol
and norethynodrel was a highly effective contraceptive [367], Since the introduction of
the combined oral contraceptive pill advances in hormonal contraception to date have
been limited to variations on the theme of oestrogen in combination with progestogen or
progestogen alone [6,368]. Alterations to pill formulations, new progestogens and new
delivery systems have increased choice, and some of these have been explored in earlier
chapters [231,369], However, as demonstrated, whilst these advances have improved
acceptability, side-effects and risks have remained essentially unchanged and women
continue to dislike or discontinue methods, often moving to less effective methods or no
method [231,353,369,370,371,372,373], Oestrogen free methods have the advantage of
fewer serious risks such as breast cancer or venous thromboembolism but are associated
with unpredictable vaginal bleeding. Unpredictable vaginal bleeding is often cited as the
commonest reason for discontinuation [214,373,374,375,376,377,378], Even the regular
pattern of bleeding characteristic of the combined pill is considered undesirable by some
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women [95]. When oral contraceptives were first marketed it was assumed that women
would prefer to have a monthly cycle because it would be perceived as more natural
[379], More recently, it has been shown that many women, regardless of age, prefer to
have either predictable bleeding less often than once a month or not to bleed at all
[93,94,95]. Hence a novel oestrogen-free pill that does not cause irregular vaginal
bleeding and reproducibly induces amenorrhoea in a high proportion of women should
prove popular. Antiprogesterones offer the possibility of such a new method of
contraception.
Definition of anti-progesterones
Anti-progesterones are compounds that bind with high affinity to progesterone receptors
(PR) but which antagonise the action of endogenous progesterone [380],
Basis for exploration
Since progesterone is essential for the establishment and maintenance of pregnancy, it




Mifepristone (RU486) is a synthetic C-19 steroid which is a potent antagonist of both
progesterone and glucocorticoid hormones [381], It was first demonstrated to show both
contraceptive and abortifacient properties in the early 1980's [380,382,383,384,385].
Despite this, for many years there was little progress in developing its contraceptive
potential. This was not due to scientific reasons but related to the political and religious
controversy surrounding RU486, or as it has more commonly become known, 'the
abortion pill'. In the last ten years, however there has been a significant amount of
research undertaken into selective progesterone-receptor modulators (SPRM) and
specifically into their use for emergency contraception.
Structure of mifepristone
Mifepristone is a 19-norsteroid that lacks the C19-methyl group of natural progesterone
and glucocorticoids. Its chemical structure has two distinctive differences from the
steroidal skeleton, a 4-dimethylamino-phenyl group substituted at the 11 beta position,
and a 1-propynyl-chain substitution at the 17alpha position (figure 1). The 17alpha
substitution is responsible for promoting higher binding affinity to the progesterone
receptor and the substitution at the 11 beta position is likely to be responsible for
mifepristone's antagonistic action, by inducing or stabilising a biologically inert receptor
conformation [386], The chemical structures of other anti-progestins are similar to that
ofmifepristone.
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Figure 1: Structure of mifepristone
Mode of action
Previously it was thought that the mode of action for all anti-progestogens was similar
and that they were purely antagonists of progesterone [380]. However, we now know
that neither of these presuppositions is true. The antagonist receptor complex is not inert
and each antagonist induces a unique set of transcriptional events [387], Also, many
have both agonist and antagonist properties. The effect produced is dependent on the
hormonal environment and the relative proportion of progesterone receptor alpha (PRa)
and progesterone receptor beta (PRO) [387].
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Pharmacology and metabolism
Absorption is rapid (70%) through the gut, and peak levels (micromolar concentrations)
appear in the bloodstream within 1-2 hours post oral administration. First-pass
metabolism however, reduces bioavailability to 40% of the oral dose in humans [382],
The pharmacokinetics follow two distinctive patterns which are dependent on dose. With
doses lower than 50mg there is an open two-compartment model of pharmacokinetics
with a peak plasma concentration of approximately 1.9 micromol/1 at l-2h and a half-life
of over 27h. Serum drug concentrations increase progressively as dosage increases from
50mg to lOOmg, but no further proportional increases occur after lOOmg. At these higher
doses (>lOOmg) there is an initial redistribution phase of up to lOh followed by zero-
order kinetics up to >24 h [388]. There is no cumulative effect on plasma concentration
after repeated doses.
Metabolism of mifepristone is extensively by demethylation and hydroxylation leading
to three active metabolites, which are themselves biologically active. These can be
measured within an hour of oral intake and their plasma levels increase in a dose-
dependent manner [389]. They have a high relative binding affinity to progesterone
receptors (PR) and their long circulating half-life suggests a possible contribution to the
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overall antiprogesterone action of mifepristone [390,391]. The demethylated metabolites
are then further hydroxylated or acetylated [392],
Un-metabolised drug can be detected for up to 10 days after oral intake, and the higher
doses are associated with plasma levels in the micromolar range for over 2 days [393].
This relatively long half-life (20-25h) and the unusual metabolic pattern of mifepristone
in humans appear to be due to plasma orosomucoid binding sites at doses above 1 OOmg
[390], Plasma clearance rate ofmifepristone in humans is 0.02 1/h/kg body weight [394],
The major excretory path is faecal, with less than 10% being renally excreted [392,395].
Safety of mifepristone
Roussel Uclaf conducted a comprehensive toxicology program in the mid-1980's
demonstrating the safety of the molecule and allowing its use in humans [396].
Short-term administration ofmifepristone appears to be safe. A single dose is eliminated
within 6-7 days of administration [397], Administering 200mg daily to healthy male
volunteers leads to a hormonal ly antiglucocorticoid state and reversible Cortisol
overproduction, with preservation of pituitary and adrenocortical reserves, but no clinical
symptoms of peripheral Cortisol deprivation [398], A different study has shown that this
disinhibition of the pituitary-adrenal axis is only observed during the morning hours of
the circadian rhythm thus changing the time of administration may minimise any side-
effects [399], One study reported that mifepristone at high doses (lOmg/kg) taken daily
for a week induced a diffuse maculopapular erythematous cutaneous eruption within two
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weeks of discontinuation of the drug in the majority (73%) of the sample of healthy male
volunteers [400]. This resolved spontaneously and none of the volunteers had a raised
eosinophil count, thus not supporting the possibility of a drug hypersensitivity or
glucocorticoid deficiency. Additionally studies where even higher doses have been
administered for even longer periods have not reported similar complications [401].
Most novel indications (e.g. contraception) require though long term administration.
Mifepristone's antiglucocorticoid action has raised the issue of safety. Prolonged
administration of daily low dose is not associated with a cumulative increase in plasma
concentration of the drug [402] but at doses, above 200mg/day clearance reaches a
limiting value and this may produce elevated plasma levels over a long period of time
[397]. Chronic exposure to 200mg daily has been associated with symptoms of Cortisol
deprivation that were severe enough to be treated with concomitant prednisolone [403],
It was suggested that this may be due to mifepristone activating and resetting the
hypothalamo-pituitary-adrenal axis at a higher level [404], However, this has not been
replicated in other studies with similar doses taken for long durations [405], At high
dose, mifepristone has been linked to biochemical hypothyroidism and it has been
advised to monitor thyroid function at high doses [406], However, with very low doses
of 2-5 mg/day, it is very unlikely that changes in thyroid function would be observed.
In contrast to pills containing oestrogens and/or progestogens, there is no theoretical
risk that such a pill would increase the risk of breast cancer or cardiovascular disease.
Rather, experimental data show that antigestogens are antimitotic in breast cancer cell
lines and animal models and hence might actually reduce the risk of malignancy
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[407,408,409],
The main concern with prolonged intake is that of exposure to unopposed oestrogen and
the possibility of the endometrium undergoing hyperplastic or malignant changes [410],
However, studies in monkeys with mifepristone and other antogestogens have shown
evidence of endometrial atrophy rather than hyperplasia [411,412,413,414], It has been
demonstrated that much of the increase in endometrial thickness is associated with cystic
dilation of the endometrial glands and the cavity itself [415], A recent study by Eisenger
et al reported the results of a study in which 40 women with fibromyoma were given 5 or
lOmg mifepristone/day for up to 1 year [416], Simple hyperplasia of the endometrium
without atypia was seen after six months only in a minority of women (28%) who took
10 mg but none in 5mg [416], One of the secondary outcomes of the multicentre double-
blind randomised controlled trial we undertook [417] was to investigate the effect of
long term administration of daily mifepristone (5mg) on endometrial thickness and
histology.
Biological effects of mifepristone
As mentioned above, antiprogestogens bind with high affinity to PR and antagonise the
action of endogenous progesterone. Progesterone receptors are distributed widely
throughout the body. Their principal function however, is in the reproductive tract
(uterus and ovary) and also the hypothalamus and anterior pituitary. Thus mifepristone
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has multiple effects on the hypothalamic-pituitary-ovarian axis and on the ovarian cycle,
depending on the time of the cycle and the dose used.
Administration in the follicular phase
Progesterone is secreted in small amounts by the pre-ovulatory follicle and together with
oestrodiol, is responsible for initiating the luteinising hormone (LH) surge which is
characteristic of an ovulatory cycle [418], Progesterone is contradictory, in that, in small
amounts it enhances the ability of oestrogen to provoke an LH surge, whilst in large
quantities it inhibits the positive feedback of oestrogen [419]. Acting locally within the
follicle progesterone plays an important role in follicle rupture. Antigestogens have the
potential to block all of these events induced by progesterone and hence interfere with
ovulation.
During the early follicular phase, mifepristone (at a dose of 3mg/kg) causes a minimal
decrease in oestrodiol level, but otherwise has no effect on the menstrual cycle [420],
Given later in the follicular phase, mifepristone decreases oestrodiol and LH levels
causing arrest of folliculogenesis and inhibition or delay of ovulation [420,421,422],
This reduction in LH pulse amplitude suggests a pituitary site of action [422], The effect
of a one-off dose is to delay the LH surge and so post mifepristone dosage follicle
recruitment restarts and ovulation occurs after approximately 2 weeks [423,424],
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If however, mifepristone is administered daily at a dose of 2 or 5mg, it does not affect
the pulsatile pattern of LH secretion. Therefore the impairment of the oestrogen induced
surge is not due to an effect of mifepristone at the hypothalamic level, nor is it due to
decreased responsiveness of the pituitary to exogenous gonadatrophin releasing hormone
(GnRH). The conclusion is that at this dose (2 or 5mg) mifepristone interferes with the
mid-cycle LH surge by a complex mechanism, possibly by directly reducing the
sensitivity of pituitary gonadatrophin to the positive feedback effects of oestrogen [425],
It is important to note that if mifepristone is given post LH surge is initiated, it does not
appear to arrest ovulation [ 116,423,426,427]. Its effect is then as described below.
Administration in the luteal phase
Antigestogens also exert powerful effects on the uterus. In the luteal phase, under the
influence of progesterone the endometrium transforms from a proliferative to a secretory
state. When the corpus luteum collapses, progesterone withdraws and this leads to
menstrual bleeding.
Early luteal phase administration of either a single dose or multiple doses of
mifepristone disrupts endometrial maturation without affecting vaginal bleeding patterns
[428,429]. There is inhibition of progesterone induced down-regulation of PR and
oestrogen receptor (ER) [428,430,431], plus antagonism of the action of progesterone on
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endometrial markers such as prostaglandin dehydrogenase (PGDH), which are known to
be progesterone dependent [432,433], In addition, if 200mg mifepristone is administered
immediately after ovulation, uterine prostaglandin (PGF2alpha) release [434], the
luminal expression ofCOX-2 [435] and the glandular expression of leukaemia inhibitory
factor (LIF) (a cytokine involved in the implantation process) are significantly reduced,
while the immunoreactivity of Ki67 (a nuclear marker of cellular proliferation) is
increased [431], The reduction in the endometrial metabolism of oestrodiol [436] and the
reduction in the markers of endometrial maturation [428] suggest that antiprogestogens
given immediately after ovulation will delay or prevent formation of a secretory
endometrium, in which case it remains proliferative and hostile to implantation [429],
If given later in the luteal phase of the cycle, mifepristone at a single dose of >50mg will
induce breakdown of the endometrium and menstrual bleeding [424,437,438], The effect
of mifepristone on the endometrium (at a time when the levels of the endometrial
progesterone receptor are relatively low) are poorly understood and it may be that
mifepristone antagonises the action of progesterone, which at the time appears to involve
the suppression of release of prostaglandins [439], There is evidence available for a
similar action of mifepristone on local prostaglandin in early pregnancy, when it has
been reported to reduce the PG-metabolising enzyme PGDH [440],
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Administration throughout the menstrual cycle
If given as a daily pill, the threshold dose of mifepristone required to disrupt endometrial
development is lmg/day [441,442] and when given as a once weekly pill then 5mg is
sufficient to inhibit normal secretory development of the endometrium [443,444], The
endometrial histology is variable. It ranges from atrophic changes to cysts lined by a
single layer of atrophic epithelium with very few mitotic cells [445], These changes are
probably due to the antiproliferative effect of mifepristone and suggestive of a low risk
of atypical hyperplasia in the long-term. As a result of the absence of ovulation and the
inactive endometrium most women experience amenorrhoea.
Contraceptive potential of mifepristone
Research has concentrated on four areas [446]; as a daily contraceptive pill; as a weekly
contraceptive pill; as a once-a-month contraceptive pill and as post-coital emergency
contraception.
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Inhibition of ovulation - potential as a daily contraceptive pill
Brown et al (2002) [447,448] undertook a double blind randomised control trial of 98
women (58 Edinburgh, 40 Shanghai) who took mifepristone 2 or 5mg daily for 120 days
[415,449], Ninety women completed the study (50 Edinburgh, 40 Shanghai). Follicular
activity (and therefore oestrogen secretion) continued during treatment with both doses
although ovulation was suppressed in the majority of the cycles (90% of 2mg cycles and
95% of 5mg cycles). The majority of women experienced amenorrhoea (65% of women
taking 2mg and 88% of those taking 5mg). Endometrial thickness increased significantly
in women in Edinburgh and decreased in those in Shanghai; histology showed either
atrophic or cystic changes with no evidence of hyperplasia. There were no pregnancies
reported in the 200 months of exposure in 50 sexually active women who had used no
other method of contraception [449], There has only been one other study assessing the
contraceptive efficacy of mifepristone [450], In that study 32 women used 0.5mg
mifepristone daily. Sixteen completed six months of use. In 141 cycles, there were five
pregnancies [450].
The findings from these preliminary studies do suggest that mifepristone in low daily
dose has the potential to be developed as a novel oestrogen-free daily oral contraceptive
pill. The findings have to be further confirmed in larger studies and that is one of the
remits of the multicentre double-blind randomised controlled trial we undertook [417].
This study and its findings are detailed below.
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Disruption of follicular development - potential as a once-a-week pill
High doses of 50mg, 25mg and 1 Omg are associated with variable inhibition of ovulation
[386,451] while small doses of 5mg and 2.5mg do not affect ovulation, the hormonal
profde or the menstrual cycle [444]. All doses have resulted in delayed endometrial
maturation and impaired secretory activity of the endometrium. The efficacy of the once-
weekly regime has been tested in two studies. The first study by Marions et al involved
18 women taking 5mg mifepristone weekly [452], In over 63 cycles, three pregnancies
occurred. In the second study, by Godfrey et al (2004), 17 women took lOmg
mifepristone weekly [453], In 56 cycles, three pregnancies occurred. Considering these
were trials the failure rate can be considered as close to that of perfect use. With the
combined oral contraceptive pill failure rate for perfect use is 1/12,000 cycles [74] and in
these studies the rate is 4.7/100 cycles and 5.3/100 cycles. In view of these data, weekly
administration has been abandoned as a potential contraceptive method.
Inhibition of implantation - potential as a once-a-month pill
The effect of giving 200 mg mifepristone in the early luteal phase of the cycle 2 days
after the mid-cycle LH surge has been tested in two small pilot studies [454,455] and one
evaluation [456]. All three have found contraceptive efficacy to be high. Post pilot
studies the main concerns with this once-a-month approach were regarding determining
the correct timing of administration as if given at the incorrect time then there is an
unpredictable disturbance in the pattern of menstrual bleeding [429]. This then makes it
very difficult for the women to time the taking of mifepristone in subsequent cycles. The
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feasibility of such an approach has been tested [454]. Women were required to use a
daily fertility monitor to predict and identify the day of onset of the LH surge. On
average women failed to perform 24% of tests in the 162 cycles analysed during the
period of high fertility. Study volunteers are generally considered a highly motivated
group and hence it is unlikely that women in the general population would have a greater
compliance rate. Consequently, at the time of initiating our research into the efficacy of
daily mifepristone, the once-a-month approach was not considered practicable until a
simpler method of determining time of administration could be developed.
However, Brown et al (2003) tried a different approach and found that mifepristone
could be given, pre-ovulation, as a once-a-month contraceptive pill without causing
significant disruption in the menstrual cycle in the majority of women for a four day
period from just prior to ovulation until LH plus 3 [457]. Subsequently, Agarwal and
colleagues (2009) have undertaken a prospective case-control study where 80 women
took 200mg mifepristone orally once a month on day 16 of a regular menstrual cycle of
28-30 days. They found that mifepristone can act as an effective monthly contraceptive
pill, given on a fixed day in the mid-cycle without detecting LH surge in women having
regular menstrual cycles [456].
Disruption of implantation or 'menstrual induction' - potential as a once-a-
month pill
Administration of mifepristone in the late luteal phase of the cycle even in doses as low
as lOmg will induce menstrual bleeding [458]. This will occur even in the presence of
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exogenous human chorionic gonadatrophin [439], This would suggest that
administration of mifepristone in the late luteal phase would disrupt implantation and
prevent pregnancy. However, although bleeding is almost always provoked in very early
pregnancy by antigestogens, studies have reported an unacceptably high pregnancy rate
for this regimen to be considered feasible [459,460,461]. It is unclear as to why the
failure rate at this stage of pregnancy is higher than that observed when abortion is
induced within 10 days of a missed period [462],
Potential for use as postcoital emergency contraception
Mifepristone has all the pharmacological properties to make it a highly effective post¬
coital contraception [463]. Multicentre trials have confirmed mifepristone to be an
effective emergency contraception (EC) method even in doses as low as lOmg
[34,35,36,37][464]. Studies have proven mifepristone to be as efficacious as
levonorgestrel for emergency contraception [465,466], Side-effects have been found to
be independent of dose but menstrual delay is significantly less likely with the lOmg
dose [467]. The mode of action ofmifepristone varies with when in the cycle it is taken.
If given before ovulation it prevents it, if given after ovulation the effect on the
endometrium is highly suggestive of impaired implantation [383,468]. Currently
Mifepristone has been licensed and is available for use as emergency contraception in
two countries - China (Bi Yum lOmg dose) and Vietnam (Ciel 25mg dose) [469],
In summary: Mifepristone is an effective method of emergency contraception and has
the potential to be developed as a once daily pill for regular contraceptive use as well as
a once-a-month pill if administration at the correct time can be guaranteed.
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Potential additional benefits offered
Amenorrhoea
Previous studies have demonstrated that mifepristone at low dose disrupts the menstrual
cycle. One study using lmg per day for duration of 150 days demonstrated that more
than half the women showed irregular bleeding or amenorrhoea [470]. Brown et al
(2002), as described earlier, studied the effects of 2mg and 5mg doses on menstrual
bleeding pattern. The study was undertaken in two centres: Edinburgh and Shanghai. In
Edinburgh, 17/26 women (65%) of those receiving 2mg daily were amenorrhoeic, as
were 21/24 (88%) of those receiving 5mg. The mean days of bleeding were 4.4 days and
0.6 days for the 2 and 5mg groups respectively. In Shanghai, 18/20 women (90%) in
both dose groups were amenorrhoiec during treatment, with mean days of bleeding of
0.4 and 0.7 respectively [415,447].
In the first study presented below, therefore, the efficacy, pattern of bleeding and other
side-effects of mifepristone at a dose of 5mg/day taken for 24 weeks were directly
compared with the progestogen-only-pill (POP), levonorgestrel [417], We hypothesized
that women given mifepristone would have a much higher incidence of amenorrhoea and
fewer days ofmenstrual bleeding.
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Protection against sexually transmitted infections and HIV
The HIV epidemic continues to be a major global public health challenge [471],
Heterosexual intercourse is now the main route of transmission of HIV. While barrier
methods such as condoms reduce the risk of transmission, there is a pressing need for
additional and complementary methods of protection [6].
The vagina is thought to be a key portal of entry for HIV and other sexually transmitted
infections (STI) in women [472], The underlying mechanisms are poorly understood.
Experiments on hysterectomized rhesus monkeys suggest that it is the vagina, rather than
the cervix or the uterus, that is the main portal of viral entry [473,474]. Epithelial
thickness and integrity modulates the ease of access of virus to immune cells and
subepithelial vasculature [475], Oestrogen-induced surface keratinisation and
hyperplasia protect rhesus monkeys against SIV inoculation [476,477], whereas
oestrogen-deficient women such as those who are post-menopausal [478,479] or on long
acting gestagens are at increased risk of HIV, presumably as a result of vaginal thinning.
Other biological variables such as the vaginal microflora [480,481,482], immune cell
populations [483,484] and natural antimicrobials also play an important role in the innate
defences of the reproductive tract [485,486,487].
Mifepristone, a potent antagonist of progesterone, has the potential to be developed for
contraception and other gynaecological uses [448,488,489]. Daily low-dose mifepristone
inhibits ovulation but maintains follicular development, thus exposing reproductive
tissues to unopposed oestrogen. Since gestagen treatment, in macaques, increases and
oestrogen treatment decreases HIV/SIV transmission the aim of the second study
detailed below was to investigate whether, the antigestagen, mifepristone modulates




A pill which contains no oestrogen and which reproducibly induces amenorrhoea in a
high proportion of women should prove popular. In further exploring this the efficacy,
pattern of bleeding and other side-effects of mifepristone at a dose of 5mg/day taken for
24 weeks were directly compared with the progestogen-only-pill (POP), levonorgestrel
[417]. We hypothesized that women given mifepristone would have a much higher
incidence of amenorrhoea and fewer days of menstrual bleeding.
Materials and Methods
This was a multicentre, double-blind, randomized controlled phase II trial comparing
two daily contraceptive pills. The primary outcome was the percentage of women who
had amenorrhoea throughout the study. Secondary outcomes included number of days
of bleeding, endometrial thickness and histology, and number of pregnancies. Before
starting, the trial was approved by the steering committee of the Contraceptive
Development Network (MRC Grant No. G9523250). It was performed in
accordance with Good Clinical Practice including regular monitoring of centres.
Between June 2003 and January 2004, a total of 97 healthy volunteers with regular
menstrual cycles (21-42 days) aged 18-40 years were recruited from four sites (34
in Sagamu, Nigeria; 18 in Cape Town, South Africa; 10 in Hong Kong, People's
Republic of China and 35 in Edinburgh, Scotland). The study was approved by local
ethical committees at all centres. All women gave written informed consent before
enrolment and were screened before entering the study by routine physical and
gynaecological examination and measurement of height, weight, blood pressure and
pulse rate. Blood samples were collected for measurement of progesterone, clinical
chemistry and haematology. The size of the uterine cavity and ovarian follicles
were measured by transvaginal ultrasound scan. Urinary hCG was also measured to
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exclude pregnancy before entering the trial. Women who had used any form of
hormonal contraception within the last 3 months of the start of the study were
excluded except in Edinburgh where nine women with regular cycles while already
using a POP were included without having to undergo a washout period.
Subjects were studied for one pretreatment cycle, six treatment cycles (24 weeks) and
for one post-treatment cycle. Subjects were randomly allocated to receive either
mifepristone 5 mg/day (one half a 10 mg tablet) (from Laboratoire Exelgyn, 6 rue
Christophe Colomb, 75 008-Paris for women in Edinburgh; and from Hualian
Pharmaceuticals Ltd, Shanghai, China for women in Hong Kong, Cape Town and
Sagamu) or levonorgestrel 0.03 mg/day (POP) (Norgeston; Schering Health Care
Limited, The Brow, Burgess Hill, West Sussex, RH15 9NE) starting on Day 1 or 2 of
the cycle. Randomization was achieved by blocked computer-generated randomization
performed individually for each centre to ensure good balance of numbers in the
different treatment groups. Each centre was given numerical sequence of coded treatment
bottles which were identical generated by statistician in Edinburgh office. Participants
were enrolled in each centre by the local investigator. The numerical sequence was
determined by the clinical trials manager in Edinburgh. To maximize, the number of
cycles observed on mifepristone without greatly reducing the power of the randomized
comparison, three times as many subjects were randomized to mifepristone as to
levonorgestrel. In Cape Town, Hong Kong and Edinburgh, daily doses were issued at
eight weekly intervals in pre-packed identical bottles containing mifepristone (a half
tablet) with placebo, or levonorgestrel with one half placebo tablet. In Nigeria,
daily doses were issued at weekly intervals. The placebo and active tablets were
both white but of slightly different size. Unused medication was returned and new
medication dispensed at this time. All subjects were sexually active and intending to
use the study drug as their sole method of contraception. However, in Cape Town and
Hong Kong some women also used condoms for protection against sexually transmitted
infection. Cycles in which dual protection was used were omitted when calculating the
months of exposure to the risk of pregnancy.
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The women were asked to record every day the amount of vaginal bleeding and adverse
events on a diary card. If bleeding occurred it was recorded as spotting (one or less
pad/tampon required) or bleeding (more than one pad/tampon required).
Subjects attended the clinic for review at eight weekly intervals during the treatment
phase and once more on Day 5-11 of the first menstrual cycle after discontinuation of
the study medication. At the end of the treatment phase a vaginal examination was
performed on all subjects and an endometrial biopsy performed in a subgroup of
volunteers. In order to identify those women who might develop hyperplasia of the
endometrium a biopsy was performed at any time during the study on all subjects if
the measurement of the uterine cavity was observed to be >12 mm ('safety biopsy').
Biopsies were performed as an outpatient procedure with a Pipelle suction curette
(Pipelle de Cornier, Laboratoire C.C.D, 60 rue Pierre Charron, 75 008-Paris-
France, Ref. 1103000). Endometrial samples were then fixed in 10% neutral buffered
formalin prior to embedding in paraffin wax. Histological examination of the
endometrial sections was conducted blind by an independent pathologist and classified
into five categories [proliferative, secretory, inactive, insufficient and cystic glandular
dilatation (CGD) as previously described (Baird et al., 2003)]. (i) Proliferative
includes 'active' in which glands are tubular, with columnar epithelial cells
showing nuclear stratification and frequent mitoses (>=5 per 20 gland profiles); and
'weakly'— simple tubular glands with columnar epithelial cells showing mild
nuclear stratification (2-4 mitoses per 20 gland profiles), (ii) Inactive—cuboidal to
columnar cells showing focal or diffuse nuclear stratification, in glands with simple
tubular or undulating profiles without significant dilatation. Resembles endometrium of
basalis in normal cycling endometrium. Glands are not atrophic, and show evidence
of limited recent growth or function, but lack the findings seen in normal cycling
proliferative endometrium. Mitoses are absent or uncommon (no more than one
mitotic figure per 20 gland profiles), (iii) Inactive with CGD—inactive glandular
epithelium as described above, with dilatation of gland lumina. Dilatation is defined
as the gland having an open lumen that forms a space, i.e. greater than four times
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the epithelial thickness, (iv) Secretory—glands are variably tortuous with cytoplasmic
vacuolation that varies according to phase of cycle. Cells are columnar, with non-
stratified nuclei showing an absence of mitoses (except for infrequent mitoses in
the early secretory phase). Stromal decidual change starts around spiral vessels,
becoming confluent in the late secretory phase. Some samples contained
inadequate amounts of tissue for accurate histological evaluation.
Ovarian function was assessed by the measurement of progesterone in venous blood
collected at screening and at 8, 16 and 24 weeks after starting treatment. The woman
was classified as having ovulated at least once if the concentration was > 15 nMol/1 in
any of the three samples. Following centrifugation the serum was stored at -20°C in
labeled sample tubes. Analysis by radioimmunoassay was carried out at the end of the
study locally by each centre. Transvaginal ultra-sonography was used to assess number
and size of follicles or cysts at screening and after 8, 16 and 24 weeks.
Statistical methods
The number of subjects on mifepristone was chosen to give an upper confidence limit of
<5% for the risk of pregnancy over the 6 months of treatment if no pregnancies
occurred in that group. To maximize, the number of cycles observed on mifepristone
without greatly reducing the power of the randomized comparison, three times as
many subjects were randomized to mifepristone as to levenorgestrel. These
numbers were also sufficient to give over 99% power to show a significant difference
in the rate of amenorrhoea over 6 months if the rate was 50% on mifepristone when
compared with the 5% anticipated in the levenorgestrel group [491]. Data analysis was
carried out using SPSS version 12 (SPSS, Inc., Chicago, IL, USA) and Excel 2003
(Microsoft Corporation). The two randomized groups were compared by chi-
squared test with Yates' correction and Mann - Whitney or Student's t-tests as
appropriate tests for binary and continuous outcomes, respectively. Analysis of
covariance adjusting for pretreatment values was used to compare the endometrial
thickness in the two groups at follow-up. Confidence limits were calculated for the
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incidence efficacy outcomes in the mifepristone group using the Poisson distribution
based on person time at risk.
Results
A total of 97 women were recruited (Fig. 2) and randomized to treatment [35 in
Edinburgh (26M, 9POP); 34 in Nigeria (26M, 8POP); 18 in Cape Town (14M, 4POP);
10 in Hong Kong (8M, 2POP)]. One subject randomized to mifepristone withdrew for
personal reasons and discarded the study drugs without taking any. Therefore, the results
of the 96 women who started treatment [73 received mifepristone (M), 23 received
levonorgestrel (POP)] were included for analysis.
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1 Withdrew (change ofmind)
69 Followed up
3 Withdrawn (1 due to
pregnancy)
1 Lost to follow up
62 Followed up


























Of the 87 women who started the study and did not use hormonal contraception in the
previous months, 66 were randomized to mifepristone and 21 to POP. An additional nine
women in Edinburgh who had regular menstrual cycles while taking POP for
contraception were transferred directly to study medication. In this subgroup, seven
were randomized to mifepristone and two to POP.
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When all centres were combined (Table 1) there were no statistically significant
differences in age, weight, height, BMI or parity between the two treatment groups
(two-sample Student's Mests). However, there were some differences in the
characteristics of the women from different centres. The women in Nigeria were
significantly older (years 33.9 ± 4.2 SD, P = 0.001) than the women in both Cape Town (26.2
±7,7) and Edinburgh (28.7 ±6.0). The BMI of women in Hong Kong (19.8 ± 1.7 kg/m2)
was significantly lower than that of women in Edinburgh (22.9 ±1.9, P < 0.001), Nigeria
(24.3 ±3.9, P= 0.001) and Cape Town (23.1 ±3.6, P = 0.014).
Table 1: Mean (SD) age, weight, height and BMI according to study drug
M POP
Age (years) 30.3 (6.3) 30.4 (6.9)
Weight (kg) 60.7 (9.1) 58.4 (6.2)
Height (cm) 161.5 (5.9) 161.3 (6.3)
BMI (kg/m2) 23.3 (3.6) 22.4(1.8)
Twenty-four women (16M, 8POP) did not complete the full 24 weeks of treatment.
Eight women withdrew for personal reasons unrelated to the study medication (e.g.
moved from the area, relationship ended); six were discontinued by the investigators
because of persistent protocol violations (e.g. poor compliance, unavailable for
follow-up). Two women withdrew because of anxiety about potential adverse affects
of the pills. Four women in the POP group discontinued because of persistent irregular
bleeding, no women in the mifepristone group discontinued for this reason (P < 0.01).
Four women withdrew because of pregnancy: three in the mifepristone group and one
while using levonorgestrel.
Seventy-two women completed the study (57M, 15POP) and took the medication for at
least 24 weeks (168-192 days).
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Menstrual bleeding pattern
There were significant differences in the pattern of menstrual bleeding between the
groups (Fig. 3). Of the 73 women who started mifepristone, 36 (49%) were
amenorrhoeic for the duration of drug treatment and only three women bled or spotted
on average for five or more days per month. In contrast, none of the women in the POP
group were amenorrhoeic. Although the number of days of bleeding was within the
range of a normal menses in the majority (61%), nine women in this group bled or
spotted for five or more days per month and four women withdrew from the study
prematurely because of continuous irregular bleeding.
Of the 57 women who took mifepristone for the full 6 months, 25 (44%) were
amenorrhoeic and a further 22 (39%) had bleeding or spotting for a total of 10 days
or less (Table 2). In comparison, of the 15 women who took POP, none (0%) were
amenorrhoeic (compared with mifepristone x2 =8.01 ,P = 0.005).
The pattern of bleeding in those women who continued to menstruate was irregular
and unpredictable in the majority in both groups. Although episodes of bleeding
in the women who took mifepristone were infrequent and slight, they were mostly
unpredictable, except in Nigeria where 4 of the 15 women who continued to bleed
had regular monthly periods. Nigerian women were more likely to experience
bleeding over the 6 month study duration (13/21; 62%) than those from other
centres [Edinburgh 4/22 (18%); Cape Town 3/9 (33%); Hong Kong 1/6 (17%)].
There was a significant difference in bleeding frequency between Nigeria and
Edinburgh (x2= 6.86; P = 0.009).
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Figure 3: Percentage of women who bled for a given number of days on average per
month in 96 women randomized to daily mifepristone or levonorgestrel (POP).
0, amenorrhoea; > 0 < 2, any bleeding < 2 days per month; 2 < 5, 2 to < 5 days
bleeding per month; 5+, 5 or more days bleeding per month











0 >0<2 2<5 5+
Average days bleeding per month
Table 2: Distribution ofmean (SD) numbers of days bleeding and/or spotting while
on drug according to treatment group, in the 72 women who took the treatment for at
least 6 months (%)
Number of
days
B leeding/spotting Bleeding only Spotting only
M POP M POP M POP
0 25 (44) 0(0) 36 (63) 0(0) 39 (68) 6(40)
1 4(7) 0(0) 0(0) 0(0) 6(10) 2(13)
2.5 8(14) 2(13) 5(9) 2(13) 8(14) 1 (7)
6-10 10 (18) 1 (7) 7(12) 1 (7) 3(5) 1 (7)
11-20 5(9) 3 (20) 5(9) 5(33) 1 (2) 2(13)
21+ 6(11) 9 (60) 5(9) 7(47) 1 (2) 3 (20)
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Ovarian function
Ovarian function was assessed at baseline, 8, 16 and 24 weeks after starting treatment
by measurement of progesterone in blood. In 33 of the 97 pretreatment samples, the
concentration of progesterone was >15 nmol/1 indicating that in just over a third of
the women the blood was collected in the luteal phase after ovulation. At each eight-
week review, there was evidence of ovulation in some women in both groups. If
a woman showed evidence of ovulation at any of the three review visits she
was classified as ovulatory. Ovulation was less likely to occur in women taking
mifepristone (14/73; 19%) than in those in the POP group although there was no
statistically significant difference (7/23, 30%; x2 = 0.72; P = 0.40). However, there
were significant differences between centres in the incidence of ovulation and
amenorrhoea. For example, while taking mifepristone only one of the 26 women in
Edinburgh (4%) ovulated when compared with 11/26 women in Nigeria (42%: x2 =
8.78; P =0.003). The proportion of women who ovulated while taking the POP
was identical in the two centres (37%).
Ultrasound examination revealed the presence of numerous small and medium-sized
follicles in the ovaries of women in both groups throughout treatment. Follicular
cysts (diameter >30 mm) were detected on eight occasions (six among women using
mifepristone and two in the POP group). The cysts were asymptomatic and resolved
spontaneously by the next examination without treatment.
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Endometrial thickness
In the mifepristone group, the width of the cavity and the thickness of the
endometrium increased with time relative to the baseline (Table 3). In contrast, there
was no statistically significant change in the POP group, and by 16 weeks the
difference in the size of the uterine cavity between the groups was statistically
significant (P = 0.043). There were differences between the centres in the extent of
the increase in size with the thickest endometrium at 24 weeks occurring in
Edinburgh(5.2 ±2.1 mm before starting, increasing to 13.8 ±7.1 at 24 weeks)(Table
4).
Table 3: Mean (SD) endometrial thickness at different times according to treatment
group
Weeks Mifepristone POP P-value
0 6.1 (2.1) [73] 5.8 (2.4) [22] NS
8 6.6 (3.4) [68] 5.3 (2.7) [19] 0.11
16 8.0 (5.2) [60] 5.1 (2.8) [15] 0.043
24 10.3 (6.8) [58] 4.0 (2.0) [15] <0.001
The P-value is from an analysis of covariance adjusted for the pretreatment value.
Numbers of subjects are shown in square brackets.
Table 4: Mean (SD) endometrial thickness at different times according to centre - for
mifepristone only
Weeks after starting Edinburgh Cape Town Hong Kong Nigeria
0 5.2 (2.1) 6.7(1.7) 6.6 (2.6) 6.4(1.8)
8 4.9 (3.4) 7.6 (3.3) 6.4 (4.4) 8.0 (3.2)
16 9.2 (5.7) 8.0 (5.0) 8.9 (7.4) 6.5 (4.4)
24 13.8 (7.1) 11.5 (8.7) 8.3 (3.6) 6.8 (4.4)
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Endometrial biopsies
A total of 39 women had at least one endometrial biopsy. Six women in the
mifepristone group had two biopsies and one had three biopsies, making a total of
47 biopsies available for examination. Twenty women (19 in the mifepristone
group and 1 in the POP group) had a 'safety biopsy' because the endometrial cavity on
ultrasound was >12 mm. A total of 31 biopsies were available from women who had
completed 24 weeks of treatment (27 mifepristone and 4 POP).
CGD was found in the endometrium of 13 of the 27 women who had a biopsy
at 24 weeks on completion of the study. The remainder were proliferative
(4), inactive (3), or insufficient for histological examination (7). Of the 19
women on mifepristone who had a 'safety' biopsy because the uterine
cavity was dilated above 12 mm, 11 showed CGD on at least one occasion.
CGD also occurred in four of nine women with normal-sized cavity who
volunteered to have an endometrial biopsy at 24 weeks. The endometrium
in the sole woman in the POP group who had a safety biopsy (cavity
13 mm) was too scanty for histological examination. None of the women in
either group showed evidence of hyperplasia or atypia.
Hysteroscopy was performed as an outpatient procedure on two women
(both in Edinburgh) with an enlarged uterine cavity (29 and 16 mm)
detected on routine ultrasound at 16 weeks. The uterine cavity was dilated with
mucous fluid and a pale oedematous looking endometrium which showed CGD on
histological examination (Fig. 4). No serious pathology was detected and one
woman opted to continue with the trial. The endometrial cavity returned to normal
size after completion of the trial.
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Figure 4: Appearance of the uterus of subject 135 who took 5 mg mifepristone per
day for 24 weeks
The subject remained amenorrhoeic throughout, (a) After 8 weeks the thickness of
the endometrium and cavity was normal; (b) at 16 weeks the cavity was dilated to 17
mm with fluid. Cyst like structures had become apparent in the cervix; (c) the cavity
was lined by pale dilated endometrium; (d) showing CGD on histology (X10); (e) by
24 weeks the cavity was still dilated; (f) by 4 weeks after stopping the cavity had
returned to nonnal after menses. Note the persistence of dilated cervical glands.
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Contraceptive efficacy
Not all the subjects were at risk of pregnancy for the duration of the study. Some
women separated from their partner, while a number of women in Cape Town and
Hong Kong used barrier methods as well as the study drug for duel protection. In
total, there were 356 months of exposure in women who took mifepristone as their
sole method of contraception and 85 in women who took POP.
Five women became pregnant during the study: four of them in the group of women
randomized to mifepristone. However, there were only three pregnancies while the
subjects were taking the study drugs. In the mifepristone group, two pregnancies
occurred (both in Capetown) during treatment and were recognized after 62 and 115
days of treatment, respectively. Conception occurred in both within the first 2 months
of treatment. One woman underwent a vacuum aspiration and the other opted to
continue with the pregnancy and delivered at term a healthy baby. Both of these
women were using condoms for dual protection. Inclusion of these two women in
the analysis of efficacy gives an estimate of 0.6% (95% confidence limits 0.07 to
2.0%) for the risk of pregnancy per month while exclusion results in an estimate of 0%
(0 and 1.1%). Two additional pregnancies occurred before starting or several weeks
after stopping mifepristone. One pregnancy occurred in a woman using
levonorgestrel and was only detected because of a routine pregnancy test 8 weeks
after starting treatment. She had a blighted ovum and the uterus was evacuated
surgically. There was no significant difference in the pregnancy rates between the
groups although the study was not powered to detect differences.
Adverse effects
There were no major adverse events in either group. Eight women (35% of those
taking POP) and 19 (36% of those on mifepristone) reported a range of symptoms
none of which were significantly different between the groups including abdominal
discomfort (12% mifepristone versus 4% POP), irregular bleeding (7%)
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mifepristone versus 9% POP), headache (8% mifepristone versus 22% POP), flushes
(7% mifepristone versus 0% POP) and mood change (3% mifepristone versus 0%
POP).
Discussion
This study has demonstrated striking differences in the pattern of menstrual bleeding
between women taking two types of oral contraceptive pills, which contain no
estrogen. The results confirm our previous study, which reported that the majority
of women taking 5 mg mifepristone every day for four months were
amenorrhoeic [448]. In the present study, over 80% of women who took
mifepristone were either amenorrhoeic or had episodes of bleeding or spotting <2
days per month. In comparison, women on levonorgestrel had frequent irregular
bleeding (>5 days per month) and none was amenorrhoeic. Four women discontinued
the POP because the bleeding pattern was unacceptable.
This study has its strengths and weaknesses. The placebo was similar but not
identical to either of the active drugs and hence the study was not truly double
blind. It would have been possible for the persistent subject and/or researcher to
identify group differences by the size of the treatment tablets. We think that this is
unlikely because each woman was supplied with two identical opaque bottles
each containing 8 weeks supply of either placebo or active drug prepared by a
member of the research team not involved with contact with the subjects.
Moreover, the difference in bleeding patterns (the primary end point) was so striking
that we think it unlikely that unblinding of an individual subject would have had a
significant impact on the overall results.
Nine women (all in Edinburgh) who were taking POP were recruited directly to the
study without at least 3 months 'wash-out'. It could be argued that in these
women there was a 'carry over' effect on the ovary and/or endometrium from the
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previous treatment. We think that it is unlikely because all women had regular
menstrual bleeding while on the POP. Moreover, at recruitment they had evidence of
ovarian activity, i.e. luteal levels of progesterone, follicles >10 mm and/or
endometrium >8 mm. Because they were randomized 2:7 POPmifepristone, they
would not bias the comparison between the groups. The seven women in this
subgroup who were randomized to mifepristone had amenorrhoea for at least 3
months after starting, illustrating one of the clinical uses when the drug becomes
available.
There were minor differences between centres in the response to the drug. However,
in all centres the bleeding pattern was better with mifepristone and the contraceptive
efficacy was high.
It is arguably in Africa where there is the greatest unmet need for contraception. The
fact that we show that it is effective in a range of cultures, including Africa, should
help facilitate its use worldwide particularly in those cultures where women who
are menstruating are subject to social taboos.
In the women in the mifepristone group who continued to bleed there were
differences between the centres in the pattern of menses. Nigerian women were
more likely to experience bleeding over the 6 months study and to show biochemical
evidence of ovulation than women in the other centres. For logistic reasons, our
assessment of ovarian function by measurement of the concentration of progesterone
every 8 weeks was imprecise. We classified a woman as being 'ovulatory' if the
level of progesterone was in the luteal phase range on any one of the three
occasions when it was collected. We argued that there would be about a one in
three chance that the progesterone level will be raised in any single sample collected
at random from normal cycling women as was found in the control cycle. Although
the majority of women in all centres failed to ovulate while taking mifepristone,
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there were significant differences in the incidence of anovulation between centres.
These differences between centres are intriguing. We have previously reported that
ovulation and menstruation were more easily suppressed by mifepristone in
Chinese women in Shanghai than in Caucasians in Edinburgh [448], The daily
dose of 5 mg mifepristone was chosen because it resulted in amenorrhoea in over
90% of women in Edinburgh. We have previously suggested that these differences in
response may be due to differences in diet and/or in metabolism of steroids.
Alternatively, there could be differences in compliance between centres although
there was no evidence from the number of returned pills that the women in Nigeria
omitted more pills than those in other centres. Moreover, a large number of tablets
would have to be missed before sub-therapeutic levels of mifepristone were reached
because of the long half-life of mifepristone [492].
One of the main reasons that women discontinue hormonal contraception
is because of menstrual irregularity [493] and this was true of women using the POP
in this study. All four women who discontinued the study specifically because of
menstrual irregularity were taking POP. The amenorrhoea or scanty bleeding
associated with mifepristone should be perceived as an advantage by many
women [93,94],
It has been argued that prolonged amenorrhoea is unnatural and even harmful.
Monthly menstruation has however been the norm only for the last 100 years. Prior to
that, most women spent their short lives either pregnant or breastfeeding and
amenorrhoeic. Absence of periods per se does no harm. If associated with
hypoestrogenism (as in the menopause or during treatment with analogues of
gonadotrophin releasing hormone) it is associated with increased risk of osteoporosis
and heart disease; if associated with a high dose of progestogen (as during the use of
Depo-Provera®) or prolonged exposure to COC (as in extended pill use) it may be
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associated with increased risk of breast cancer and heart disease [491], Amenorrhoea
during mifepristone use is not accompanied by hypoestrogenism and, as stated
earlier the risk of breast cancer may be reduced [407,408]. A recent paper
reported that mifepristone prevented the development of breast cancer in transgenic
mice with null mutation of BRCAl/p53 [409].
Concern has been expressed that with prolonged intake of antiprogestogens the
endometrium would undergo hyperplastic or malignant changes due to continued
exposure to unopposed oestrogen [410], However, studies in monkeys with
mifepristone and other antigestogens have shown evidence of endometrial atrophy
rather than hyperplasia [411,412,413,414], In keeping with our previous
report, the endometrial cavity widened progressively with time in women in
Edinburgh, but not in the other centres [448], We have previously reported that
much of the apparent increase in endometrial thickness is associated with cystic
dilation of the endometrial glands and the cavity itself [447], A recent paper reported
the results of a study in which 40 women with fibromyoma were given 5 or 10 mg
mifepristone/day for up to 1 year [416], Simple hyperplasia of the endometrium
without atypia was seen after 6 months only in a minority of women (28%) who took
10 mg but none at 5 mg.
In the present study, the commonest histological picture was of inactive CGD. This
CGD was only found in those women taking mifepristone. The cause of this unusual
change is unknown. It is unlikely to be due to the effects of unopposed estrogen as it
has been demonstrated to occur in women who have profound suppression of ovarian
follicular development and where oestrogen levels are low [447,448], Moreover, it
occurs more commonly in those women taking 10 mg mifepristone per day than in
those taking 5 mg in whom the secretion of ovarian oestradiol is higher [416].
Novel observations in this study were the hysteroscopy finding of atrophic and/or
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oedematous endometrium. Hysteroscopy revealed that the apparent thickness of the
endometrial cavity as measured on ultrasound reflected dilation of the glands and
cavity rather than true hyperplasia of the endometrium. It demonstrates the
limitation of using measurements of endometrial thickness by ultrasound alone as
a marker of endometrial pathology. The cause of this accumulation of fluid and its
nature is unknown but similar findings have been reported in rabbits following
treatment with mifepristone [414]. It may be that the mechanism, which normally
allows the passage/and or re-absorption of fluid from the endometrial glands and
uterus, is obstructed leading to an accumulation of fluid within the uterus.
This study has confirmed that mifepristone is potentially a highly effective
contraceptive. Even in Nigeria where there was biochemical evidence of ovulation
in 42% of women there were no pregnancies in the mifepristone group. In our
previous study, we reported no pregnancies in 50 women who used
mifepristone at a dose of 2 or 5 mg/day for 4 months [448]. The present study
extends our contraceptive experience to a total of 556 women cycles. The two
pregnancies in women taking mifepristone occurred in women in South Africa who
were also using condoms as protection against sexually transmitted disease including,
HIV/ AIDS. It is possible that these women may have omitted to take their pills
every day because they thought that they were protected from the risk of pregnancy
by the use of condoms.
In conclusion, the present study demonstrates that mifepristone at a daily dose of 5
mg is a safe and potentially effective contraceptive. The relatively high incidence of
amenorrhoea or reduced amount of scanty bleeding is likely to be better accepted by
women than the irregular unpredictable menstrual bleeding that occurs in the majority
of women taking the POP. The reduction of menstrual blood loss should convey
health benefits to women particularly in developing countries where the incidence of
anaemia is high. Because of its antagonism of progesterone the risk of breast
cancer may be reduced rather than increased as is the case with COCs containing
estrogen and progestogens [494], A large multicentre phase III trial is required
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Protection again sexually transmitted diseases and HIV would be a significant non-
contraceptive benefit for any method of contraception. We explored whether daily
low-dose antigestogen, mifepristone, modulates underlying mechanisms involved in
transmission of STI's including HIV by investigating its effects on vaginal
morphology, steroid receptor and natural antimicrobial [secretory leukocyte protease
inhibitor (SLPI), human beta defensins mRNA (HBD1, HBD2, HBD3, HBD5),
granulysin and elafin] content [490]. We also report the pharmacokinetics and
pharmacodynamics of 5 mg mifepristone supplied by Hualian Pharmaceuticals Co.
Ltd. (Shanghai, China), which has been used in the present study as well as in
previous studies [448].
Subjects and methods
We report two pilot studies using 5 mg mifepristone — the study on vaginal
epithelium that was carried out in Edinburgh and the pharmacokinetic study in
Helsinki.
Effects of mifepristone on vagina
A single-center, open, single-group study concerning female volunteers was
undertaken. Eight healthy subjects with a mean age of 35 years (range, 27-39 years)
and a mean body mass index (BMI) of 23 kg/m2 (range, 17.3-28.2 kg/m2) who had
regular menstrual cycles (25-42 days) were recruited to the study. The women agreed
to refrain from the use of vaginal medications during the study period or from sexual
intercourse 48 h prior to vaginal biopsy. Women who had breast-fed or had taken
hormonal contraception less than 3 months prior to the study and those with vaginal
or pelvic infections (current or past) were excluded. The proposal was approved by
the local ethics committee (institutional review board). All women gave written
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informed consent before enrolment and were screened before entering the study.
Screening included a full medical, gynaecological history and examination, including
measurement of height, weight, blood pressure and pulse. Blood samples were
collected for measurement of routine clinical chemistry and haematology (liver
function tests, urea and electrolytes, glucose, full blood count). BHCG was measured
to exclude pregnant women from the study. Subjects were studied for one pre-
treatment cycle, one cycle of treatment (approximately 33 days) and one post-
treatment cycle. Each subject was reviewed on Day 12 of the pre-treatment menstrual
cycle (Visit 1), at the end of treatment (Visit 2)
and on Day 12 of the post-treatment menstrual cycle (Visit 3). Subjects were given a
menstrual record card and were asked to record all vaginal bleeding.
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Assessment of ovarian function
Ovarian function was monitored by measurement of ovarian steroids in urine and
plasma and by transvaginal sonography. All subjects collected twice weekly samples
of early morning urine during the study period, starting in the early follicular phase
(Days 1-5) of the pretreatment cycle. Aliquots were frozen and stored at -20°C until
assayed for estrone glucuronide (E1G), pregnanediol glucuronide (PdG) and
creatinine (Cr). PdG was measured using a direct enzyme immunoassay, while E1G
was measured by direct immunoassay. Ovarian follicular activity during treatment
was compared with that during the follicular phase of the pre-treatment cycle, and the
activity was scored as complete suppression, partial suppression or continued
follicular activity. Ovulation was deemed to have occurred if the excretion of PdG
exceeded 0.5 mmol/mol Cr and was at least threefold higher than that in the preceding
week. A detailed description of this methodology is given in our previous report
[448]. Blood samples were collected at all study visits and assayed for oestradiol (E2)
and progesterone (P) using radioimmunoassay (RIA). Assay characteristics and
methodology have been described in our previous reports [448], A transvaginal
ultrasound scan was carried out at all study visits, and ovarian dimensions, follicle
number and diameter and presence of ovarian cysts were recorded.
Vaginal biopsy
A full-thickness vaginal biopsy was taken from the lateral vaginal wall 4 cm proximal
to the hymeneal ring on Day 12 of the pre-treatment cycle (Visit 1) and, again, after
completion of treatment (Visit 2). One ampoule of Citanest with octapressin (3%;
prilocaine hydrochloride, 30 mg/mL; felypressin, 0.03 U/mL; Dentsply) was injected
into the lateral vaginal wall as a local anesthetic and haemostatic agent. This also
elevated the target vaginal tissue sufficiently to permit easy access for a biopsy.
Vaginal biopsy was performed using a long Schumacher forceps. Vaginal tissues were
stored in RNAlater (Applied Ltd., Cambridgeshire, UK; RNAlater is an aqueous
storage reagent to stabilize and protect RNA) and neutral-buffered formalin (NBF; for
future preparation of paraffin-embedded tissue for immunohistochemistry). A second
biopsy was taken if adequate sample was not obtained from the first biopsy. Vaginal
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bleeding from the biopsy site was controlled using either silver nitrate or, if necessary,
a Vicryl 3-0 suture (Ethicon, UK), depending on the amount of bleeding.
An endometrial biopsy was collected using Pipelle endometrial sampler (Prodimed,
Neuilly-en-Thelle, France) at end of treatment (Visit 2), fixed in NBF and embedded
in paraffin. Endocervical and posterior fornix swabs were collected at all study visits
and cultured for pathogenic organisms, for example, gonococcus, trichomonas and
streptococcus, which might influence the parameters studied in target vaginal tissues.
Safety parameters
At each study visit, blood pressure and pulse were measured, and blood was taken for
measurement of routine clinical chemistry and hematology. In addition, each subject
was asked to report any health problems or adverse events that had occurred since the
last visit.
Vaginal thickness measurement
Vaginal tissue samples were embedded in paraffin, and serial 5um sections were cut
at a 90° angle to the vaginal surface epithelial layers. The sections were stained with
hematoxylin and eosin, and digital images were captured at xlO eyepiece
magnification using a Spot microscope connected to a Windows PC computer. Image
Proplus 4.5 (Media Cybernetics, Silver Spring, CO, USA) software was calibrated to
match the eyepiece used to capture the image. The surface and basement membranes
of vaginal epithelium were outlined using a trace tool within the software (Fig. 5).
The software automatically calculated the average distance between the two traced
outlines.
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Figure 5: Vaginal thickness measurement. Average thickness between surface and
basement membrane (trace tool, Image Proplus 4.5, Media Cybernetics).
Immunohistochemical (IHC) localization of oestrogen receptor alpha (ERa),
oestrogen receptor beta (ERC), progesterone receptor (PR), androgen receptor
(AR) and proliferation marker phospho-histone H3 (PH3)
Immunohistochemistry was carried out on both the vaginal and endometrial biopsies
for the following proteins of interest: ERa (Novocastra, Newcastle-upon-Tyne, UK),
ERB (Serotec, Oxford, UK), PR (A+B) (Novocastra), AR (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA), PH3 (Upstate Biotechnology, Poole, UK) and SLPI
(Hycult Biotechnology, Cambridge, UK). All antibodies used were mouse
monoclonal, except for PH3, which was a rabbit polyclonal. They were tested
individually at a range of dilutions and at different antigen retrieval conditions to
determine the protocol that gave the least background and highest specific staining
(Table 5). Positive and negative controls were included in every run. In most cases,
negative controls were performed by adding a matched IgG control antibody (mouse
IgG, Sigma, Poole, Dorset, UK; rabbit IgG, Vector Laboratories, Peterborough, UK)
of the same species and at the same antibody concentration as the primary antibody.
Protocols were carried out either on the bench or with the use of a Bond-X automated
immunohistochemistry staining machine (Vision Biosystems, Newcastle, UK).
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All tissue sections were initially prepared in a similar manner. Five-micron paraffin-
embedded tissue sections were dewaxed in Histoclear (National Diagnostics, Hessle,
UK) and rehydrated in descending grades of alcohol to distilled water (dH20).
Antigen retrieval was then carried out by heating the sections either in a microwave
oven (setting: high) or in a Tefal Clipso pressure cooker (Setting 2/high, Tefal,
Nottingham, UK). The buffer concentration and duration of antigen retrieval varied
depending on protocol (Table 1). Sections were left to cool in both cases for 20 min.
Endogenous peroxidase activity was quenched by immersion in 3% hydrogen
peroxide (BDH, Poole, UK) in methanol for 30 min at room temperature. For AR
only, sections were incubated in avidin for 15 min at room temperature (Vector
Laboratories), followed by incubation in biotin (Vector Laboratories), also for 15 min
at room temperature. Nonspecific binding of the primary antibody was blocked by
incubating the sections for 20 min at room temperature in a 1:5 dilution of
nonimmune serum (Autogen Bioclear, Holly Ditch Farm, Wilts, UK) in phosphate-
buffered saline containing 5% bovine serum albumin. All immunostaining methods
employed a detection system dependent on visualization of the reaction using a horse¬
radish peroxidase enzyme and the chromagen 3' 3-diaminobenzidine (DAB). After
the DAB step, the sections were counterstained in hematoxylin before dehydrating
them in ascending grades of alcohol and mounting them from xylene with Pertex
(Cellpath pic., Hemel Hempstead, UK). Full details of each individual protocol are
given in Table 5.
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Table 5: Immunohistochemistry protocol
Protein Tissue IHC method Antigen retrieval Primary Negative Detection system
antibody control
ERa Vagina Bond-X Pressure cook: 1:100 mouse MlgGl Biotinylated secondary and
machine 0.01M sodium anti-Era 1:1300 ABC detection (Vision
ABC detection citrate, pH6, 5min 3h at room biosystems)
temperature









cook: 1:40 mouse anti-
ERB
Serum a Biotinylated rabbit antimouse
antibody and ABC-
Endomet
ABC- glycine/EDTA, pH Overnight at 4° streptavidin (both from
num
streptavidin 8, 7min DAKO, Cambridgeshre, UK)
PR Vagina Goat antimouse Microwave: 0.01M 1:80 mouse anti- MlgGl Goat antimouse envision
envision system sodium citrate, PR 1:2000 system (DAKO)
Endomet
rium
pH6, 10 min 37°C for 60min
AR Vagina Biotinylated Pressure cook: 1 MOO rabbit RIgG Biotinylated goat antirabbit
secondary and 0.01M sodium anti-AR 1:2000 antibody and ABC-Elite
Endomet
rium
ABC-Elite citrate, pH i, 5min Overnight at 4°C (both from Vector
Laboratories
H3 Vagina Goat antirabbit Pressure cook: 1:1000 rabbit RIgGI Goat antirabbit envision








SLPI Vagina Biotinylated Microwave: 0.01M 1:50 mouse anti- MIgG Biotinylated horse antimouse
secondary and
ABC-Elite





pH6, lOmin Overnight at 4°C
a




We used a descriptive methodology as there is no quantitative or semiquantitative
methodology established for analysis of vaginal tissue samples in our laboratory. The
intensity and distribution of immunostaining for ER, ERB, PR, AR, PH3 and SLP1 are
described for vagina (epithelium and stroma) and endometrium (glands, stroma and
surface epithelium), and differences between pre- and post-treatment samples were
analyzed.
RNA extraction
Tissue was minced using a standard sterile surgical scalpel blade and immersed in 2
mL of Tris-buffered saline (Sigma-Aldrich, St. Louis, MO, USA). The mixture was
homogenized for 60 s and incubated overnight at 4°C. The following day, tissue
sample was warmed to room temperature and 200ug of bromochloropropane was
added. The mixture was centrifuged at 14,000 rpm at 4°C for 15 min, and aqueous-
phase RNA (supernatant) was transferred to a fresh tube. Five hundred microliters of
isopropanol was added and incubated at 4°C for 60 min. The mixture was centrifuged
for 10 min; the supernatant was discarded, and the pellet was washed with 1 mL of
70% ethanol. The mixture was centrifuged for 5 min,
and the supernatant was discarded, allowing the pellet to dry for 5 min. The pellet was
resuspended in 20 uL of RNA solution. To standardize measurements between the
various
biopsy specimens, we assessed the same amount of RNA in each sample. The amount
of specific amplicon is related to ribosomal 18S, which is constant relative to the
amount of
cDNA present and, subsequently, to an experimental internal control. The RNA was
reverse transcribed (TaqMan Reverse Transcription Reagents Kit, Applied
Biosystems, Foster City,
USA) and polymerase chain reaction (PCR) amplified (TaqMan Universal Master
Mix, No Amp Erase UNG, Applied Biosystems) according to the manufacturer's
instructions. PCR amplification of cDNA was performed on an ABI Prism 7700
Sequence Detection System (Applied Biosystems). Specific forward and reverse
165
primers (300 nmol/L) and probe (200 nmol/L, all synthesized by BioSource UK,
Nivelles, Belgium) for the natural antibiotic were also added. Ribosomal 18S cDNA
was measured using TaqMan Ribosomal RNA Control Reagents (VIC dye, Applied
Biosystems) in each sample as an internal control following the manufacturer's
protocol. Samples were measured in triplicate, and no template controls were included
in all runs. Primers and probes for quantitative PCR were designed using the PRIMER
EXPRESS program (Applied Biosystems; Table 6) [496,497,498,499,500,501], and
probes were fluorescently labeled with the proprietary dyes FAM (5') and TAMRA
(3').
Table 6: Sequences of quantitative PCR primers and probes for natural antimicrobials




















































A pharmacokinetic study of 5 mg of mifepristone was carried out among the same
cohort of women who had previously participated in another pharmacokinetic study
[502], The study was approved by the Institutional Review Board of the Helsinki
Central Hospital and the Finnish National Agency for Medicines; all subjects signed
an informed consent document. Subject characteristics, methodology, collection of
sample, analysis of serum levels of mifepristone and calculation of pharmacokinetic
parameters were as described previously [502], In brief, six healthy women, with
regular menstrual cycles (23-36 days), a mean age of 32 years (range, 21-45) and a
BMI that ranges from 19 to 26 kg/m2, volunteered for the study. The 10-mg
mifepristone tablets supplied by Hualian Pharmaceuticals Co. Ltd. were halved, and a
dose of 5 mg, po, was ingested on Day 10 or 11 of the menstrual cycle. Blood samples
were collected at 0, 1, 2, 4 and 8 h and, thereafter, daily for the next 6 days and on
Day 10 following mifepristone ingestion. Mifepristone was measured in serum by
RIA after extraction with n-hexane:ethyl acetate and separation by column
chromatography using ChromosorbR [503]. The detection limit is 0.36 nmol/L, and
the intra-assay and interassay coefficients of variation were 8.4% and between 10.3%
and 13.6%, respectively.
Statistical analysis
Statistical analysis was performed using SPSS (SPSS, Inc., Chicago, IL, USA) and
Excel 2002 (Microsoft Corporation, Reading, UK). Sex steroid, vaginal thickness and
pharmacokinetic data are expressed as mean with either standard error of the mean or
standard deviation. Menstrual cycle data are expressed as mean and range.
Nonparametric tests (Friedman's test, Wilcoxon Signed Rank Test and Mann-
Whitney test) were used to compare sex steroid level, menstrual data, vaginal
thickness and natural antimicrobial RNA content before and after treatment.
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Results
Effects of mifepristone on vagina
All eight subjects completed the study. The subjects took mifepristone 5 mg/day, po,
for an average of 33 days (range, 28^10).
The average length of the control menstrual cycle was 27 days (range, 24-29), while
that of the control menstrual period was 5.7 days (range, 4-9). All eight women
reported amenorrhea during ingestion of mifepristone. The time from discontinuing
the mifepristone treatment to the next bleeding episode was 17 days (range, 10-23);
thus, the length of the mifepristone cycle was 50 days (range, 38-63). Average length
of the bleeding episode after discontinuation of mifepristone was 5.1 days (range, 4-
7).
During the treatment with mifepristone, seven of the eight subjects experienced either
complete suppression of ovarian activity (3/8 women, Fig. 6A, Subject 8) or persistent
follicular activity but no ovulation (4/8 subjects, Fig. 6B, Subject 4). In the remaining
subject (Subject 7, Fig. 6C), there was a threefold rise in the excretion ofpregnanediol
in the first 10 days of treatment, suggesting the formation of a corpus luteum.
Flowever, there was no menstrual bleeding when the level of pregnanediol dropped 14
days after starting the mifepristone. In this subject, a persistent ovarian cyst with a 42-
mm diameter was detected at completion of treatment (Day 40) when the level of P
(14 nmol/L) was slightly raised, which was consistent with a persistent unruptured
partially luteinized follicle.
Multiple follicles were detected by transvaginal ultra- sound (diameter of the largest
ranged from 10 to 29 mm) in all eight subjects. The concentrations of E2 in blood
samples collected at Visit 2 on the last day of mifepristone were compatible with
persistent follicular activity (496±pmol/L). In seven of eight women, the
concentration of P was <10 nmol/L (3±1 nmol/L), indicating lack of ovulation.
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Figure 6. Excretion of metabolites of ovarian steroids in women taking 5 mg of
mifepristone for 31-36 days. Estrone, E1G; pregnanediol, PdG; x-axis shows
timescale; Day 0, start of treatment. Pretreatment (negative values), treatment (boxed)
and follow-up cycles are shown. Black bars represent menstrual episodes; arrow
denotes vaginal biopsy. (A) Complete suppression of ovarian activity. (B) Persistent
follicular activity but no ovulation.(C) Single ovulatory episode and no menstruation
following fall in pregnanediol levels.
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Endometrial histology
Endometrial biopsies obtained at the end of mifepristone treatment displayed inactive
or weakly proliferative endometrium in seven of the eight subjects. In one subject
(Subject 9), tortuous glands with evidence of intraluminal secretion were seen. As
expected, there was strong immunostaining of ERa and ERB as well as of PR (A+B)
and AR in both glands and stroma. Histological evidence of mitosis was absent or
infrequent in all samples.
Vaginal histology and vaginal thickness
Vaginal biopsy was obtained in all subjects without complications both before and
after mifepristone administration. In seven of eight subjects the pretreatment vaginal
biopsy was performed between Day 6 and Day 16 of the follicular phase prior to
ovulation as confirmed by the hormone levels (mean±SEM: E2, 659±141 pmol/L, P,
4.3±10 nmol/L). In the remaining subject (Subject 5), ovulation had already occurred
on the day of biopsy (Day 14 of menstrual cycle) as indicated by high circulating
concentration of P (44 nmol/L). Post-treatment vaginal biopsy was performed on Day
33 (range, 28—40) of treatment.
The histology of the vagina showed the expected basal layer of epithelium mounted
by up to 20 layers of more superficial desquamating cells (Fig. 5). Vaginal thickness
was not altered during administration of mifepristone (342±40um vs. 303±69um; p
=0.2, NS).
Steroid receptor expression in the vagina (ERa, ERB, AR and PR)
There was nuclear staining of ERa, ERB and AR in both vaginal stroma and in the
epithelium. Immunoreactivity extended through the basal and intermediate layers but
not through the superficial layer of vaginal epithelium (Fig.7). Staining was far more
evident in the epithelium as compared with the stroma. There was no significant
difference in sex steroid receptor immunostaining after mifepristone administration.
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Apart from a few scattered nuclei in the stroma, the basal layer of vaginal epithelium
immunostaining for PR was confined to stroma (Fig. 7). There was no significant
difference in PR immunoreactivity after administration ofmifepristone.
PH3 immunoreactivity
PH3 immunostaining was confined to
vaginal epithelium (Fig. 7). There was
following treatment with mifepristone.
scattered nuclei in the basal layers of the
no significant change in immunoexpression
Natural antimicrobial mRNA and protein expression
SLPI mRNA was present in vagina, and this epitope was localized to the superficial
layer of the vaginal epithelium both before and after mifepristone administration (Fig.
7). SLPI immunostaining was also demonstrated in the superficial layers of luminal
and glandular epithelium of the endometrium (Fig. 7). SLPI mRNA expression was
unchanged following treatment with mifepristone (p>0.05, Wilcoxon test). HBD1,
HBD2, HBD3, HBD5, granulysin and elafin mRNA were present in the vagina. The
expression was unchanged following treatment with mifepristone (p>0.05, Wilcoxon
test).
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Figure 7. IHC localization of ERa, ERJ3, PR, AR and PH3 in the vagina [epithelium (epth) and
stroma (str)] and endometrium [gland (glnd) and stroma (str)] before and after treatment with 5 mg
mifepristone. Scale bar =100 Am; inserts denote negative controls. Strong expression of ERa (A and
B), ERh (D and E) and AR (J and K) in the basal and parabasal layers of epithelium and a relative lack
of PR (G and H) in the epithelium (there was no observed change following treatment); PH3
expression in the basal layers (M and N; arrows) and endometrium [postmifepristone (O; arrows)];
strong expression of all steroid receptors in the posttreatment endometrium (C, F, I and L); SLPI
confined to superficial layers of vaginal epithelium (P and Q) and endometrial glands (R).
Pre-mifepristone Post-mifepristone Endometrium
Safety parameters
There was no derangement in heart rate, blood pressure or in haematology and
biochemistry parameters including liver function tests during the study. Vaginal and
cervical bacteriology swab tests cultured negative for pathogenic organisms in all
subjects. Vaginal biopsy was well tolerated by all women. One woman had possible
low-grade endometritis following endometrial biopsy and was successfully treated
with a 7-day course of antibiotics.
Pharmacokinetics of 5 mg mifepristone
Serum levels (mean±SD) of mifepristone following ingestion of 5 mg mifepristone
are summarized in Fig. 8. Mean Clliax measured at 1 h was 641.7 nmol/L (range, 502-
740 nmol/L). All subjects showed a similar pattern of descending serum
concentrations of mifepristone. The elimination phase half-life was 18±5.1 h
(mean±SD). The mean (SD) areas-under-concentration-curves AUCo_s h and AUCo 24
h were 2.4 (0.5) and 4.8 (1.3) Amol/L, respectively.
Figure 8. Serum levels (mean±SD) of mifepristone following ingestion of 5 mg. The
data are depicted on both linear (lower) and semilogarithmic (insert) scales.









The vagina is a key portal of entry for HIV and other STIs. In this article, we report
the effect of a potential new contraceptive pill on different parameters involved in the
natural defenses of the vagina to infection. Vaginal epithelial thickness, steroid
receptor and natural antimicrobial content and distribution were unchanged following
treatment with mifepristone for 30—40 days. Vaginal epithelial thickness is regulated
by the levels of circulating oestrogen. Epithelial thickness is maximal at time of
ovulation [504,505,506,507] and decreases in the luteal phase and postmenopause
[504], There is a significant reduction in circulating oestrogen levels following long-
term gestagen treatment [506]. Severe vaginal atrophy has been demonstrated in
primate studies, and this clearly increases the risk of SIV transmission [508],
However, the response of human vaginal epithelium to gestagen-induced hypo-
oestrogenism is variable. A small but significant decrease (10%) in thickness has been
demonstrated in one study [506], whereas most other studies have demonstrated no
change [509,510], Paradoxically, vaginal epithelial hyperplasia has been reported in
users of depot medroxyprogesterone acetate (DMPA), oral contraceptive pill and P
implants [472,509,511]. E2 levels in all three treatment groups were significantly
lower compared with normal menstruating women. The steroid receptor content and
distribution were similar except for PR, which was suppressed in the DMPA group.
It is difficult to reconcile all available data into a working hypothesis due to
differences in study designs and methodology. The vagina has diverse embryological
origins [512]; Ildgruben et al. (2005) used a cross-sectional study design and sampled
lateral vaginal fornices, whereas we used a longitudinal study design and sampled
lateral midvaginal wall in keeping with other reports [511].
174
Although vaginal epithelium clearly responds to circulating oestrogen, the underlying
cellular and molecular mechanisms are poorly understood. We localized PH3, a
marker for mitosis and cellular proliferation, to a few scattered nuclei in the basal
layers of the vaginal epithelium. The strong nuclear expression of ER and AR in the
basal and parabasal layers suggests a role in the regulation of epithelial proliferation.
Oestrogen treatment induces surface keratinization and hyperplasia of primate vaginal
epithelium, and we expected a similar change in mifepristone-treated vaginal samples
due to unopposed oestrogen effect. The observed epithelial thickness in control
samples in the present study (mean pre-treatment thickness, 342um) is comparable to
other reports [472,509,510], Thickness was unchanged following mifepristone
treatment, and this agrees with similar work in cynomolgus monkeys [513], There are
several possible explanations for our findings. Firstly, mifepristone treatment did not
have any effect on level of circulating steroid hormones. Secondly, PR was localized
to a few scattered nuclei in the basal layers of vaginal epithelium and, hence,
mifepristone, a high-affinity PR ligand, did not have any direct epithelial effects.
Consistent with previous reports, we have demonstrated a strong immunoexpression
of ER and AR as well as a relative lack of PR in the vaginal epithelium compared to
subepithelial stroma [514,515,516,517,518,519,520,521], The distribution of steroid
receptors has obvious implications for the development of topical and parenteral
steroid treatment. Available data, including the present study, indicate that it is likely
that estrogen preparations will act via epithelial ER, whereas P preparations are likely
to have an endocrine and paracrine effect after binding with the subepithelial PR. The
role of AR in the genital tract is unclear, but AR may play a role in regulating
endometrial proliferation [522,523,524] and in modulating vaginal blood flow [514]
and female genital sexual arousal [521],
The endometrium sampled at the end of mifepristone treatment showed persistent
proliferative histology and strong ER, PR and AR expression, which is consistent with
our previous reports [447,523] and which demonstrates that the mifepristone
preparation used in this study is comparable to that we have used previously from
another source (Exelgyn, Paris).
The expression, regulation and role of natural antimicrobial compounds in the female
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reproductive tract are extensively reviewed elsewhere [498]. We have investigated
natural antimicrobials that regulate innate protection at mucosal interfaces. SLPI has
been shown to play an important role in limiting transmission of HIV [486,525,526]
and other lower genital tract infection [485]. SLPI mRNA has been demonstrated in
vaginal fluid previously [485,486]. In the present article, we demonstrate mRNA in
vaginal tissue and immunolocalize the protein to the superficial layers of the vaginal
epithelium. The expression in superficial layers of surface and glandular endometrium
is in keeping with previous reports [497]. HBD1 [527] and elafin [528] mRNA have
been reported in human vagina. We show that HBD2, HBD3, HBD5 and granulysin
mRNA are present in vaginal tissue. HBD4 mRNA was not previously demonstrated.
Natural antimicrobial expression is modulated by hormonal treatment, and up-
regulation of endometrial SLPI by P is attenuated in the presence of mifepristone
[501], Reassuringly, expression and distribution of natural antimicrobials were
unchanged following mifepristone treatment.
Low-dose mifepristone suppressed menstruation and ovulation in a majority of
women in the present study. This adds to similar observations in our previous reports
[448,529] and also demonstrates the biological activity of mifepristone supplied by
Hualian Pharmaceuticals Co. Ltd. The pharma-cokinetic properties of the 5-mg dose
from the above supplier follow a first-order linear kinetic pattern [502,530], The half-
life of 18 h is shorter than the 20 h previously reported for 10 mg mifepristone,
whereas the AUC0-24 h was half that of the 10-mg dose [502], All women received
planned treatment for at least 5 days beyond the expected date of menstruation (33
days) so that any post-treatment vaginal bleeding was due to withdrawal of
mifepristone rather than to a spontaneous menstruation. Fortuitously, Subject 7 was
administered mifepristone for 40 days. She did not bleed, although there was evidence
of ovulation and formation of corpus luteum followed by a significant decrease in
pregnanediol levels. This supports our previous reported findings that mifepristone-
induced amenorrhea is a result of direct endometrial effects that are possibly mediated
by a rise in glandular and luminal glucocorticoid and AR [531 ].
In summary, we have shown that low-dose mifepristone does not influence vaginal
thickness and proliferation. We have demonstrated that ER (ERa and ERB), PR, AR,
SLPI and other natural antimicrobials are present in the human vagina. There is no
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change in epitope expression following mifepristone treatment. The presence and
distribution of vaginal steroid receptors have implications for the development of




Reproductive health has been identified as both a fundamental human right and also a
social and economic imperative [8].
Unintended pregnancy is common worldwide. A study by Hubacher et al (2008)
estimates that in sub-Saharan Africa just over one third (39%) of pregnancies are
unintended [532]. Our study similarly found that one third (35%) of all pregnancies
were not clearly intended (10% of pregnancies were clearly unintended and 25% were
ambivalent) [46],
Contraception is a means to reduce unintended pregnancy.
In the context of this background the studies included in this thesis were devised. The
overarching theme of the thesis was to improve choice and use of contraception
primarily by development of new methods of contraception - in this case,
mifepristone. However recognising that development of any method, let alone
mifepristone which is surrounded by political and ethical controversy, takes at least
ten to fifteen years as not only does the method require to be developed but often the
infrastructure to support the method has to be established too, it was felt to be
imperative that we continue to improve uptake and use of existing methods by trying
to achieve a better understanding of current behaviours of women and couples, with
respect to contraceptive use and risk taking, and also identify what adaptations to
current methods and services might be acceptable. Findings could then be translated
to adapt existing methods and shape services to better suit those at risk of unintended
pregnancy.
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Study 1: Exploring levels of unintended pregnancy and use of
emergency contraception
A study was undertaken to explore levels of unintended pregnancy and use of
emergency contraception (EC) [46] in an effort to better understand behaviours of
women and couples with respect to contraceptive use and risk taking. Worldwide the
prevalence of use of contraception has increased with time [223] and this study found
that of those attending for induced abortion, 74% were using a method of
contraception in the month they became pregnant (appendix 1). This finding is
slightly lower than those of Schunmann et al (2006) (84%) [70] and Garg et al (2001)
(98% of those undergoing repeat abortion and 83% of those undergoing first time
abortion) [73]. Data suggests that true method failure accounts for only 5% of
unintended pregnancies occurring when contraception is correctly and consistently
being used [74,75,76]. The remaining 95% is due to non-use or less effective use of
modern methods of contraception. This very high failure rate is likely to reflect the
difficulty of using non-permanent methods consistently and correctly.
The study demonstrated that even when risk of unintended pregnancy has occurred
only one in ten women acted to try and prevent pregnancy by using emergency
contraception (EC) and only 65% of those women used EC with every act of
unprotected intercourse in the month of becoming pregnant. Other studies have
demonstrated that failure to recognise risk of pregnancy is common [161] and neither
advance provision of EC to keep at home or availability of EC over the counter in UK
pharmacies have resulted in increased use or reduced unintended pregnancies
[169,170,171,175],
This study exploring intendedness of pregnancy and use of EC does require to be
replicated in different settings to see if findings elsewhere are similar. However, it
seemed evident from the results of the survey that there is a real need for women and
couples to receive accurate information about pregnancy risk and that unless this risk
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is recognised and acknowledged EC is unlikely to make a substantial difference to
pregnancy rates. It also made evident that for contraception to be successful it must
firstly be used but equally importantly must be used correctly and consistently. Thus
firstly there is a need to make contraceptive methods, including EC, as accessible as
possible and as attractive as possible. Secondly there is a need to encourage women,
especially those who want to avoid pregnancy and are taking risks, either by non-use
or by incorrect or inconsistent use of contraception, to take up use of methods which
have long duration of action and do not require any active adherence once initiated.
Such methods comprise implants, injectables and intra-uterine devices and are better
known as long-acting reversible contraception (LARC).
Study 2: Assessing continuation rates of Implanon®
Consequently a study was undertaken to attempt to quantify acceptability of
Implanon® by assessing continuation rates [231], As discussed in chapter 3,
continuation rates act as one objective measure of acceptability. Continuation rates of
all methods of contraception are generally disappointing [233] and are lower for
methods which do not require intervention by a health professional [233]. In clinical
trials of Implanon® where participants are highly motivated and where there is
regular follow-up they are between 90 and 95% at six months and 80 and 88% at 12
months. In clinical practice users of Implanon® are at most followed up once after
three months and thereafter are only reviewed if there are any problems or when the
implant is due for removal. In this 'real life' study of Implanon® use continuation
rates were found to be encouraging with 75% continuing at 1 year, 59% at two years
and just under half (47%) continuing for 2 years and 9 months [231]. These rates
should reassure healthcare providers and commissioners that increasing uptake of this
LARC as recommended in the National Institute of Health and Clinical Excellence
(NICE) guideline (2005) [ 180] is worth the effort and the cost. The fact that more than
one third of women chose to continue to use Implanon® once their first implant had
expired reflects a strong level of satisfaction on the part of users.
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It is widely acknowledged that at the time this study was conducted (2005) and even
more recently [224] the most commonly used forms of reversible hormonal
contraception are condoms and oral contraceptive pills [224], These are notoriously
difficult to use consistently and correctly [86,179]. The NICE guideline published in
October 2005 recommended that healthcare providers give information on and offer a
choice of all methods, including LARC [180], They defined LARC to comprise any
of three methods: intrauterine devices - both non-hormonal (IUD) and hormonal
(IUS); Implanon® and Depo-provera® [180].They stated that contraceptive service
providers should be aware of three things: that all currently available LARC are more
cost-effective than the combined oral contraceptive pill even at one year of use; that
the IUD, the IUS and Implants are more cost-effective than the injectable
contraceptives; and that increasing the uptake of LARC methods will reduce the
numbers of unintended pregnancies [180]. The data from this study on continuation
rates added to the body of knowledge being collated by the NICE at the time in
producing guidance on the effective and appropriate use of LARC [180]. It also added
impetus to the argument for increased provision of Implanon® outside of the family
planning setting thus making it more easily available to women.
Study 3: Exploring the acceptability of self-administration of
subcutaneous Depo-Provera®
In keeping with the proposed medium term strategy to adapt existing methods to
increase acceptability and taking into consideration that Depot medroxyprogesterone
acetate (DMPA) when given intramuscularly was less cost-effective than other
methods of LARC [180] the opportunity was taken to explore the theoretical,
acceptability of self administered subcutaneous depot medroxyprogesterone (DMPA-
SC) [369],
DMPA is another important method of long-acting reversible contraception.
Anecdote suggests that in the UK it is increasingly popular among young women, and
among women of all ages who like the convenience of amenorrhoea. In the USA the
fall in teenage pregnancy rates has been attributed to increased use of Depo-Provera®
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[100], The need to attend a health professional every three months simply for a single
injection is a clear disadvantage of the method, both for users and for commissioners
of healthcare services due to its expense relative to other methods [180].
Subcutaneous DMPA should therefore be far more cost-effective as women would
only have to attend a clinic annually. Additional costs would be incurred in setting up
and maintaining a reminder system and a potential rise in telephone enquiries.
Additionally the outset cost would be higher as women would require training to self-
administer however if the system is adhered to then in the long-term the cost would be
lower as found with other long-acting methods of contraception [180].
In the survey administered to current DMPA users a third of all DMPA users were
approached and completed the survey. Two thirds (67%) of current users expressed a
theoretical interest in self-administration. In the second survey 70% of current users,
40% of ex-users and 26% of never-users expressed a theoretical interest in self
administration. We were somewhat surprised that the ability to self-administer the
injection, and thereby the reduction of the number of clinic visits, might increase the
acceptability of Depo-Provera® both to women who have never used it and to those
who have tried but discontinued the method. It is likely, however, that this is an
overestimate since the reasons for discontinuation, given by ex-users, generally
related to the side effects and not to the need to attend a health professional four times
each year. Similarly the reasons given for not using DMPA related to side-effects and
not the frequency of clinic attendance.
In conclusion, the advent of a form of Depo-Provera® which would allow women to
self-administer is likely to be a benefit to perhaps as many as half of the women
choosing this method and the results from the surveys also suggest that use of
injectable contraception may increase were self administration possible [369],
Since the surveys were undertaken subcutaneous depot medroxyprogesterone
(DMPA-SC) has been licensed and made available for use. To date, it remains a
method that is administered in health clinics. A study by Picardo et al (2010) explored
the feasibility of administering DMPA-SC in a pharmacy setting in a pilot randomised
controlled trial of 50 women [533]. They found that most women found the pharmacy
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setting convenient (70%), private (100%) and were satisfied with the pharmacy as a
clinical site (89%). There were no significant differences in satisfaction between the
two sites (family planning clinic vs. pharmacy) and they concluded that
administration by a pharmacist is a feasible option.
Having demonstrated that self-administration of DMPA is theoretically an attractive
option for women, in considering the reality of self-administration, the success of
such a scheme and the health economics involved need to be tested scientifically. Our
findings have been taken forward by researchers at the University of Carolina [534]
and also the PATH organisation [535].
Researchers at the University of North Carolina have recently completed a one year
prospective observational study assessing user-satisfaction, feasibility and
continuation rates of self-administration of DMPA-SC [534], Results of this study are
awaited.
The PATH organisation published a briefing summary earlier this year (July 2011)
specifying that the next steps for DMPA-SC are to assess acceptability of self-
administration in developing countries; assess the training, systems, policies, and
infrastructure necessary to sustainably implement a home-based delivery program
including self-administration and to assess storage and waste disposal requirements
and options in developing countries [535],
Most importantly subcutaneous DMPA has the potential to expand the choice of
available contraception and it is only by offering choice that the maximum number of
women will be protected and the greatest savings to the health service be gained
[222],
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Studies 4 and 5: Further development of mifepristone as a potential
novel contraceptive
Alongside these studies exploring how best to improve choice and use of existing
methods two studies were undertaken to further develop a potential new method of
contraception, mifepristone.
Mifepristone is a novel oestrogen-free contraceptive method with potential to be
developed as either a monthly pill or a daily pill. It has been proven effective as a
method of emergency contraception but is licensed in only two countries due to the
politics and controversy that surround it.
In the first study the effects of 5mg daily mifepristone were compared to the daily
progesterone-only-pill (POP), levonorgestrel, and demonstrated that mifepristone at a
daily dose of 5mg is a safe and potentially effective contraceptive [417], Striking
differences in the bleeding patterns between the two comparison groups were
demonstrated. Eighty percent of women randomised to mifepristone were either
amenorrhoeic or had less than 2 days bleeding or spotting per month. In contrast, none
of the women in the POP group were amenorrhoeic and 20% had less than 2 days
bleeding or spotting per month. These results confirmed those of previous studies of
mifepristone [415].
The relatively high incidence of amenorrhoea or reduced amount of scanty bleeding
experienced with mifepristone is likely to be better accepted than the irregular
unpredictable menstrual bleeding that occurs in the majority of women taking the
POP. The reduction in blood loss should convey health benefits to women particularly
in developing countries where the incidence of anaemia is high.
Concern has been expressed that with prolonged intake of antiprogestogens the
endometrium would undergo hyperplastic or malignant changes due to continued
exposure to unopposed oestrogen [410], In our study, the commonest histological
picture was of inactive cystic glandular dysplasia (CGD). This CGD was only found
in those women taking mifepristone. The cause of this unusual change is unknown
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and is unlikely to be due to the unopposed effect of oestrogen as it has been
demonstrated to occur in women who have profound suppression of ovarian follicular
development and where oestrogen levels were low [447,448]. Novel observations
from the study were the hysteroscopy finding of atrophic and /or oedematous
endometrium. Hysteroscopy revealed that the apparent thickness of the endometrial
cavity as measured on ultrasound reflected dilation of the glands and cavity rather
than true hyperplasia of the endometrium. The cause of this accumulation of fluid and
its nature is unknown but similar findings have been reported in rabbits following
treatment with mifepristone [414], It may be that the mechanism that normally allows
the passage/ and or re-absorption of fluid from the endometrial glands and uterus, is
obstructed leading to an accumulation of fluid within the uterus.
This study demonstrated that mifepristone at a daily dose of 5mg is a safe and
potentially effective contraceptive [417].
The next step in its development would be to undertake a large multicentre phase III
trial to further assess contraceptive efficacy and safety, particularly with respect to
endometrial cancer.
In the second study changes in vaginal morphology, steroid receptor and natural
antimicrobial content following treatment with low-dose mifepristone were assessed.
It is known that the vagina is a key portal of entry for HIV and other sexually
transmitted infections (STIs). The aim was to investigate whether mifepristone
modulated underlying mechanisms involved in transmission of HIV/SIV [490], The
absence of changes in vaginal thickness, steroid receptor and natural antimicrobial
content and their distribution in this preliminary study suggest that in contrast to other
oestrogen-free contraceptives, mifepristone is unlikely to be associated with increased
risk of transmission of HIV and other STIs [490].
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Progress with development of antigestogens since 2005
Mifepristone
These studies of mifepristone were completed by 2005. Since then we are no further
forward in developing mifepristone's potential as a daily low-dose pill. However, a
prospective case-control study undertaken by Agarwal and colleagues (2009) found
that mifepristone 200mg can act as an effective monthly contraceptive pill, given on a
fixed day in the mid-cycle without detecting LH surge in women having regular
menstrual cycles [456]. Regardless of this development the path of mifepristone's
development is faced with hurdles and political controversy. It is most commonly
known for its abortifacient properties and whilst both daily and monthly mifepristone
appear to be effective, marketing either of these does run the risk of enabling women
to easily access medication that can be overdosed in order to induce an abortion.
These issues need to be resolved before further development of either of these
methods.
However, progress has been made in two areas - firstly with regard to safety concerns
and secondly with respect to development of antigestogens as contraceptives.
Safety of progesterone receptor modulators (PRMs)
A potential concern about continuous daily treatment with a progesterone antagonist
is that the endometrium would be chronically stimulated by oestrogen (unopposed
oestrogen) leading to development of endometrial cancer. There has been much
debate about the histological findings, post treatment with PRM's, of the
endometrium.
The primary concerns have been centred on possible associations with endometrial
hyperplasia. Although, several changes have been identified in endometrial samples
from women receiving PRM treatment, descriptions of these changes have not fitted
into the existing lexicon for histology or pathology, and at the time of our study no
common labels had been devised. Instead, how samples were diagnosed was
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dependent largely on the pathologist's experience in examining PRM-treated
endometrial tissue. Therefore, in 2006 a National Institute of Child Health and Human
Development workshop was held to discuss the properties of progesterone receptor
modulators (PRMs), the effects of perturbed hormonal control of the endometrium
and the need for further understanding of the biology of progesterone receptor action
to facilitate the development of new PRMs [536], A panel of seven expert
pathologists was convened at this meeting to evaluate endometrial changes associated
with a minimum of three months of chronic treatement of PRMs. Four different
agents were used in the treatment regimens but the pathologists were blinded to
treatment regimen or agent. Some of the slides used were from our double blind
randomised controlled trial of mifepristone versus levenorgestrel where women took
mifepristone for six months.
Overall a "class effect" was noted, designated as PRM associated endometrial change
(PAEC). The panel agreed that the endometrial biopsies did not fit into a classification
of either proliferative or secretory endometrium but exhibited an ususual architecture
that could be characterised as glandular dilatation. There was no evidence of
hyperplasia or cytological atypia in any of the endometrial biopsies. Expression of
proliferative markers Ki67 and PH3 was increased in post-treatment endometrial
glandular epithelium compared to baseline, however, baseline biopsies were taken
during the secretory phase when proliferative activity is at very low levels.
Consequently, the panel concluded that overall there was little evidence of mitosis
and this was consistent with a proposed anti-proliferative effect of PRMs. The panel
concluded that the biopsies did not reveal evidence of safety concern. They did,
however, feel that more study would be needed to identify long-term outcomes of
PRM treatment, rather than relying on pathologists and histologists to extrapolate
information from biopsies obtained after a short period of PRM exposure [536,537].
Development as an emergency contraceptive
A selective progesterone receptor modulator (SPRM), ulipristal acetate (ellaOne®),
has been developed for use as an oral emergency contraceptive tablet and was
licensed for use in the UK on October 1st 2009 [469],
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Ulipristal acetate (ellaOne®)
EllaOne® is now widely available throughout Europe (27 countries) and also in
Singapore, Malaysia and the United States [469], It is used to prevent unintended
pregnancy for up to five days post unprotected sexual intercourse or contraceptive
failure.
Mechanism of action
Administering ulipristal acetate before ovulation causes delayed follicle development
and release, probably as a result of suppression of oestrodiol levels [538]. If taken
during the LH peak, follicular rupture and ovum release may also be delayed [539],
During the latter part of the menstrual cycle, ulipristal acetate's effect may be
attributed to its ability to decrease endometrial thickness [538],
Efficacy
The safety and efficacy of ulipristal acetate 30mg for EC has been evaluated in two
pivotal phase three trials [540,541], Fine et al. (2010) evaluated ulipristal acetate use
by a total of 1,241 women. Pregnancy rate was 2.1% (95% CI 1.4-3.1%) which met
the protocol-defined criteria for success. Additionally, efficacy did not decrease over
time. Pregnancy rates were: 2.3% (1.4-3.8%), 2.1% (1.0-4.1%) and 1.3% (0.1-4.8%)
for intervals of 48 to 72 hours, more than 72-96 hours and more than 96-120 hours
respectively [541], The second phase three trial was by Glasier et al. (2010) [540].
The study assessed the non-inferiority of ulipristal acetate to levonorgestrel. Women
were randomly assigned to either ulipristal 30mg (n=1104) or levonorgestrel 1.5mg
(n=1117). In the efficacy-evaluable population, administration of EC-drug within 72
hours of unprotected intercourse resulted in 37 pregnancies. Of that group, 22 women
(2.6%; 95% CI 1.7-3.9) were in the levonorgestrel group (n=852) and 15 women
(1.8% 95% CI 1.0-3.0) were in the ulipristal acetate group (n=844). This finding was
not statistically significant. Of those women treated at 72-96 hours post unprotected
intercourse (n=203), three pregnancies occurred. All three were in the levonorgestrel
group. This difference was statistically significant (P=0.037). Overall the pregnancy
rate (0-72hours) with ulipristal (1.4%) was significantly lower than the expected rate
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(5.5%) (p=0.001). The pregnancy rate (0-72hours) with levonorgestrel was 2.6%; the
expected rate had been 5.4% (p=0.001). Therefore, the authors concluded that
ulipristal is non-inferior to levonorgestrel [538,540].
Safety and tolerability
Ulipristal acetate is generally well tolerated and its adverse effects and risks are
considered to be no more severe than those of levonorgestrel [539,541], It may cause
a delayed onset of the next expected menstrual period, although this effect is usually
transient and the menstrual cycle typically returns to normal for subsequent cycles
[538],
Dosage and administration
The recommended dosage is a single 30mg oral tablet, taken after unprotected
intercourse or contraceptive failure. The drug should be taken as soon as possible and
within five days (120 hours) of the incident [538],
Strengths and limitations of the studies presented in this thesis
Each of the studies presented in this thesis had their various strengths and limitations.
Unintended pregnancy and use of emergency contraception study
This was a large questionnaire survey which aimed to survey every pregnant woman
over seven and a halfmonths in a variety of clinic locations. Its strengths included use
of a validated tool (LMUP) to measure intendedness of pregnancy and, considering
the complex logistics of clinic locations spread throughout Lothian, both the handout
(78% abortion clinic; 93% antenatal clinic; 92% pregnancy support clinics) and
response rates were excellent (78% abortion clinics; 86% antenatal clinics; 79%
pregnancy support clinics). The main limitation of this study was selection bias.
Health care professionals, either due to time pressures or due to professional
judgement of the woman's emotional state, did not hand out a questionnaire to every
woman. This was more prevalent in the abortion clinics (22%) than in the antenatal or
pregnancy support centre clinics (7-8%) p<0.001, A further limitation of the study
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was that in an effort to ensure completion we tried to minimise the number of
questions. However it would have been valuable to have some demographic
questions, especially postcode. If this study were to be repeated I would suggest that
the demographic fields could be completed ahead of time by staff and this would
reduce the likelihood of selection bias and allow for comparison of baseline
demographic characteristics of responders to non-responders. It would, however,
require a time commitment from the staff looking after these women, both of which
are difficult due to the multiple pressures faced in these clinics.
The strengths and limitations of the methodology are discussed separately below.
Implanon® survey
This was a questionnaire survey which aimed to assess continuation rates of
Implanon® use in a large family planning clinic setting. The main strength of this
survey was that it used 'real life' data. Due to the multiple capture methodology of
case note review followed by postal questionnaire followed by telephone the loss to
follow up was minimised (15%). Limitations of the study included lack of ethical
approval. For the study we undertook, ethical approval was not required but had we
obtained it we would have been able to collect more demographic data, including
postcode, and this would have allowed us to undertake some comparative analyses.
For those who responded via letter or telephone they were asked to recall when they
had their implant removed. For some this will have been some time previously and
hence recall bias is very likely in these cases. We could have further strengthened our
study by carrying out a survival analysis similar to previous studies looking at
continuation rates [228,229], The survey methodology is discussed below.
Depo-provera® survey
This was a pilot study to identify if women would be interested in self-administration
of subcutaneous depo-provera® and it found that many women would in theory. Its
strengths included that it managed to survey a third of the depo-provera users in the
clinic. The overall response rate was excellent (100% for questionnaire 1 and 87% for
questionnaire 2). This is likely to have been due to having very short questionnaires
and also because both were to be completed on site.
Similarly to the previous study limitations included lack of ethical approval and hence
no demographic data being collected which then limited the statistical analyses
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possible. The poor layout of questionnaire two was an additional limitation. It led to
questions 6 and 7 being very poorly answered. When the data was inspected we found
that current users and past users had response rates of 92 and 94% respectively whilst
non-DMPA users had response rates of 72% for those who had never considered
DMPA and 39% for those who had considered DMPA in the past but not used it. This
led us to reviewing the layout of the questionnaire and finding that having questions 6
and 7 below question 3 meant that it was very likely that non-DMPA users felt it did
not apply to them. Additionally below the question directed to non-DMPA users (Q5)
was a request to seal the envelope and return the questionnaire to reception so it is
likely that many felt that there were no further questions to respond to.
Mifepristone versus levenorgestrel study
This was a multi-centre randomised controlled trial comparing the frequency of
amenorrhoea (primary outcome), bleeding patterns, side-effects and efficacy in
women taking 5mg daily mifepristone or 0.03mg levenorgestrel for a duration of 24
weeks. This study had many strengths. It was a randomised control trial and it was
performed in accordance with good clinical practice guidelines. Assessment bias was
reduced by double blinding. By being a multi-centre study it showed effectiveness in
a range of cultures and allowed for generalisability. There was a focussed question
where the population was well defined as were the intervention and the outcomes
studied. A power calculation was undertaken for amenorrhoea though not for efficacy
or ovulation and this would have been useful. The use of a 3:1 ratio for
mifepristone:levenorgestrel was very useful for increasing the power of the study.
Using block computer generated randomisation performed individually for each
centre ensured a balanced 3:1 allocation.
Limitations included that the study was potentially not truly double blind. The
placebo tablet was similar but not identical to either of the active drugs and hence it
would have been possible for the persistent subject and/or the researcher to identify
which was which. Whilst a multicentre approach has great benefits with respect to
generalisability and recruitment it also has its limitations. It is possible that whilst
there was a clear protocol there may have been some centre differences in research
methods. We tried to minimise this by holding regular meetings between centres,
having the network director (Professor Baird) and the network coordinator (Dr
Morrow) visit each site annually and review both the methodologies and the case
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notes during these visits. The assessment of ovarian function by eight weekly
progesterone levels was imprecise and ifwe were to repeat the study it might be better
to ask for twice weekly urine samples. In the analysis we possibly should have used
an intention to treat analysis and thus included the one lady who left the trial before it
started.
Mifepristone effect on the vagina study
This was a small pilot study to assess the changes in vaginal morphology, steroid
receptor and natural antimicrobial content following treatment with low-dose
mifepristone. The aim was to understand if mifepristone might be protective against
STI's including HIV. The study had a number of strengths. It had ethical approval and
was performed in accordance with good clinical practice. Vaginal biopsies were taken
both before and after treatment allowing for comparison to be made. Ovarian function
was measured in a much more reliable way, using urinary tracking, than in the
previous study. The next step would be to carry out a larger study with a longer
duration of intake ofmifepristone.
Questionnaire survey methodology strengths and limitations
Three of the studies (chapters 2-4) involved structured questionnaire surveys
[46,231,417]. Structured questionnaires involve the use of fixed (standardised)
questions and/or scales which are presented to respondents in the same way, with no
variation in question wording, and with mainly pre-coded response choices. We
administered them in a variety of ways - on-site completion, postal and by telephone.
Of these three routes postal completion is the least successful and our response rates
clearly demonstrated this (47% response rate for postal returns as opposed to 100%
and 89% response rate for questionnaires completed on-site and by telephone). The
reasons for using this methodology included: (i) the ability to collect unambiguous
and easy to count answers, leading to quantitative data for analysis; (ii) greater ease of
data collection and analysis; (iii) the ability to include large samples of people
(especially in the study of levels of unintended pregnancy and EC use) at low cost.
Additionally we were able to collect routine information from questionnaires and
supplement information from medical notes, where permission to access them had
been obtained.
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Disadvantages of this methodology included that pre-coded responses are not
necessarily sufficiently comprehensive and not all answers may be easily
accommodated. Some respondents may therefore have felt 'forced' to choose
inappropriate pre-coded answers that may not have fully represented their views.
Additionally, structured self-administered questionnaires rely on the assumption that
questions can be worded and ordered in a way that will be understood by all
respondents. As we found this is not always be justified. In the second self-
administered DMPA-SC questionnaire offered to every woman attending an
Edinburgh family planning clinic we found that unfortunately the response rates for
questions regarding self-administration and clinic attendance (questions 6 and 7,
questionnaire 2) were lower than expected when compared to other questions on the
same questionnaire. On further investigation it was found that response to these
questions by current and previous users were 92% and 94% respectively whilst
response by non-DMPA users was 65% and 68% suggesting that poor design layout
might have been the cause. We were however able to allow for some measure of
validity and reliability of the questionnaires as both questionnaires administered for
the purpose of the DMPA-SC survey indicated that 70% of users would be interested
in self-administration. Two further disadvantages of questionnaire surveys are recall
bias, loss to follow up (specifically due to change of addresss in the case of the
Implanon® survey) and non-response bias which reduces the effective sample size
and can result in loss of precision of the survey estimates. The latter is especially a
problem where surveys are not completed on-site.
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Relevance of this research in Scotland
The research findings presented in this thesis have been particularly relevant to recent
policy developments in Scotland. Specifically, the findings have advocated for
increasing awareness of risk of unintended pregnancy in women and couples;
increasing ease of access to emergency contraception; encouragement of correct and
consistent use of contraception and specifically LARC methods; and further
development of novel methods of contraception as well as exploring the reality of
self-administration ofDMPA-SC.
In January 2005, as we were completing our research, the Scottish government
launched the first phase of 'Respect and Responsibility: A Strategy and Action Plan
for Improving Sexual Health' [542], For the first time government policy set out a
framework for improving sexual health in Scotland and access to information and
services, whilst allowing flexibility for local services to respond to local needs. It
recognised that sexual health is not just the absence of disease, but includes a range of
ethical, moral, cultural and social issues and is firmly based on the principles of
respect for self, respect for others and strong relationships.
Actions were geared towards:
• Improving the quality, range and consistency, accessibility and cohesion of sexual
health services
• Supporting everyone in Scotland to acquire and maintain the knowledge, skills
and values necessary for good sexual wellbeing and thus avoid sexually
transmitted infections and unintended pregnancy
• Positively influencing cultural and social factors that impact on sexual health
The aim of the first phase of the strategy (2005-8) was to focus on supporting
improvements in sexual health provision [542]. The NICE guidance (to which our
data contributed) published later that year was absorbed into the frameworks evidence
base and became a key part of the strategy [180],
One of the outcomes from this framework during the first phase, in keeping with our
research findings, was that EC became available for free from pharmacies (LNG not
ellaOne which is only available on prescription) [543].
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The second phase of the plan was launched in 2008 and is now nearing its end [544],
In the second phase focus shifted from supporting improvements in sexual health
provision to achieving cultural and behavioural change. A key focus has been
encouraging awareness, access to and use of LARC, all in keeping with the findings
from the research presented in this thesis. New developments within the second phase
included a new Scottish government website (launched June 2009)
(http://www.sexualhealthscotland.co.uk/), social marketing campaigns [545], led by
the Scottish Government and NHS Health Scotland, as well as the publication of an
HIV Action Plan.
The social marketing campaign was launched in July 2009 and it was specifically
aimed at 'Giving you more choice' and even more importantly was called the longer-
lasting contraception campaign [545]. Its aims in the short term were to increase
awareness of contraceptive choices, particularly the IUD, IUS and implants; in the
medium term increase use of these and the number of health professionals offering
these methods and in the long term reduce the number of unintended pregnancies and
repeat terminations.
The Scottish Government are currently in the process of drafting a new sexual health
framework which will outline the strategic aims for sexual health for 2011-15.
The above policy and its outcomes appear to be making an impact on levels of
unintended pregnancy. For the past two years there has been a fall in the number and
rate of abortions with 12,826 in 2010, compared with 13,108 in 2009 and 13, 902 in
2008 (representing rates of 12.3/1000 women aged 15-44 in 2010, 12.6 in 2009 and
13.3 in 2008) [3]. This fall is a change to the overall pattern of increase since the
implementation of the 1967 Abortion Act, although small dips for short periods (e.g.
1981-3) have been observed before and one cannot guarantee that this fall will
continue nor can we be certain as to the cause [3].
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Conclusion
In this thesis I have sought to explore a number of areas, all pertaining to trying to
reduce the levels of unintended pregnancy, in an effort to increase the knowledge base
in this field. It has now been some years since this research was carried out. The
benefit of this is that I can see that the findings have been both relevant and useful to
other researchers, practitioners and policymakers.
Appendix 1: Contraceptive use in month of becoming pregnant by those
attending for termination of pregnancy
Method of contraception No. women using (%)
N=907
No method 238 (26.2)
Withdrawal 33 (3.6)
Breastfeeding 5 (0.6)











74% of those attending for termination were using a method of contraception in the
month that they conceived.
Over one third (36%; 278/770) women who were using a method when asked
admitted
"I/we were using contraception but not on every occasion".
71% of those who scored less than 3 on the LMUP i.e had a clearly unintended
pregnancy were either using no method of contraception or less effective methods
(condoms/withdrawal, NFP, breastfeeding or cap/diaphragm).
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Unintended pregnancy and use of emergency contraception
among a large cohort ofwomen attending for antenatal care
or abortion in Scotland
Fatim Lakha, Anna G lasier
Summary
Loncet2006;368:1782-87 Background Unintended pregnancy is common. Although many unintended pregnancies end in induced abortion,
up to a third of those proceeding to birth might be unplanned. Some of these pregnancies could be prevented by
emergency contraception. We have sought to establish how many pregnancies ending in either childbirth or abortion
are unintended, and what proportion ofwomen use emergency contraception to try to prevent pregnancy.
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Methods 2908 women who attended an Edinburgh hospital for antenatal care and 907 attending for abortion fully
completed a self-administered questionnaire including a validated measure of pregnancy intention and questions
about emergency contraceptive use.
Findings 814 (89 -7%) of 907 pregnancies among women requesting abortion were unintended compared with only
250 (8 - 6%) among 2908 women who planned to continue pregnancy. However, only 1909 (65 -6%) of continuing
pregnancies were intended. The rest of the women were ambivalent about pregnancy intention. In women who
continued with their pregnancies intendedness was related to age, with unintended pregnancy most probable in
young women (p<0 0001). Emergency contraception was used by 113 (11-8%) ofwomen who requested abortion but
only 40 (1%) of those planning to continue pregnancy. In those whose pregnancy was continuing, the proportions
reporting use of emergency contraception were higher in young women than in older women and in those who
reported that their pregnancies were unintended than in those who meant to become pregnant (both pcOOOOl).
Interpretation Unintended pregnancy is common, even among women planning to continue pregnancy. However,
EC use is low even among women with no intention of conceiving, and is thus unlikely to reduce unintended
pregnancy rates. Rather, we need to find ways to improve the use of regular contraception.
Introduction:
Unintended pregnancy is common. In the UK, almost
200000 pregnancies are terminated every year.1,2
Additionally, a substantial number of births result from
unintended conception. In a questionnaire survey of
2000 mothers who were randomly selected from birth
registrations in 1989 and interviewed 6 months after
childbirth, almost a third of pregnancies (31-3%) were
"unplanned".1 A simple measure of pregnancy intention
was devised and validated by Barrett and colleagues4 in
2004 (table 1); however, there have been no estimates of
pregnancy intendedness in women in the UK since 1989.
Up to a quarter of pregnancies that end in induced
abortion in the UK arise from unprotected sexual
intercourse; most of the rest are the result of inconsistent
or incorrect use of contraceptives (eg, missed pills) or
accidental damage of barrier contraceptives (eg, a burst
condom).5,6 Emergency contraception can prevent
pregnancy if used within 72 hours of unprotected sex.7*
The only marketed product in the UI< (oral levonorgestrel
1 • 5 mg) is thought to prevent over 80% of pregnancies
depending on how soon after intercourse it is used.7
Trussell and colleagues" estimated that ifevery woman in
the USA used emergency contraception every time it was
needed, 1 • 7 million unintended pregnancies, over half of
which end in abortion, could be prevented every year.
Although knowledge of emergency contraception in the
UI< is high, use is rather low. In 2003-04, 6% ofwomen
aged 16—49 years had used emergency contraception
within the previous year although more than 94% of
women knew about it."1 One small study showed that
about 11% of women presenting for abortion in the UK
in 2000 had used emergency contraception to try to
prevent the pregnancy,5 but there are no data on the use
of emergency contraception among women who
continued with their pregnancies.
In 2005, we undertook a questionnaire survey designed
to quantify pregnancy intention and use of emergency
contraception among women who presented over the
course of 8 months to a large teaching hospital in
Edinburgh, UK, for antenatal care, or to attend the
pregnancy support centre (women who have a history or
high likelihood of miscarriage), or for termination of
pregnancy.
Methods
From July 5, 2004, until Feb 28, 2005, all women booking
for antenatal care or abortion in the New Royal Infirmary
ofEdinburgh, were invited to complete a self-administered
questionnaire asking about pregnancy intention and use
of emergency contraception. We excluded women whose
fetus was shown to have died, by ultrasonography, and
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those who were unable to read or write English well
enough to understand or complete the questionnaire.
Women who were judged by the nursing staff to be
distressed about the clinical consultation were not offered
the questionnaire. This judgment applied mainly to
women presenting at the abortion clinic.
Before seeking ethics approval for the study, we asked
207 women to read and comment on a draft information
sheet and questionnaire. The final questionnaire
consisted of 15 questions about age, pregnancy gestation,
contraceptive use (including emergency contraception)
in the month of conception, and pregnancy intention.
Intendedness was measured by using Barrett and
colleagues' instrument (table l).4 For the intendedness
-score, the answer to each of the six questions was scored
■from 0 to 2, so the total scores ranged from 0 (least
intended) to 12 (most intended). Although Barrett and
colleagues emphasised that there were no obvious cutoff
=points on the range of scores obtained, they suggested
that three score groups were identifiable: 10-12 (planned),
-4-9 (ambivalent), and 0-3 (unplanned).4 These three
groups were used for the purposes of analysis and
discussion. Ethics approval for the survey was obtained
from the local research ethics committee.
On the basis of an estimated proportion of emergency
contraceptive use of at least 10%s among women
-presenting for abortion and our estimate of 2% for
women continuing their pregnancies, a sample size of
1000 women undergoing abortion and 4500 booking for
antenatal care was needed to ensure that the upper
confidence limit for proportion of emergency contra¬
ceptive use was only 50% higher than the lower limit.
The study was powered to 90% and the confidence
intervals set to 95%. Quality control checks were done on
5% ofall data entries. Data were analysed by use of Excel
(2003) and SPSS (version 12).
Groups were compared byx2 tests for binary data, Mann-
Whitney tests for intendedness scores, and two-sample
t tests for age and gestation. Ages in different intendedness
groups were compared by one-way ANOVA.
■Results
5686 pregnant women attended the hospital during the
study period, 5630 of whom were eligible to participate
(figure 1). Less than 1% ofwomen were judged to be too
distressed to be offered a questionnaire. 1285 (78%) of
1645 women attending for abortion were given the
questionnaire and it was returned by 1006 (78%). 2905
(93%) of women attending the antenatal clinic and 810
(92%) of those attending pregnancy support centre were
given the questionnaire; of those women, 2496 (86%)
and 643 (79%), returned the questionnaire, respectively
(figure 1). Women attending for abortion were younger
than those planning to continue their pregnancies and
women seeking abortion or attending the pregnancy
support clinic attended hospital at an earlier gestation
than those women attending an antenatal clinic (table 2).
Question Answer Score
Ql. At the time of conception Always used contraception 0
Inconsistent use 1
Not using contraception 2
Q2. In terms of becoming a mother Wrong time 0
OK but not quite right 1
Right time 2
Q3. Just before conception Did not intend to become pregnant 0
Changing intentions 1
Intended to get pregnant 2
Q4-Just before conception Did not want a baby 0
Mixed feelings about having a baby 1
Wanted a baby 2
Q5- Before conception Had never discussed children 0
Discussed but no firm agreement 1
Agreed pregnancywith partner 2
Q6. Before conception No actions 0
Health preparations (1 action*) 1
Health preparations (a2 actions*) 2
Health preparations included: taking folic acid supplements; stopping or reduction of smoking; stopping or reduction
ofdrinking alcohol; healthy eating; seeking medical advice before conception.
Table 1: Pregnancy intendedness instrument4
3815 women answered all six questions in the
intendedness measure, 2908 of them continuing their
pregnancy and 907 who requested abortion. 814 (89 • 7%)
ofwomen who requested abortion had a total score of 3
or less, which suggests that their pregnancies were
unintended (table 2). Only two women who wanted an
abortion scored 10 or more (intended) and 91 (10-0%)
were ambivalent about the intendedness ofthe pregnancy
Figure 1: Study profile











Mean (SD) 250(6-7) 30-3(6-2) 29-6 (5-8) 29-7(5-9) <0-0001 0-002
Range 10-45 14-44 15-44 14-44
Gestation (days)
Mean (SD) 56 (19) 58(15) 92(17) 87(21) <0-0001 <0-0001
Range 7-181 16-129 44-270 16-270
Total intendedness score, n (%)
10-12 (intended) 2 (0-2%) 402 (65 4%) 1507(65-7%) 1909 (65-6%) <0-0001 0-42
4-9 (ambivalent) 91 (10-0%) 140 (22-8%) 609 (26-6%) 749(25-8%)
0-3 (unintended) 814(89-7%) 73(11-9%) 177(7-7%) 250 (8-6%)
EC used in conception cycle
Yes 113 (11-8%) 17(2-7%) 23 (1-0%) 40 (1-4%) <0-0001 0-002




74(65%) 7(41%) 13 (56%) 20 (50%) 0-12 0-42
Oemergency contraception. "Seeking abortion versus total continuing with their pregnancy. tAttending
niscarriage clinic versus those attending the antenatal clinic. tPercentage is of those answering "Yes" to use of
mergency contraception in conception cycle.
able 2: Characteristics ofwomen, use of emergency contraception, and intendedness score
(score 4—9), (figure 2), Of the women who planned to
continue their pregnancies, 250 (8-6%) scored less than
3 (unintended), 1909 (65-6%) scored 10 or more
(intended) and 749 (25 • 8%) had some ambivalence about
their intention to conceive (score 4—9) (table 2, figure 2).
Intendedness was associated with age in women who
chose to continue with their pregnancies; women who
had intended to become pregnant were significantly
older than those who were ambivalent or had unintended
pregnancy. There was no significant association between
age and intendedness in women presenting for abortions
(table 3). 113 (11-8%) women presenting for abortion
used emergency contraception to try to prevent pregnancy
whereas only 40 (1-4%) of those continuing with their
pregnancies had done so (table 2). Of the women who
used emergency contraception, 74 (65%) of those
attending for abortion and 20 (50%) of those continuing
with their pregnancy said they had used it after every
episode ofunprotected intercourse during the menstrual
cycle in which they got pregnant. Women who used
emergency contraception were significantly more likely
to score low rather than high on the intendedness scale,
both in the abortion group and in those continuing their
pregnancies (table 4). In women continuing with their
pregnancies, young age was significantly associated with
emergency contraception use (p<0-0001). Age was not
related to emergency contraception use in women
seeking abortion, but in this group, women who
presented before 39 days of gestation were significantly
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Figure 2. Spread of intendedness scores forwomen undergoing induced
abortion and for all women continuing their pregnancies (including those
seen in the miscarriage clinic).
0=least intended pregnancies, 12=most intended.
Discussion
In Edinburgh in 2005, only two-thirds of pregnancies
destined to end in childbirth were clearly intended, one
in ten was unintended, and around a quarter of women
were somewhat ambivalent about their intention to
become pregnant. When Barrett and colleagues
developed their instrument, they took care to describe
the differences in the meaning of the words "planned
and unplanned", "intended and unintended", and
"wanted and unwanted".4 In 1989, Fleissig" used the
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Mean age (years)
Seeking Miscarriage Antenatal Continuing
abortion clinic clinic pregnancy total
Intended 310 31-9 310 31-2
Ambivalent 24-9 28-3 27-3 27-5
Unintended 24-8 25-8 25-6 25-7
p 0-28 <0-0001 <0-0001 <0-0001
p values are from one-way ANOVA.






0-19 19 (9-3%) 1(3-7%) 6 (3-6%) 7(3-6%)
20-24 35 (11-1%) 8(7-8%) 7(2-3%) 15 (3-7%)
25-29 34(17-4%) 2 (1-6%) 5 (0-9%) 7(1-0%)
30-34 10 (8-8%) 4(2-1%) 2 (0-2%) 6 (0-6%)
a35 11(10-4%) 2 (1-2%) 3 (0-7%) 5 (0 8%)
P* 0-64 0-011 00001 <0-0001
Gestation (days)
0-39 21 (22-8%) 2 (5-0%) 0 2 (5-0%)
40-79 74 (10-6%) 9 (2-5%) 2 (0-9%) 11 (1-8%)
80-119 6 (8-7%) 1(2-5%) 17 (1-0%) 18 (1-0%)
zl20 2 (14 3%) 0 3(3 8%) 3 (3 8%)
P* 0-015 0-48 0-13 0-19
Intendedness
Intended 0 6 (1-6%) 1 (0-1%) 7(0-4%)
Ambivalent 4(4-7%) 7(5-0%) 14(2-4%) 21 (2-9%)
Unintended 96 (12-3%) 3(4-1%) 6 (3-5%) 9(3-7%)
P* 0-031 0-054 <00001 <0-0001
Percentages are the proportion ofwomen in that age, gestational stage, or
intendedness group who used emergency contraception. Information is not
available for all participants. * ^test for trend.
Table 4: Trends in maternal age, gestational stage, and pregnancy
intendedness among women using emergency contraception
word "unplanned" and the questionnaire was completed
by women 6 months post partum. Despite the difference
in timing of the survey, and differences in wording of
the questionnaires, the proportion of pregnancies that
are "planned" or "intended" has not changed since
Fleissig"s study. This finding is perhaps surprising given
the demographic changes (falling birth rates, later age of
first childbirth)", changes in sexual behaviour,12 and the
increase in contraceptive choice in the past 25 years."
The relation between age and intendedness among
women continuing their pregnancies is unsurprising.
The findings that over 90% of pregnancies ending in
abortion were unintended and that only 10% of women
requesting abortion were ambivalent about their
pregnancies is consistent with the findings of a smaller
study of 300 women in Edinburgh undergoing abortion,
in which a similar proportion claimed to have used
emergency contraception.' In that study a modified
version of the intendedness measure was used in a
face-to-face interview rather than in a self-administered
questionnaire. Despite the methodological differences,
both studies show that most women who requested
abortion had no intention to conceive.
One in ten women undergoing abortion and a quarter
ofwomen continuing with their pregnancies seemed to
have some ambivalence about pregnancy intention. Since
the number ofwomen who were ineligible for the study
or deemed to be too distressed to be given the
questionnaire was small we do not believe that inclusion
of these women would have altered the findings.
The observation of a relation between intendedness and
emergency contraception use adds weight to the validity of
Barrett and colleagues' scoring system. The results also
suggest that, women who are ambivalent about their
pregnancies are more likely to continue than to have them
terminated. The association between use of emergency
contraception and earlier gestational stage at presentation
among women requesting abortion is probably related to
heightened awareness of the risk of pregnancy since they
recognised that they were at risk of pregnancy before
missing a menstrual period. Use of emergency
contraception was related to age only for women who
were continuing with their pregnancy, perhaps because
younger women are more ambivalent about avoiding
pregnancy than older women.
The availability and use of emergency contraception
varies around the world. Although use ofa combination of
oral contraceptive pills as a substitute for emergency
contraception has always been possible, in many countries
a dedicated product has only recently become available.
Generally, use does not start to increase until such a
product becomes available (eg, in Nigeria and the USA in
1998, in France in 1999, and in India in 2002). In much of
sub-Saharan Africa, the former Soviet Union, and the
Middle East, a dedicated product is not available. In a 2001
survey of 880 female undergraduates in Nigeria, ofwhom
34% had had an abortion in the past, 58% knew about
emergency contraception, but only 2% had ever used it." In
a group of 623 women who sought contraception or
abortion in India—where an estimated 5-6 million
abortions occur each year, most of them illegal—only 6%
knew about emergency contraception and none had ever
used it." In more developed countries, knowledge of
emergency contraception is greater and more women use
it. Among women undergoing abortion, the proportion
who said they had used emergency contraception to try to
prevent the pregnancy was 1-3% in the USA in 2000,"
2-9% in Sweden in 2000,17 and 9-2% in France in 2002."
Use of emergency contraception has increased in the UK
since it was first licensed in 1984. In a questionnaire study
ofwomen presenting for abortion in Dundee in 1984,1%
of women had tried to prevent the pregnancy with
emergency contraception." When the study was repeated
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in 1996, 7% of women had used emergency contra¬
ception.20 Nevertheless, emergency contraception is
unlikely to prevent many pregnancies if, as in our survey
ofwomen who became pregnant, only one in ten women
who definitely did not want to become pregnant use it in
cycles when they have put themselves at risk of
pregnancy, and not much more than half of those use it
with every act ofunprotected intercourse. The availability
of emergency contraception over the counter in UK
pharmacies does not seem to have resulted in increased
use.2'
Other studies have shown that failure to recognise the
need to use emergency contraception is common. In a
questionnaire study of 1365 women who had induced
abortions in France, 90% had heard of emergency
contraception but only a third had ever used it and only
9% had used it in the cycle in which they became
pregnant.18 38% of the women were aware that they had
put themselves at risk ofpregnancy in the cycle in which
they conceived—most of these were either not using
contraception or were relying on condoms or withdrawal.
Nine out of ten of them knew about emergency
contraception but only one in four of them used it. More
than half the women did not realise that they were at risk
of pregnancy, and only 2-8% used emergency
contraception. Lack of knowledge of how and when to
use emergency contraception, difficulties with getting
hold of it, and reservations about using it are all
commonly cited barriers to its use.22 However, without
these barriers, most women who have become pregnant
and could have used emergency contraception to prevent
an unwanted pregnancy failed to do so. Several studies,
from various settings, in which women were given a
supply of emergency contraception in advance of need
have shown that three out of four women who put
themselves at risk of pregnancy, even when they had a
supply at home, did not use emergency contraception
because they did not recognise—or did not acknowledge—
the risk.25-"
Although 98% ofwomen who wish to avoid pregnancy
use contraception in the UK,10 abortion rates continue to
rise.1,2 Unintended pregnancies that end in childbirth,
unless they occur in teenagers, are of less concern to
policymakers than those that end in abortion, but they do
affect the lives of the women involved. Understanding of
sexual behaviour and patterns of contraceptive use is
crucial for development of interventions to reduce
unintended pregnancy. This survey needs to be repeated
in other settings, and ifthe findings are similar elsewhere,
a strategy will need to be developed to improve contra¬
ceptive use. We need to find ways to raise awareness of
the real risks of pregnancy associated with lack of use of
contraception or with incorrect or inconsistent use.
Emergency contraception is unlikely tomake a substantial
difference to pregnancy rates. Condoms and oral
contraceptive pills are themost commonly used reversible
methods of contraception in the UK and both rely on
consistent use for their effectiveness. Condom use is
commonly inconsistent, and compliance with oral
contraception is not easy. In one US study, 47% ofwomen
reported missing one or more pills per cycle and 22%
reported missing two or more.26 In a study that used
electronic diaries to record compliance, 63% of women
missed one or more pills in the first cycle ofuse, and 74%
did so in the second cycle.27We need to encourage women
who clearly want to avoid pregnancy and are taking risks
to use long-acting contraceptive methods (implants and
intrauterine devices) that do not depend on compliance
for their effectiveness.2"
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Abstract
Background: Long-acting reversible methods of contraception can potentially reduce unintended pregnancy. There are few data on "real-
life" continuation rates of the contraceptive implant Implanon®.
Materials and Methods: Three hundred twenty-four women choosing Implanon® in a community family planning clinic in Scotland were
followed up by case note review (n = 236) or postal questionnaire (n = 87) 3 years after insertion of the implant (1 woman chose not to
disclose her home address).
Results: Data were available for 85% of the women. Continuation rates were 89% (CI 84-91) at 6 months, 75% (CI 69-79) at 1 year, 59%
(CI 52-63) at 2 years and 47% (CI 40-52) at 2 years and 9 months. Of the 68 women who discontinued Implanon® within 1 year, 62 (91%)
did so because of unwanted side effects, the most common being frequent and/or unpredictable bleeding (n =42, 62%). Almost half changed
to a less-effective method of contraception; however, one third (n=99, 39%) chose to use a second implant when the first one expired.
Conclusions: Continuation rates of Implanon® in this clinic setting in the UK make it a cost-effective method of contraception and justify its
widespread provision.
© 2006 Elsevier Inc. All rights reserved.
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1. Introduction
Unintended pregnancy is a global problem. A recent
guideline from the National Institute of Health and Clinical
Excellence (NICE) in the UK suggested that increased
uptake of long-acting reversible methods of contraception
(LARC) would reduce unintended pregnancy [1],
Implanon® is a long-acting reversible contraceptive that
lasts for 3 years and is independent of compliance for its
effectiveness [2], It has been suggested that the high up¬
front cost of the implant (UK £90 in 2005) limits its
availability in parts of the UK [1] and perhaps in other
countries. Cost-effectiveness of all methods of contraception
depends on their associated continuation rates, but this is
particularly relevant for the very long acting methods
* Corresponding author. NHS Lothian Family Planning and Well
Woman Service, EH4 1NL Edinburgh, Scotland, UK. Tel.: +44 131 332
7941, fax: +44 131 332 2931.
E-mail address: anna.glasier@lpct.scot.nhs.uk (A.F. Glasier).
(implants and intrauterine contraceptives). Continued use
of Implanon® has been shown to be high in international
clinical trials, with more than 80% ofwomen still using the
method after 2 years [3]. However, participants in prospec¬
tive trials often have relatively high continuation rates of
drugs because the inclusion criteria for trials are rigid and
tend to bias toward a willingness/likelihood to continue the
method. Regular study-related follow-up visits serve as a
positive reinforcement, and in countries where women have
to pay for contraception and where healthcare is expensive,
provision of free supplies and services through clinical trials
ensures good compliance [4], "Real-life" data are much
harder to come by. Moreover, much of the data for
Implanon® come from developing countries where the
availability of and access to other methods of contraception
are usually limited and where continuation rates are often
high. In a review of evidence from European settings, the
NICE guideline concluded that 20-25% of women will
discontinue Implanon® within 1 year of insertion and that
up to 44% will stop using the method within 2 years [1].
0010-7824/$ - see front matter © 2006 Elsevier Inc. All rights reserved,
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Only two small studies have investigated continuation
rates in the clinic setting in the UK. One study followed up
191 women for only 1 year [5]. In the other study, which
followed up very few women for 3 years, the probability
that Implanon® was still being used at 3 years was .53 [6].
To determine continuation rates of Implanon® in clinical
practice, we undertook a retrospective case note review and
questionnaire survey 3 years after insertion of Implanon® in
a cohort of 326 new users attending a large family planning
clinic in Edinburgh, Scotland.
2. Materials and methods
Case notes for all women attending the clinic for
Implanon® insertion between January 1 and December
31, 2001, were reviewed at the end of 2004. If the implant
had been removed in the clinic, data were obtained from the
case records. Women who had not returned to the clinic for
Implanon® removal (and who had consented to being
contacted when first attending the clinic) were contacted to
remind them about the need for removal of their implant
before 3 years of use was completed. These women were
also asked to complete a brief questionnaire to determine
whether Implanon® had been removed and, if so, the date
and reason for removal of the implant, where the procedure
was done, and the method of contraception used for the first
3 months after discontinuation of Implanon®. Three
attempts at contact were made: twice by mail and once by
telephone. An interval of 2 weeks was maintained between
each attempt at contact.
Data were analyzed using Excel 2003 (Microsoft
Corporation) and SPSS version 12 (SPSS, Inc., Chicago,
IL, USA). Ages of women continuing for more or less than
2 years were compared using a two-sample t test.
Cumulative discontinuation rates were computed using
descriptive statistics. Many women returned to the clinic
slightly before 3 years after Implanon® insertion to ensure
that replacement contraception was available for use.
Women returning for implant removal more than 2 years
and 9 months after insertion were deemed to have used the
implant for its full duration.
3. Results
Three hundred twenty-four women had Implanon®
inserted in 2001. Median age at insertion was 26 years
(range, 15-49). Information about implant removal was
available for a total of 277 women (85%). Two hundred
thirty-six of these women had their implant removed in the
clinic, and data were collected from their case records.
Letters were sent to 87 women who had not returned to the
clinic for implant removal; 1 woman chose not to disclose
her home address. Forty-one women responded and
returned the questionnaire. All 46 women who failed to
respond to the request for information were no longer
residing at the address recorded in their case records.
Table 1
Contraceptive method used following removal of Implanon®
Method " (%)
No method (pregnancy desired) 28 (8)
Implanon® 99 (39)
IUD/IUS 12(5)
Depo Provera® 8 (3)
Sterilization 16 (6)
Combined pill 45 (18)
Progestogen-only pill 17 (7)
Condom 55 (22)
Withdrawal 2 (<1)
For the 277 women in whom information was available,
continuation rates of Implanon® were 89% (CI 84-91) at
6 months, 75% (CI 69-79) at 1 year, 59% (CI 52-63) at
2 years and 47% (CI 40-52) at 2 years and 9 months.
Thirty-three women did not return for implant removal
until at least 1 month after 3 years of use; the longest
duration of use was 4 years and 8 days. Continuation rates
were independent of age.
Sixty-eight women discontinued Implanon® within 1 year;
62 of them (91%) did so because of unwanted side
effects. The most common documented reason for implant
removal was frequent and/or unpredictable bleeding
(n=42, 62%). Weight gain accounted for 21% of removals
(« = 14) and mood change accounted for 16% (/7 = 11). Of
the six women who discontinued within 1 year for reasons
other than side effects, five did so because they wished
to become pregnant and one because she was no longer in
a relationship.
Data on the contraceptive chosen for use following
Implanon® removal were collected (Table 1). Twenty-three
women (8%) were actively tiying to conceive. Thirty-nine
percent of women had a second implant inserted, while
another 14% chose an alternative long-acting method or
sterilization. More than 47% of the women elected to use a
less effective method of contraception.
4. Discussion
Continuation rates of all methods of contraception are
generally disappointing. In an international review of
discontinuation rates after 1 year of use of hormonal
contraception, rates varied from 19% (for Norplant) to
62% (the combined pill) [7]. Discontinuation rates are
higher for methods that do not require removal by a
health professional [8], In this study of women in
Edinburgh, continuation rates among women in whom
data could be obtained might best be described as
reasonable with just under 60% continuing for 2 years
and just under half continuing for 3 years. The fact that
nearly 40% continued to use Implanon® for contraception
after 3 years is encouraging.
The present study involved a cohort of women attending
a clinic that offers all currently licensed methods of
contraception free of charge. Routine follow-up consisted
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of at most one visit to the clinic 6-12 weeks after insertion
of the implant. Women were free to attend the clinic for
review at any time, and Implanon® was removed on request
at no cost. Follow-up rates in our study were quite good at
85%. In a postal survey of UK women followed up after
Implanon® insertion in the East Midlands, the response rate
was only 44% [5]. Although clinical trials have more
frequent data collection and higher rates of follow-up,
continuation rates in this cohort of Scottish women should
be generally representative of UK women attending a
community family planning clinic.
We have no idea as to how long those women lost to
follow-up continued to use their Implanon®, and it does not
seem worthwhile to guess. Only a dozen general practices
(family doctors) in the area offer Implanon® removal and
only to women who are registered with them. It is likely that
most of these women continued to use Implanon® until they
moved away from Edinburgh.
Robust data on patterns of contraceptive use in the UK
are lacking. However, in the United States, 40% of married
women and 61% of unmarried women using a reversible
method of contraception change it over the course of 2 years
[9]. Many — especially those with more years of educa¬
tion — change from a more-effective method to a less-
effective method. This study similarly demonstrates that
almost half of the women, despite wishing to avoid
pregnancy, chose a less-effective method of contraception
when they stopped using Implanon®. This is unfortunate
since data from the United States and the UK suggest that
using condoms or oral contraceptives is much more likely to
risk unintended pregnancy [10,11]. In contrast, there are
data to show that contraceptive implants are associated with
lower rates of unintended pregnancy than either condoms or
contraceptive pills [12].
Using preliminary data from this study, the NICE
guideline on LARC concluded that Implanon® is a cost-
effective method of contraception and more cost-effective —
even if used only for 1 year — than either the combined
oral contraceptive pill or condoms [1]. Concerns that the
high up-front costs of this method are unjustified because
discontinuation rates are high are unfounded as this study
has shown that continuation rates for Implanon® in real life
in the UK are not unreasonable when compared with those
of clinical trials and with data for other contraceptives. This
should reassure health care providers and commissioners
that increasing the uptake of this long-acting method as
recommended in the NICE guideline is worth the effort and
the cost. The fact that more than one third of women chose
to continue to use the implant when their first one had
expired reflects a strong level of satisfaction on the part of
the users.
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Abstract
Depo-Provera (depot medroxyprogesterone acetate, or DMPA) is an important contraceptive option for women worldwide. Currently, it is
only available in intramuscular form requiring regular quarterly routine attendance at a health facility. A new subcutaneous preparation has
been developed. This is self-administrable and could potentially reduce need for routine attendance to an annual visit.
In a questionnaire survey of 176 women currently using DMPA, 67% would prefer to self-administer. Of the 33% who did not wish to self-
administer, the most common reasons were a fear of needles (62%) and concern regarding incorrect administration (43%). In a second survey
of 313 women not currently using DMPA, 64% ofwomen said they would prefer to attend less often for contraceptive supplies. Twenty-six
percent of women who had never used DMPA and 40% of ex-users would seriously consider DMPA if self-administration were possible.
Our findings would suggest that the advent of subcutaneous self-administrable Depo-Provera with appropriate training and reminder
system is likely to be beneficial and popular with many women.
© 2005 Elsevier Inc. All rights reserved.
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I. Introduction
Depo-Provera® (depot medroxyprogesterone acetate, or
DMPA) is a long-acting, progestogen-only, injectable
contraceptive currently used by around 13 million women
worldwide. Depo-Provera is very commonly used in some
developing countries; in South Africa, for example, more
than 50% of women using contraception use DMPA [1].
In contrast, Depo-Provera is used by only a small minority
of women in more developed countries. According to
the National Survey of Family Life and Growth, only
3% of women in the United States in 1995 were using
Depo-Provera [2]. Even in the United Kingdom, where
use is perhaps the highest among the more developed
countries, only 6% of women aged 25-29 years were using
Depo-Provera in 2000/2001 [3],
Depo-Provera is currently formulated as an aqueous
microcrystalline suspension administered by deep intramus¬
cular injection at a dose of 150 mg every 12 weeks. This
* Corresponding author. Contraceptive Development Network, Centre
for Reproductive Biology, University of Edinburgh, Edinburgh, EH16 4BS
Scotland, UK. Tel.: +44 1212426360; fax: +44 1316216363.
E-mail address: fatim.lakha@ed.ac.uk (F. Laklia).
1 The author is a member of the International Advisory Board to Pfizer
for DMPA-SC.
dosing schedule requires routine attendance at a health
facility four times each year. In contrast, the World Health
Organization recommends that women using oral contra¬
ception need be seen by a health professional only once
each year [4], Thus, although an inexpensive method of
contraception per se (£5 per dose in the United Kingdom),
Depo-Provera involves increased costs to health services
when compared with all other available methods. It also
creates greater cost and inconvenience for the user.
A new micronized preparation of DMPA has recently
been developed [5]. A dose of 104 mg (in 0.65 mL) given
by subcutaneous injection has an efficacy and duration of
action similar to DMPA-IM. However, the subcutaneous
preparation, DMPA-SC, can be self-administered. In antic¬
ipation of DMPA-SC becoming available in the United
Kingdom, we undertook two questionnaire surveys to
determine whether women currently using Depo-Provera
would want to self-administer and whether the opportunity
to do so would make DMPA a more attractive method to
women who are not currently using it.
2. Subjects and methods
During December 2003, a self-administered question¬
naire (Appendix A/Questionnaire 1) was offered to women
0010-7824/$ - see front matter © 2005 Elsevier Inc. All rights reserved,
doi: 10.1016/j.contraception.2004.12.002
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attending a large family planning clinic in Edinburgh for
repeat DMPA injection. The questionnaire was attached to
every packet of DMPA, thus ensuring that it was offered to
eveiyone. Women were asked if, after appropriate instruc¬
tion, they would be interested in giving themselves the 3
monthly injections. If they responded positively, they were
asked whether, and how, they would prefer to be reminded
of the date when their injection was due. Women who were
not interested in self-administering Depo-Provera were
asked to choose one or more reason, from a list of possible
reasons, why they would not want to self-administer.
For 2 weeks during the spring of 2004, a second self-
administered questionnaire was offered to every woman
attending the same Edinburgh family planning clinic
(Appendix B/Questionnaire 2). Women were asked about
current and ever use of all available methods of contracep¬
tion. Those who had used but discontinued DMPA in the
past were asked to choose from a list their reasons for
discontinuation. Women who had never used it, but had
considered it, were also asked to choose from a similar list
what had deterred them from trying it.
All women were asked whether the opportunity to self-
administer Depo-Provera, and thereby to attend clinics only
once a year, would make them reconsider using the method.
Both questionnaires were analyzed using SPSS.
3. Results
One-hundred seventy-six women currently using Depo-
Provera completed Questionnaire 1. The response rate was
100%. Sixty-seven percent of women (118) said they would
like to self-administer DMPA. Of these, 89% felt that they
would need reminding of the date of injection. Thirty-three
percent of women felt that being told the dates for the next
three injections at the time of their annual review would
suffice; 30% ofthem preferred to receive a reminder letter, and
25% a text message, j ust prior to the date ofthe next injection.
Of the 58 women (33%) who did not wish to self-
administer DMPA, the most common reason was a dislike or
'fear' of needles (62%), 43% were concerned that they
would administer the contraceptive incorrectly, while 33%
felt it was important to see a doctor every 3 months. Twelve
Table 1
Contraceptive method currently used by women completing Questionnaire 2
Main method of contraception Number of % Respondents
respondents
Combined oral contraceptive pill 143 44
Barrier methods 64 20
Intrauterine system/intrauterine device 34 11
Progcsteronc-only pill 24 7
Contraceptive implant 20 6
Depo-Provcra (DMPA) 10 3
No method 8 2
Withdrawal 7 2





Reasons for discontinuing or not choosing Depo-Provera among women
completing Questionnaire 2





Change in bleeding pattern:
Irregular 40 26
Amenorrhea 19 30
Weight gain 35 41
Mood swings 27 Qna
Headaches 10 Qna
12 Weekly visits 10 11
Painful injection/fear of needles 6 20
Wish for return of fertility/not wanting 6 20
a delay in resumption of fertility
Not being able to stop the Qna 23
contraception immediately
Adverse opinions from friends/family Qna 19
Qna=question not asked.
percent of women were disinclined to self-administer
because they were worried that they might forget.
Three-hundred seventy copies of Questionnaire 2 were
distributed and 323 were returned completed (87%). The
main method of contraception being used by the women who
completed Questionnaire 2 is shown in Table 1. Ten women
were using Depo-Provera and seven ofthem (70%) expressed
an interest in self-administration. Two hundred sixty-five
women had never used Depo-Provera; their reasons for not
choosing the method are shown in Table 2. One hundred
sixty-five of them answered the question about self-admin¬
istration. Sixty-one percent said they would prefer to attend
the clinic less often for supplies of contraception. Twenty-six
percent (43 women) said they would 'seriously consider'
using Depo-Provera if self-administration was possible.
Forty-eight women (15%) had used DMPA in the past
but had discontinued the method for reasons shown in
Table 2. Thirty-four of 44 women (77%) who answered
were interested in a method which allowed them to reduce
the number of times they attended a clinic for contraception.
Eighteen of 45 women (40%) who answered the relevant
question said they would be interested in using DMPA again
if it were available for self-administration.
4. Discussion
Depo-Provera is an important method of contraception.
Anecdote suggests that in the United Kingdom it is
increasingly popular among young women and among
women of all ages who like the convenience of amenorrhea.
In the United States, the fall in teenage pregnancy rates has
been attributed to increased use of Depo-Provera [6], The
need to attend a health professional every 3 months simply for
a single injection is a clear disadvantage of the method.
In our survey, two out of three women currently using
Depo-Provera expressed a theoretical interest in self-
administration. It is, of course, very likely that a number
of them, when offered the real option of self-administration
16 F. Lakha et al. / Contraception 72 (2005) 14-18
would not take up the offer, and that more would find that
they were unable or unwilling to give themselves an
injection when the time came for it. Self-injected medication
is the norm for diabetics and for some people with migraine
or arthritis or undergoing infertility treatment. In most cases,
the injections are self-administered daily or at least twice
weekly. It is possible that women would never gain
sufficient practice to become confident in self-administering
an injection only four times each year. In a trial of self-
administration of the once/monthly combined injectable
contraceptive undertaken in Brazil, 14% refused to partic¬
ipate at the onset and another 31% declined after being
trained to self-administer using oranges [7], At the end of
the study (three injections in total), more than 80% of
women had been successful in giving their own injections
and only 50% expressed a preference to continue self-
administration. Just how many women, who in our survey
said they would like to self-administer Depo-Provera, would
do so in reality is the subject of a future study.
It is highly likely that many health care professionals
would be skeptical about women's ability to self-administer
Depo-Provera and, particularly, to do so at the correct time.
Presently, if an injection is more than 2 weeks late, it is
recommended that the next injection is withheld until
pregnancy can be reasonably excluded [4], If women were
given their own injections, it is possible that there would be a
greater chance that an injection would be given late and
possibly given when conception had already occurred. In our
clinic, we do not currently send reminders to women using
DMPA but simply inform them when they attend for their
injection, when the next one is due. All are clearly informed
when they start to use the method, that the injection interval is
12 weeks. Since we do not presently remind them to attend the
clinic for their injection, only the desire to avoid late injection
when pregnancy had already occurred should stimulate us to
have a system in place to remind them to self-inject. In a
randomized trial designed to test whether an intensive
reminder system would improve compliance among 250
women using Depo-Provera in the United States [8], intensive
reminders did not improve continuation rates. Women
receiving either mailed or telephone reminders were no less
likely to return to the clinic on time than women given an
appointment at the time of the first injection. One could argue
that the need to make arrangements (including travel, and
possibly taking time offwork) to attend a clinic for injections
would, in fact, be more likely to lead to mistimed injections
compared with the ease of having the drug at home.
We were somewhat surprised that the ability to self-
administer the injection, and thereby would enable women
to reduce the number of clinic visits, might increase the
acceptability of Depo-Provera, both to women who have
never used it and to those who have tried but discontinued
the method. It is likely, however, that this is an overestimate
since the reasons for discontinuation of DMPA generally
related to the side effects (Table 2) and not to the need to
attend a health professional four times each year.
In conclusion, the advent of a fonn of Depo-Provera
which would allow women to self-administer is likely to be
a benefit to perhaps as many as half of the women choosing
this method. Our survey also suggests that use of injectable
contraception may increase where self-administration pos¬
sible. We have discussed the concept in our clinic and
suggest that women who express a wish to self-administer
Depo-Provera should be given the appropriate training
allowing an annual clinic visit with three injections supplied
for home use. The success of such a scheme, and the health
economics involved, will need to be tested scientifically.
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Appendix A. Questionnaire 1
The jag at home!!!
Imagine—no more visits to the doctors every 11 weeks
for your jag! Just once a year!!
Interested? Keep on reading.
Soon the Depo-Provera injection will be available for
you to give to yourself.
It is safe, easy and less painful.
Unlike today when it has to go deep into your muscle,
the new way will be to inject it just under the skin (similarly
to what diabetics do 3 times every day). We would supervise
you the first time and if you were happy, you could take 3
injections home with you. Your next routine appointment
would be a year later—just like women on the pill!!
Please answer the following 2 questions.
Your answers are strictly confidential and anonymous.
1. Would you want to give yourself your injection?
Yes □ (please go to question 2)
No □ (please go to question 3)
2. How would you want to be reminded that it was time
for your next injection? (Please pick ONE only)
Do not want any reminders □ Letter □
Told the next 3 dates in advance
when I attended □ Phonecall □
Text message □ Email □
3. Why not?
Worried about giving it correctly □
Prefer to see the doctor every 11 weeks □
Would forget □
Just do not want to give it to myself □
Other reason — please tell us
Thank you for completing the questionnaire. Please hand
it back to reception.
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Appendix B
Depo-provera contraception
- your views on a new version that can be administered at home
Depo-provera ('the jag') is a form of hormonal contraception that presently is administered 3-monthly by
intra-muscular injection. This has to be given by a doctor or nurse, and so requires a visit to the health
centre or family planning clinic.
It is hoped that in the near future, a new form of depo-provera injection will be available that involves an
injection just under the skin (similar to the injection that diabetics give themselves) instead of the current
form which is injected into the thigh muscle. The first injection would be supervised, and if you were happy
about it you would take the next 3 injections home with you
We are carrying out this survey to find out what women who are not currently using depo-provera think
of this development. Your answers are strictly confidential and it would be appreciated if you would answer
the questions below by ticking the boxes beside the most appropriate answers. Many thanks.
Q1. What method of contraception are you currently using?
I I combined oral contraceptive pill
condomsfmale/female)
□ IUD /1US (coil)
diaphragm / cap
| other (please specify)
I I progesterone only pill
I I contraceptive implant (e.g Implanon)
I I natural family planning / rhythmn method
I I withdrawal
Q2. Have you ever used the 3-monthly depot injections?
yesQ ZD no
please go to Q3 please go to Q4
Q3. What was/were you reason/s for stopping
:Z] painful injection




i ~1 wishing to return to fertility/ get pregnant
□ irregular bleeding
I I absent periods
I I other (please specify)
it?
Q6 Would you regard it an advantage if you
could reduce the number of visits to your
doctor/ clinic for contraception?
yes[D ZD no
Q7. Would you consider depo-provera if you
were able to give the injection to yourself?
yes ZD ZD"0
Q4. Have you ever considered using depot as a
contraceptive method?
yes ZD ZD no (p|eaSe go to Q6 and Q7)
please go to Q5 J'
Q5. What was/were you reason/s for not using it?
ZD fear of needles/ injections
fear of weight gain
having to attend the doctor/clinic every
3 months for the injection
fear of irregular bleeding
ZD prefer to have a period every month
ZD delay in return to fertility
not being able to stop the contraception
straight away (it is with you for 3 months)








Pleaseseal your completed questionnaire in





amily Planning and Well Woman Services, Dean Terrace. Edinburgh, EH4 1NL
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ACKGROUND: The acceptability and continuation rate of oral contraceptive steroids are limited by unpredictable
ceding and the fear of long-term risks such as breast cancer. By inhibiting ovulation and by altering the receptivity
the endometrium, antagonists of progesterone, such as mifepristone, could be developed as estrogen-free novel con-
■rceptives. METHODS: Multicentre, double-blind, randomized controlled trial comparing frequency of amenor-
oea (primary outcome), bleeding patterns, side effects and efficacy in women taking daily 5 mg mifepristone
= 73) or 0.03 mg levonorgestrel (progestogen-only pill; POP, n = 23) for 24 weeks. RESULTS: More women
ire amenorrhoeic while taking mifepristone than POP (49 versus 0% P< 0.001), and fewer women bled or
otted for >5 days per month (4 versus 39% P < 0.001). Forty-eight percent of women who took mifepristone for
■months had cystic glandular dilatation of the endometrium but none showed hyperplasia or atypia. There were
pregnancies in 356 months of exposure in women who used only mifepristone for contraception. Two pregnancies
-curred in women taking mifepristone who were also using condoms for dual protection. CONCULSIONS: Daily
■ifepristone (5 mg) is an effective oral contraceptive pill which has a better pattern of menstrual bleeding than an
"isting POP (levonorgestrel).
ywords: antiprogestins; contraception; levonorgestrel; mifepristone; progestogen-only pill
■traduction
fty years have passed since the first clinical trials in Puerto
co demonstrated that a daily pill containing ethinyl estradiol
d norethynodrel was a highly effective contraceptive (Pincus
al., 1958). Contraceptive development since the introduction
the pill has been limited to variations on the theme of steroid
rmones [new delivery systems, different progestogens, lower
ses of estrogen (Baird and Glasier, 1999; Population
-ports, 2003)]. Oral contraceptives, containing either proges-
gen or a combination of estrogen with progestogen, are
-pular because they are highly effective and easy to use
aird and Glasier, 1999; Population Reports, 2003).
jwever, continuation rates are often disappointingly low.
The commonest reason for discontinuation of combined oral
contraception (COC) is breakthrough bleeding (Rosenberg
and Waugh, 1998) but fear of breast cancer (Collaborative
Group on Hormonal Factors in Breast Cancer, 1995; Larsson
et al., 1997; Althius et al., 2002), and to a lesser extent
venous thromboembolism, are significant disincentives to
both uptake and continuation despite the obvious convenience
of relief of dysmenorrhoea and other symptoms related to
menstruation (ESHRE Capri Workshop Group, 2005).
Progestogen-only pills (POP) have the advantage of fewer
serious risks but are associated with unpredictable vaginal
bleeding which is the commonest reason for discontinuation
(McCann and Potter, 1994; Fraser, 1999). In many surveys,
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Daily mifepristone as a contraceptive pill
fewer than 50% of women continue using oral contraceptives
for >12 months (D'Arcangues et al., 1992).
Even the regular pattern of monthly bleeding characteristic
of the combined pill is considered undesirable by some
women. When oral contraceptives were first marketed it was
assumed that women would prefer to have a monthly cycle
because it would be perceived as more 'natural' (Pincus
1965). Recently, it has been shown that many women, regard¬
less of age, prefer to have either predictable bleeding less often
than once a month or not to bleed at all (Den Tonkelaar and
Oddens, 1999; Glasier et al., 2003).
Mifepristone is a synthetic C19 steroid which is a potent
antagonist of progesterone (Ulmann, 2000). There is very
little information about the use of mifepristone (or other pro¬
gesterone receptor modulators) for contraception in spite of
the fact that the original clinical publication 23 years ago
demonstrated its contraceptive as well as abortifacient proper¬
ties (Herrman et al., 1982; Baird, 2001). The lack of progress
with these compounds has not been due to scientific reasons
but relates to the political and religious controversy surround¬
ing RU486 ('the Abortion Pill'). In low daily doses, mifepris¬
tone has been shown to inhibit ovulation by suppressing the
pre-ovulatory surge of LH and acting directly on the endome¬
trium to induce amenorrhoea in the majority of women (Ledger
etal, 1992; Croxatto etal, 1993; Cameron et al., 1995; Brown
et al., 2002). We have previously demonstrated in a pilot study
that mifepristone at a dose of 2 or 5 mg/day has contraceptive
potential (Brown et al., 2002). In contrast to pills containing
estrogens and/or progestogens, there is no theoretical risk
that such a pill would increase the risk of breast cancer or car¬
diovascular disease. Rather, experimental data show that anti-
gestogens are antimitotic in breast cancer cell lines and animal
models and hence might actually reduce the risk ofmalignancy
(Horowitz, 1992; Klijn et al., 2000; Poole et al., 2006).
A pill which contained no estrogen and which reproducibly
induced amenorrhoea in high proportion of women should
prove popular. In the present study, therefore, we directly com¬
pared the pattern of bleeding and other side effects of mifepris¬
tone at a dose of 5 mg/day for 24 weeks with a method of
contraception in common use in the UK, the POP (levonor-
gestrel). We hypothesized that women given mifepristone
would have a much higher incidence of amenorrhoea and
fewer days of menstrual bleeding.
Materials and Methods
This was a multicentre, double-blind, randomized controlled phase II
trial comparing two daily contraceptive pills. The primary outcome
was the percentage of women who had amenorrhoea throughout the
study. Secondary outcomes included number of days of bleeding,
endometrial thickness and histology, and number of pregnancies.
Before starting, the trial was approved by the steering committee of
the Contraceptive Development Network (MRC Grant No.
G9523250). It was performed in accordance with Good Clinical
Practice including regular monitoring of centres.
Between June 2003 and January 2004, a total of 97 healthy volun¬
teers with regular menstrual cycles (21-42 days) aged 18-40 years
were recruited from four sites (34 in Sagamu, Nigeria; 18 in Cape
Town, South Africa; 10 in Hong Kong, People's Republic of China
and 35 in Edinburgh, Scotland). The study was approved by local
ethical committees at all centres. All women gave written informed
consent before enrolment and were screened before entering the
study by routine physical and gynaecological examination and
measurement of height, weight, blood pressure and pulse rate. Blood
samples were collected for measurement of progesterone, clinical
chemistry and haematology. The size of the uterine cavity and
ovarian follicles were measured by transvaginal ultrasound scan.
Urinary hCG was also measured to exclude pregnancy before entering
the trial. Women who had used any form of hormonal contraception
within the last 3 months of the start of the study were excluded
except in Edinburgh where nine women with regular cycles while
already using a POP were included without having to undergo a
washout period.
Subjects were studied for one pretreatment cycle, six treatment
cycles (24 weeks) and for one post-treatment cycle. Subjects were ran¬
domly allocated to receive either mifepristone 5 mg/day (one half a
10 mg tablet) (from Laboratoire Exelgyn, 6 rue Christophe Colomb, S
75 008-Paris for women in Edinburgh; and from Hualian Pharmaceu- §•
ticals Ltd, Shanghai, China for women in Shanghai, Cape Town and L
Sagamu) or levonorgestrel 0.03 mg/day (POP) (Norgeston; Schering Si
Health Care Limited, The Brow, Burgess Hill, West Sussex, RH15 §
9NE) starting on Day 1 or 2 of the cycle. Randomization was achieved JT
by blocked computer-generated randomization performed individu- t
ally for each centre to ensure good balance of numbers in the different |
treatment groups. Each centre was given numerical sequence of coded 3
treatment bottles which were identical generated by statistician in g
Edinburgh office. Participants were enrolled in each centre by the
local investigator. The numerical sequence was determined by the o'
clinical trials manager in Edinburgh. To maximize, the number of 3
cycles observed on mifepristone without greatly reducing the power |"
of the randomized comparison, three times as many subjects were ran- ^
domized to mifepristone as to levonorgestrel. In Cape Town, Hong ~
Kong and Edinburgh, daily doses were issued at eight weekly intervals &
in pre-packed identical bottles containing mifepristone (a half tablet) g*
with placebo, or levonorgestrel with one half placebo tablet. In —
Nigeria, daily doses were issued at weekly intervals. The placebo ^
and active tablets were both white but of slightly different size. o
Unused medication was returned and new medication dispensed at ^
this time. All subjects were sexually active and intending to use the r.
study drug as their sole method of contraception. However, in Cape 3
Town and Hong Kong some women also used condoms for protection 5
against sexually transmitted infection. Cycles in which dual protection q
was used were omitted when calculating the months of exposure to the 5
risk of pregnancy. q
The women were asked to record every day the amount of vaginal
bleeding and adverse events on a diary card. If bleeding occurred it o
was recorded as spotting (one or less pad/tampon required) or bleed- ~
ing (more than one pad/tampon required).
Subjects attended the clinic for review at eight weekly intervals
during the treatment phase and once more on Day 5-11 of the first
menstrual cycle after discontinuation of the study medication. At the
end of the treatment phase a vaginal examination was performed on
all subjects and an endometrial biopsy performed in a subgroup of
volunteers. In order to identify those women who might develop
hyperplasia of the endometrium a biopsy was performed at any time
during the study on all subjects if the measurement of the uterine
cavity was observed to be >12 mm ('safety biopsy'). Biopsies were
performed as an outpatient procedure with a Pipelle suction curette
(Pipelle de Cornier, Laboratoire C.C.D, 60 rue Pierre Charron,
75 008-Paris-France. Ref. 1103000). Endometrial samples were then
fixed in 10% neutral buffered formalin prior to embedding in paraffin
wax. Histological examination of the endometrial sections was
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lducted blind by an independent pathologist and classified into five
egories [proliferative, secretory, inactive, insufficient and cystic
indular dilatation (CCD) as previously described (Baird et al.,
33)]. (i) Proliferative includes 'active' in which glands are
mlar, with columnar epithelial cells showing nuclear stratification
.1 frequent mitoses (> = 5 per 20 gland profiles); and 'weakly'—
tple tubular glands with columnar epithelial cells showing mild
clear stratification (2-4 mitoses per 20 gland profiles), (ii) Inac-
e—cuboidal to columnar cells showing focal or diffuse nuclear stra-
cation, in glands with simple tubular or undulating profiles without
nificant dilatation. Resembles endometrium of basalis in normal
cling endometrium. Glands are not atrophic, and show evidence
limited recent growth or function, but lack the findings seen in
rmal cycling proliferative endometrium. Mitoses are absent or
common (no more than om mitotic figure per 20 gland profiles).
) Inactive with CGD—inactive glandular epithelium as described
ove, with dilatation of gland lumina. Dilatation is defined as the
ind having an open lumen that forms a space, i.e. greater than
tr times the epithelial thickness, (iv) Secretory—glands are variably
tuous with cytoplasmic vacuolation that varies according to phase
cycle. Cells are columnar, with non-stratified nuclei showing an
sence of mitoses (except for infrequent mitoses in the early
■retory phase). Stromal decidual change starts around spiral
ssels, becoming confluent in the late secretory phase. Some
nples contained inadequate amounts of tissue for accurate histologi-
evaluation.
Ovarian function was assessed by the measurement of progesterone
venous blood collected at screening and at 8, 16 and 24 weeks after
rting treatment. The woman was classified as having ovulated at
ist once if the concentration was > 15 nMol/1 in any of the three
nples. Following centrifugation the serum was stored at — 20°C
labelled sample tubes. Analysis by radioimmunoassay was carried
t at the end of the study locally by each centre. Transvaginal ultra-
nography was used to assess number and size of follicles or cysts at
reening and after 8, 16 and 24 weeks.
jtistical methods
te number of subjects on mifepristone was chosen to give an upper
nfidence limit of <5% for the risk of pregnancy over the 6 months
treatment if no pregnancies occurred in that group. To maximize,
; number of cycles observed on mifepristone without greatly redu-
tg the power of the randomized comparison, three times as many
bjects were randomized to mifepristone as to levenorgestrel.
tese numbers were also sufficient to give over 99% power to show
significant difference in the rate of amenorrhoea over 6 months if
e rate was 50% on mifepristone when compared with the 5% anti-
■pated in the levenorgestrel group (Collaborative Study Group, 1998).
Data analysis was carried out using SPSS version 12 (SPSS, Inc.,
licago, IL, USA) and Excel 2003 (Microsoft Corporation), The
•o randomized groups were compared by chi-squared test with
ates' correction and Mann-Whitney or Student's t-tests as appropri-
e tests for binary and continuous outcomes, respectively. Analysis of
ivariance adjusting for pretreatment values was used to compare the
idometrial thickness in the two groups at follow-up. Confidence
nits were calculated for the incidence efficacy outcomes in the mife-
istone group using the Poisson distribution based on person time at
sk.
■esults
total of 97 women were recruited (Fig. 1) and randomized to
eatment [35 in Edinburgh (26M, 9POP); 34 in Nigeria (26M,
Figure 1: Flow chart of patients through the study
8POP); 18 in Cape Town (14M, 4POP); 10 in Hong Kong (8M,
2POP)]. One subject randomized to mifepristone withdrew for
personal reasons and discarded the study drugs without taking
any. Therefore, the results of the 96 women who started treat¬
ment [73 received mifepristone (M), 23 received levonorgestrel
(POP)] were included for analysis.
Of the 87 women who started the study and did not use hor¬
monal contraception in the previous months, 66 were random¬
ized to mifepristone and 21 to POP. An additional nine women
in Edinburgh who had regular menstrual cycles while taking
POP for contraception were transferred directly to study medi¬
cation. In this subgroup, seven were randomized to mifepris¬
tone and two to POP.
When all centres were combined (Table 1) there were no
statistically significant differences in age, weight, height,
BMI or parity between the two treatment groups (two-sample
Student's r-tests). However, there were some differences in
the characteristics of the women from different centres. The
women in Nigeria were significantly older (years 33.9 ± 4.2
SD, P = 0.001) than the women in both Cape Town (26.2 +
7,7) and Edinburgh (28.7 + 6.0). The BMI of women in
Hong Kong (19.8 + 1.7 kg/m2) was significantly lower than
that of women in Edinburgh (22.9 ± 1.9, P < 0.001), Nigeria





Age (years) 30.3 (6.3) 30.4 (6.9)
Weight (kg) 60.7 (9.1) 58.4 (6.2)
Height (cm) 161.5 (5.9) 161.3 (6.3)
BMI (kg/m2) 23.3 (3.6) 22.4 (1.8)
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Q Mifepristone (n = 73)
■ POP (n = 23)
>0<2 2<5 5+
Average days bleeding per month
Figure 2: Percentage of women who bled for a given number of days
on average per month in 96 women randomized to daily mifepristone
or levonorgestrel (POP).
0, amenorrhoea; > 0 < 2, any bleeding <2 days per month; 2 < 5, 2
to <5 days bleeding per month; 5+, 5 or more days bleeding per
month
(24.3 + 3.9, P = 0.001) and Cape Town (23.1+3.6, P =
0.014).
Twenty-four women (16M, 8POP) did not complete the full
24 weeks of treatment. Eight women withdrew for personal
reasons unrelated to the study medication (e.g. moved from
the area, relationship ended); six were discontinued by the
investigators because of persistent protocol violations (e.g.
poor compliance, unavailable for follow-up). Two women
withdrew because of anxiety about potential adverse affects
of the pills. Four women in the POP group discontinued
because of persistent irregular bleeding, no women in the mife¬
pristone group discontinued for this reason (P < 0.01). Four
women withdrew because of pregnancy: three in the mifepris¬
tone group and one while using levonorgestrel.
Seventy-two women completed the study (57M, 15POP) and
took the medication for at least 24 weeks (168-192 days).
Menstrual bleeding pattern
There were significant differences in the pattern of menstrual
bleeding between the groups (Fig. 2). Of the 73 women who
started mifepristone, 36 (49%) were amenorrhoeic for the dur¬
ation of drug treatment and only three women bled or spotted
on average for five or more days per month. In contrast, none
of the women in the POP group were amenorrhoeic. Although
the number of days of bleeding was within the range of a
normal menses in the majority (61%), nine women in this
group bled or spotted for five or more days per month and
four women withdrew from the study prematurely because of
continuous irregular bleeding.
Of the 57 women who took mifepristone for the full 6
months, 25 (44%) were amenorrhoeic and a further 22 (39%)
had bleeding or spotting for a total of 10 days or less
(Table 2). In comparison, of the 15 women who took POP,
none (0%) were amenorrhoeic (compared with mifepristone
X: = 8.01,/' = 0.005).
The pattern of bleeding in those women who continued to
menstruate was irregular and unpredictable in the majority in
both groups. Although episodes of bleeding in the women
who took mifepristone were infrequent and slight, they were
mostly unpredictable, except in Nigeria where 4 of the 15
women who continued to bleed had regular monthly periods.
Nigerian women were more likely to experience bleeding
over the 6 month study duration (13/21; 62%) than those
from other centres [Edinburgh 4/22 (18%); Cape Town 3/9
(33%); Hong Kong 1/6 (17%)]. There was a significant differ¬
ence in bleeding frequency between Nigeria and Edinburgh
(X2 = 6.86; P = 0.009).
Ovarian function
Ovarian function was assessed at baseline, 8, 16 and 24 weeks
after starting treatment by measurement of progesterone in
blood. In 33 of the 97 pretreatment samples, the concentration
of progesterone was > 15 nmol/1 indicating that in just over a
third of the women the blood was collected in the luteal phase
after ovulation. At each eight-week review, there was evidence
of ovulation in some women in both groups. If a woman
showed evidence of ovulation at any of the three review
visits she was classified as ovulatory. Ovulation was less
likely to occur in women taking mifepristone (14/73; 19%)
than in those in the POP group although there was no statisti¬
cally significant difference (7/23, 30%; x2 = 0.72; P = 0.40).
However, there were significant differences between centres
in the incidence of ovulation and amenorrhoea. For example,
while taking mifepristone only one of the 26 women in
Edinburgh (4%) ovulated when compared with 11/26 women
in Nigeria (42%: \2 = 8.78; P = 0.003). The proportion of
women who ovulated while taking the POP was identical in
the two centres (37%).
Ultrasound examination revealed the presence of numerous
small and medium-sized follicles in the ovaries of women in
both groups throughout treatment. Follicular cysts (diameter
>2
c~
Table 2: Distribution of mean (SD) numbers of days bleeding and/or spotting while on drug according to treatment group, in the 72 women who took the
treatment for at least 6 months (%)
Number of days Bleeding/spotting Bleeding only Spotting only
M POP M POP M POP
0 25 (44) 0(0) 36 (63) 0(0) 39 (68) 6(40)
1 4(7) 0(0) 0(0) 0(0) 6(10) 2(13)
2.5 8(14) 2(13) 5(9) 2(13) 8(14) 1 (7)
6-10 10(18) 1 (7) 7(12) 1 (7) 3(5) 1 (7)
11-20 5(9) 3 (20) 5(9) 5 (33) 1 (2) 2(13)
21 + 6(U) 9 (60) 5(9) 7(47) 1 (2) 3 (20)
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■ble 3: Mean (SD) endometrial thickness at different times according to
atment group
:eks Mifepristone POP /'-value
6.1 (2.1) [73] 5.8 (2.4) [22] NS
6.6 (3.4) [68] 5.3 (2.7) [19] 0.11
8.0 (5.2) [60] 5.l(2.8)[15| 0.043
10.3 (6.8) [58[ 4.0 (2.0) [15] <0.001
e P-value is from an analysis of covariance adjusted for the pretreatment
ue. Numbers of subjects are shown in square brackets.
30 mm) were detected on eight occasions (six among women
ing mifepristone and two in the POP group). The cysts were
ymptomatic and resolved spontaneously by the next examin-
on without treatment.
idometrial thickness
the mifepristone group, the width of the cavity and the thick-
ss of the endometrium increased with time relative to the
seline (Table 3). In contrast, there was no statistically signifi-
nt change in the POP group, and by 16 weeks the difference
the size of the uterine cavity between the groups was statisti-
lly significant (P = 0.043). There were differences between
; centres in the extent of the increase in size with the thickest
dometrium at 24 weeks occurring in Edinburgh (5.2 ±
I mm before starting, increasing to 13.8 ±7.1 at 24 weeks)
able 4).
idometrial biopsies
total of 39 women had at least one endometrial biopsy. Six
mien in the mifepristone group had two biopsies and one
d three biopsies, making a total of 47 biopsies available for
amination. Twenty women (19 in the mifepristone group
d 1 in the POP group) had a 'safety biopsy' because the endo-
;trial cavity on ultrasound was > 12 mm. A total of 31 biop-
:s were available from women who had completed 24 weeks
treatment (27 mifepristone and 4 POP).
CGD was found in the endometrium of 13 of the 27 women
to had a biopsy at 24 weeks on completion of the study. The
mainder were proliferative (4), inactive (3), or insufficient for
stological examination (7). Of the 19 women on mifepristone
10 had a 'safety' biopsy because the uterine cavity was
lated above 12 mm, 11 showed CGD on at least one occasion.
3D also occurred in four of nine women with normal-sized
vity who volunteered to have an endometrial biopsy at 24
:eks. The endometrium in the sole woman in the POP
oup who had a safety biopsy (cavity 13 mm) was too
>ble 4: Mean (SD) endometrial thickness at different times according to
ntre for mifepristone only
eeks after starting Edinburgh Cape Town Hong Kong Nigeria
5.2 (2.1) 6.7 (1.7) 6.6 (2.6) 6.4(1.8)
4.9 (3.4) 7.6 (3.3) 6.4 (4.4) 8.0 (3.2)
9.2 (5.7) 8.0 (5.0) 8.9 (7.4) 6.5 (4.4)
13.8 (7.1) 11.5 (8.7) 8.3 (3.6) 6.8 (4.4)
scanty for histological examination. None of the women in
either group showed evidence of hyperplasia or atypia.
Hysteroscopy was performed as an outpatient procedure on
two women (both in Edinburgh) with an enlarged uterine
cavity (29 and 16 mm) detected on routine ultrasound at 16
weeks. The uterine cavity was dilated with mucous fluid and
a pale oedematous looking endometrium which showed CGD
on histological examination (Fig. 3). No serious pathology
was detected and one woman opted to continue with the trial.
The endometrial cavity returned to normal size after com¬
pletion of the trial.
Contraceptive efficacy
Not all the subjects were at risk of pregnancy for the duration
of the study. Some women separated from their partner, while
a number of women in Cape Town and Hong Kong used barrier
methods as well as the study drug for dual protection. In total,
there were 356 months of exposure in women who took mife¬
pristone as their sole method of contraception and 85 in women
who took POP.
Five women became pregnant during the study: four of them
in the group of women randomized to mifepristone. However,
there were only three pregnancies while the subjects were
taking the study drugs. In the mifepristone group, two pregnan¬
cies occurred (both in Capetown) during treatment and were
recognized after 62 and 115 days of treatment, respectively.
Conception occurred in both within the first 2 months of treat¬
ment. One woman underwent a vacuum aspiration and the
other opted to continue with the pregnancy and delivered at
term of a healthy baby. Both of these women were using
condoms for dual protection. Inclusion of these two women
in the analysis of efficacy gives an estimate of 0.6% (95% con¬
fidence limits 0.07 to 2.0%) for the risk of pregnancy per month
while exclusion results in an estimate of 0% (0 and 1.1%). Two
additional pregnancies occurred before starting or several
weeks after stopping mifepristone. One pregnancy occurred
in a woman using levonorgestrel and was only detected because
of a routine pregnancy test 8 weeks after starting treatment.
She had a blighted ovum and the uterus was evacuated surgi¬
cally. There was no significant difference in the pregnancy
rates between the groups although the study was not powered
to detect differences.
Adverse effects
There were no major adverse events in either group. Eight
women (35% of those taking POP) and 19 (36% of those on
mifepristone) reported a range of symptoms none of which
were significantly different between the groups including
abdominal discomfort (12% mifepristone versus 4% POP),
irregular bleeding (7% mifepristone versus 9% POP), headache
(8% mifepristone versus 22% POP), flushes (7% mifepristone
versus 0% POP) and mood change (3% mifepristone versus
0% POP).
Discussion
This study has demonstrated striking differences in the pattern
of menstrual bleeding between women taking two types of oral
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Figure 3: Appearance of the uterus of subject 135 who took 5 mg mifepristone per day for 24 weeks.
The subject remained amenorrhoeic throughout, (a) After 8 weeks the thickness of the endometrium and cavity was normal; (b) at 16 weeks the
cavity was dilated to 17 mm with fluid. Cyst like structures had become apparent in the cervix; (c) the cavity was lined by pale dilated endome¬
trium; (d) showing CGD on histology (X10); (e) by 24 weeks the cavity was still dilated; (f) by 4 weeks after stopping the cavity had returned
to normal after menses. Note the persistence of dilated cervical glands
contraceptive pills, which contain no estrogen. The results
confirm our previous study, which reported that the majority
of women taking 5 mg mifepristone every day for four
months were amenorrhoeic (Brown et al., 2002). In the
present study, over 80% of women who took mifepristone
were either amenorrhoeic or had episodes of bleeding or spot¬
ting <2 days per month. In comparison, women on levonorges-
trel had frequent irregular bleeding (>5 days per month) and
none was amenorrhoeic. Four women discontinued the POP
because the bleeding pattern was unacceptable.
This study has its strengths and weaknesses. The placebo
was similar but not identical to either of the active drugs and
hence the study was not truly double blind. It would have
been possible for the persistent subject and/or researcher to
identify group differences by the size of the treatment tablets.
We think that this is unlikely because each woman was sup¬
plied with two identical opaque bottles each containing
8 weeks supply of either placebo or active drug prepared by
a member of the research team not involved with contact
with the subjects. Moreover, the difference in bleeding patterns
(the primary end point) was so striking that we think it unlikely
that unblinding of an individual subject would have had a sig¬
nificant impact on the overall results.
Nine women (all in Edinburgh) who were taking POP were
recruited directly to the study without at least 3 months
'wash-out'. It could be argued that in these women there was
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carry over' effect on the ovary and/or endometrium from the
jvious treatment. We think that it is unlikely because all
tmen had regular menstrual bleeding while on the POP.
oreover, at recruitment they had evidence of ovarian activity,
. luteal levels of progesterone, follicles >10 mm and/or
dometrium >8 mm. Because they were randomized 2:7
)P:mifepristone, they would not bias the comparison
tween the groups. The seven women in this subgroup who
:re randomized to mifepristone had amenorrhoea for at
ist 3 months after starting, illustrating one of the clinical
js when the drug becomes available.
There were minor differences between centres in the
-ponse to the drug. However, in all centres the bleeding
-ttern was better with mifepristone and the contraceptive effi-
:y was high.
It is arguably in Africa where there is the greatest unmet
ed for contraception. The fact that we show that it is effective
a range of cultures, including Africa, should help facilitate
use world wide particularly in those cultures where
>men who are menstruating are subject to social taboos.
-In the women in the mifepristone group who continued to
:ed there were differences between the centres in the
ttern ofmenses. Nigerian women were more likely to experi-
ce bleeding over the 6 months study and to show biochemical
idence of ovulation than women in the other centres. For
jistic reasons, our assessment of ovarian function by
lasurement of the concentration of progesterone every
weeks was imprecise. We classified a woman as being
vulatory' if the level of progesterone was in the luteal
ase range on any one of the three occasions when it was
llected. We argued that there would be about a one in
ee chance that the progesterone level will be raised in any
lgle sample collected at random from normal cycling
)men as was found in the control cycle. Although the
ljority of women in all centres failed to ovulate while
:ing mifepristone, there were significant differences in the
.'idence of anovulation between centres.
These differences between centres are intriguing. We have
eviously reported that ovulation and menstruation were
:>re easily suppressed by mifepristone in Chinese women in
langhai than in Caucasians in Edinburgh (Brown et al.,
-02). The daily dose of 5 mg mifepristone was chosen
cause it resulted in amenorrhoea in over 90% of women in
linburgh. We have previously suggested that these differ-
ces in response may be due to differences in diet and/or in
:tabolism of steroids. Alternatively, there could be differ-
ces in compliance between centres although there was no
idence from the number of returned pills that the women
Nigeria omitted more pills than those in other centres. More-
er, a large number of tablets would have to be missed before
■b-therapeutic levels of mifepristone were reached because of
e long half-life of mifepristone (Heikinheimo et al., 2003).
One of the main reasons that women discontinue
irmonal contraception is because of menstrual irregularity
I'Arcangues et al., 1992) and this was true of women using
e POP in this study. All four women who discontinued the
idy specifically because of menstrual irregularity were
king POP. The amenorrhoea or scanty bleeding associated
with mifepristone should be perceived as an advantage by
many women (Den Tonkelaar and Oddens, 1999; Glasier
et al., 2003).
It has been argued that prolonged amenorrhoea is unnatural
and even harmful. Monthly menstruation has however been the
norm only for the last 100 years. Prior to that, most women
spent their short lives either pregnant or breastfeeding and
amenorrhoeic. Absence of periods per se does no harm. If
associated with hypo-estrogenism (as in the menopause or
during treatment with analogues of gonadotrophin releasing
hormone) it is associated with increased risk of osteoporosis
and heart disease; if associated with a high dose of progestogen
(as during the use of Depo Provera) or prolonged exposure to
COC (as in extended pill use) it may be associated with
increased risk of breast cancer and heart disease (Collaborative
Study Group, 1998). Amenorrhoea during mifepristone use is
not accompanied by hypo-eslrogenism and, as stated earlier
the risk of breast cancer may be reduced (Horowitz, 1992;
Klijn et al., 2000). A recent paper reported that mifepristone
prevented the development of breast cancer in transgenic
mice with null mutation of BRCA1 /p53 (Poole et al., 2006).
Concern has been expressed that with prolonged intake of
antiprogestogens the endometrium would undergo hyperplastic
or malignant changes due to continued exposure to unopposed
oestrogen (Murphy et al., 1995). However, studies in monkeys
with mifepristone and other antigestogens have shown evi¬
dence of endometrial atrophy rather than hyperplasia (Van
Uem et al., 1989; Ishwad et al., 1993; Neulins et al., 1995;
Chwalisz et al., 2000). In keeping with our previous report,
the endometrial cavity widened progressively with time in
women in Edinburgh, but not in the other centres (Brown
et al., 2002). We have previously reported that much of the
apparent increase in endometrial thickness is associated with
cystic dilation of the endometrial glands and the cavity itself
(Baird et al., 2003). A recent paper reported the results of a
study in which 40 women with fibromyoma were given 5 or
10 mg mifepristone/day for up to 1 year (Eisinger et al.,
2005). Simple hyperplasia of the endometrium without atypia
was seen after 6 months only in a minority of women (28%)
who took 10 mg but none at 5 mg.
In the present study, the commonest histological picture was
of inactive CGD. This CGD was only found in those women
taking mifepristone. The cause of this unusual change is
unknown. It is unlikely to be due to the effects of unopposed
estrogen as it has been demonstrated to occur in women who
have profound suppression of ovarian follicular development
and where oestrogen levels are low (Brown et al., 2002;
Baird et al., 2003). Moreover, it occurs more commonly in
those women taking lOmg mifepristone per day than in
those taking 5 mg in whom the secretion of ovarian estradiol
is higher (Eisinger et al., 2005).
Novel observations in this study were the hysteroscopy
finding of atrophic and/or oedematous endometrium. Hystero¬
scopy revealed that the apparent thickness of the endometrial
cavity as measured on ultrasound reflected dilation of the
glands and cavity rather than true hyperplasia of the endome¬
trium. It demonstrates the limitation of using measurements
of endometrial thickness by ultrasound alone as a marker of
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endometrial pathology. The cause of this accumulation of fluid
and its nature is unknown but similar findings have been
reported in rabbits following treatment with mifepristone
(Chwalisz et al., 2000). It may be that the mechanism, which
normally allows the passage/and or re-absorption of fluid
from the endometrial glands and uterus, is obstructed leading
to an accumulation of fluid within the uterus.
This study has confirmed that mifepristone is potentially a
highly effective contraceptive. Even in Nigeria where there
was biochemical evidence of ovulation in 42% of women
there were no pregnancies in the mifepristone group. In our
previous study, we reported no pregnancies in 50 women
who used mifepristone at a dose of 2 or 5 mg/day for 4
months (Brown et al., 2002). The present study extends our
contraceptive experience to a total of 556 women cycles. The
two pregnancies in women taking mifepristone occurred in
women in South Africa who were also using condoms as pro¬
tection against sexually transmitted disease including, HIV/
AIDS. It is possible that these women may have omitted to
take their pills every day because they thought that they were
protected from the risk of pregnancy by the use of condoms.
In conclusion, the present study demonstrates that mifepris¬
tone at a daily dose of 5 mg is a safe and potentially effective
contraceptive. The relatively high incidence of amenorrhoea
or reduced amount of scanty bleeding is likely to be better
accepted by women than the irregular unpredictable menstrual
bleeding that occurs in the majority of women taking the POP.
The reduction of menstrual blood loss should convey health
benefits to women particularly in developing countries where
the incidence of anaemia is high. Because of its antagonism
of progesterone the risk of breast cancer may be reduced
rather than increased as is the case with COCs containing
estrogen and progestogens (ESHRE Capri Workshop, 2005).
A large multicentre phase III trial is required further to assess
contraceptive efficacy and safety, particularly with respect to
endometrial cancer.
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Abstract
Background: We have previously shown that the antigestagen mifepristone is contraceptive when given in a daily dose of 5 mg, po.
Epidemiological studies suggest that gestagen-only contraceptives may increase the risk of transmission of human immunodeficiency virus
(HIV) due to effects on the vaginal defenses to infection. We investigate the effects ofmifepristone on vaginal thickness, steroid receptor and
natural antimicrobial content and pharmacokinetics of mifepristone.
Methods: In a pilot study, eight women were given mifepristone 5 mg/day for an average of 33 days. Ovarian function was assessed by
measurement of estradiol and progesterone in blood and their metabolites in urine and by serial ultrasound of their ovaries. Vaginal biopsies
were collected before (late proliferative) and after taking mifepristone.
Results: All subjects showed a similar pattern of descending serum concentrations of mifepristone. The elimination phase half-life was
18±5.1 h (mean±SD). Mean Cmax measured at 1 h was 641.7 nmol/L (range, 502-740 nmol/L). All eight women reported amenorrhea for
the duration of treatment and seven of eight women showed biochemical and ultrasound evidence of anovulation. There was no significant
change in vaginal thickness following treatment [342+40 pm pretreatment, 303±69 pm posttreatment (mean±SEM); p>.05]. Estrogen
(ERa, ERp) and androgen receptor were expressed in both vaginal epithelium and subepithelial stroma, whereas progesterone receptor was
expressed predominantly in the subepithelial stroma. There was no change in receptor content and distribution following mifepristone
treatment. Natural antimicrobial mRNA [secretory leukocyte protease inhibitor, human beta defensins mRNA (HBD1, HBD2, HBD3,
HBD5), granulysin and elafin] was extracted from the vaginal tissues, and the content was unaffected by mifepristone treatment.
Conclusion: The absence of changes in vaginal thickness, steroid receptor and natural antimicrobial content and its distribution in this
preliminary study suggests that in contrast to other estrogen-free contraceptives, mifepristone is unlikely to be associated with the increased
risk of transmission of HIV and other sexually transmitted infections.
© 2007 Elsevier Inc. All rights reserved.
Keywords: Mifepristone; Vaginal thickness; Steroid receptors; Natural antimicrobial; Pharmacodynamics
1. Introduction
The state of the vaginal microenvironment affects a
woman's risk of human immunodeficiency virus (HIV)
This study was supported by a grant to the Contraceptive
Development Network from the Department for International Development
and the Medical Research Council, United Kingdom (G9523250).
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0131 242 6360; fax: +44 0131 242 6363.
E-mail address: dtbaird@ed.ac.uk (D.T. Baird).
transmission. Several human and nonhuman primate studies
have shown that long-acting gestagen treatment increases
the transmission of HIV [1-3], simian immunodeficiency
virus (STV) [4] and other sexually transmitted infections
(STIs) [5,6]. The underlying mechanisms are poorly
understood. Experiments on hysterectomized rhesus
monkeys suggest that the vagina, rather than the cervix or
the uterus, is the main portal of viral entry [7,8].
Epithelial thickness and integrity modulate the ease
of access of virus to immune cells and subepithelial
vasculature [9]. Estrogen-induced surface keratinization
0010-7824/$ - sec front matter © 2007 Elsevier Inc. All rights reserved,
doi: 10.1016/j.contraception.2006.11.013
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and hyperplasia protect rhesus monkeys against SIV
inoculation [10,11], whereas estrogen-deficient women such
as those who are postmenopausal [12,13] or on long-acting
gestagens are at increased risk of HIV, presumably as a
result of vaginal thinning. Other biological variables such as
vaginal microflora [14-16], immune cell populations
[17,18] and natural antimicrobials [19-21] also play an
important role in innate defenses of the reproductive tract.
Mifepristone, a potent antagonist ofprogesterone (P), has
the potential to be developed for contraception and other
gynecological uses [22-24], Daily low-dose treatment
inhibits ovulation but maintains follicular development, thus
exposing reproductive tissues to unopposed estrogen. Since
gestagen treatment increases and estrogen treatment
decreases HIV/SIV transmission, the aim of the present
study was to investigate whether the antigestagen mifepris¬
tone modulates underlying mechanisms involved in trans¬
mission. We investigated vaginal morphology, steroid
receptor and natural antimicrobial [secretory leukocyte
protease inhibitor (SLPI), human beta defensins mRNA
(HBD1, HBD2, HBD3, HBD5), granulysin and elafin]
content. We also report the pharmacokinetics and pharma¬
codynamics of 5 mg mifepristone supplied by Hualian
Pharmaceuticals Co. Ltd. (Shanghai, China), which has been
used in the present study as well as in previous studies [23],
2. Subjects and methods
We report two pilot studies using 5 mg mifepristone —
the study on vaginal epithelium that was carried out in
Edinburgh and the pharmacokinetic study in Helsinki.
2.1. Effects ofmifepristone on vagina
A single-center, open, single-group study concerning
female volunteers was undertaken. Eight healthy subjects
with a mean age of 35 years (range, 27-39 years) and a mean
body mass index (BMI)of23 kg/m2 (range, 17.3-28.2 kg/nr)
who had regular menstrual cycles (25-42 days) were
recruited to the study. The women agreed to refrain from
the use of vaginal medications during the study period or
from sexual intercourse 48 h prior to vaginal biopsy. Women
who had breast-fed or had taken hormonal contraception less
than 3 months prior to the study and those with vaginal or
pelvic infections (current or past) were excluded. The
proposal was approved by the local ethics committee
(institutional review board). All women gave written
informed consent before enrolment and were screened before
entering the study. Screening included a full medical,
gynecological history and examination, including measure¬
ment of height, weight, blood pressure and pulse. Blood
samples were collected for measurement of routine clinical
chemistry and hematology (liver function tests, urea and
electrolytes, glucose, full blood count). (3HCG was measured
to exclude pregnant women from the study. Subjects were
studied for one pretreatment cycle, one cycle of treatment
(approximately 33 days) and one posttreatment cycle. Each
subject was reviewed on Day 12 of the pretreatment
menstrual cycle (Visit 1), at the end of treatment (Visit 2)
and on Day 12 of the posttreatment menstrual cycle (Visit 3).
Subjects were given a menstrual record card and were asked
to record all vaginal bleeding.
2.2. Assessment ofovarian function
Ovarian function was monitored by measurement of
ovarian steroids in urine and plasma and by transvaginal
sonography. All subjects collected twice weekly samples of
early morning urine during the study period, starting in the
early follicular phase (Days 1-5) of the pretreatment cycle.
Aliquots were frozen and stored at —20°C until assayed for
estrone glucuronide (E1G), pregnanediol glucuronide (PdG)
and creatinine (Cr). PdG was measured using a direct
enzyme immunoassay, while E1G was measured by direct
immunoassay. Ovarian follicular activity during treatment
was compared with that during the follicular phase of the
pretreatment cycle, and the activity was scored as complete
suppression, partial suppression or continued follicular
activity. Ovulation was deemed to have occurred if the
excretion of PdG exceeded 0.5 mmol/mol Cr and was at
least threefold higher than that in the preceding week.
A detailed description of this methodology is given in our
previous report [23]. Blood samples were collected at all
study visits and assayed for estradiol (E2) and P using
radioimmunoassay (RIA). Assay characteristics and meth¬
odology have been described in our previous reports [23].
A transvaginal ultrasound scan was carried out at all study
visits, and ovarian dimensions, follicle number and diameter
and presence of ovarian cysts were recorded.
2.3. Vaginal biopsy
A full-thickness vaginal biopsy was taken from the
lateral vaginal wall 4 cm proximal to the hymeneal ring on
Day 12 of the pretreatment cycle (Visit 1) and, again, after
completion of treatment (Visit 2). One ampoule of Citanest
with octapressin (3%; prilocaine hydrochloride, 30 mg/mL;
felypressin, 0.03 U/rnL; Dentsply) was injected into the
lateral vaginal wall as a local anesthetic and hemostatic
agent. This also elevated the target vaginal tissue sufficient¬
ly to permit easy access for a biopsy. Vaginal biopsy was
performed using a long Schumacher forceps. Vaginal tissues
were stored in RNAlater (Applied Ltd., Cambridgeshire,
UK; RNAlater is an aqueous storage reagent to stabilize and
protect RNA) and neutral-buffered formalin (NBF; for
future preparation of paraffin-embedded tissue for immu-
nohistochemistry). A second biopsy was taken if adequate
sample was not obtained from the first biopsy. Vaginal
bleeding from the biopsy site was controlled using either
silver nitrate or, if necessary, a Vicryl 3-0 suture (Ethicon,
UK), depending on the amount of bleeding.
An endometrial biopsy was collected using Pipelle
endometrial sampler (Prodimed, Neuilly-en-Thelle, France)
at end of treatment (Visit 2), fixed in NBF and embedded in
paraffin. Endocervical and posterior fornix swabs were
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Fig. 1. Vaginal thickness measurement. Average thickness between surface
and basement membrane (trace tool, Image Proplus 4.5, Media Cybernetics).
collected at all study visits and cultured for pathogenic
organisms, for example, gonococcus, trichomonas and
streptococcus, which might influence the parameters studied
in target vaginal tissues.
2.4. Safety parameters
At each study visit, blood pressure and pulse were
measured, and blood was taken for measurement of routine
clinical chemistry and hematology. In addition, each subject
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was asked to report any health problems or adverse events
that had occurred since the last visit.
2.5. Vaginal thickness measurement
Vaginal tissue samples were embedded in paraffin, and
serial 5-pm sections were cut at a 90° angle to the vaginal
surface epithelial layers. The sections were stained with
hematoxylin and eosin, and digital images were captured at
xlO eyepiece magnification using a Spot microscope
connected to a Windows PC computer. Image Proplus 4.5
(Media Cybernetics, Silver Spring, CO, USA) software was
calibrated to match the eyepiece used to capture the image.
The surface and basement membranes of vaginal epithelium
were outlined using a trace tool within the software (Fig. 1).
The software automatically calculated the average distance
between the two traced outlines.
2.6. Immunohistochemical (IHC) localization of estrogen
receptor alpha (ERa.), estrogen receptor beta (ERji),
progesterone receptor (PR), androgen receptor (AR) and
proliferation marker phospho-histone H3 (PH3)
Immunohistochemistry was carried out on both the
vaginal and endometrial biopsies for the following proteins
of interest: ERa (Novocastra, Newcastle-upon-Tyne, UK),
ER|3 (Serotec, Oxford, UK), PR (A+B) (Novocastra), AR
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA),
PH3 (Upstate Biotechnology, Poole, UK) and SLPI (Hycult
Biotechnology, Cambridge, UK). All antibodies used were
mouse monoclonal, except for PH3, which was a rabbit
polyclonal. They were tested individually at a range of
dilutions and at different antigen retrieval conditions to
determine the protocol that gave the least background and
Table 1
Immunohistochemistry protocol
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AR Vagina Biotinylated secondary
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H3 Vagina Goat antirabbit
Endometrium envision system
SLPI Vagina Biotinylatcd secondary
Endometrium and ABC-Elite
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citrate, pH 6, 10 min
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" The anti-ERp antibody has been previously prcabsorbed with the peptide to which it had been raised [25].
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highest specific staining (Table 1). Positive and negative
controls were included in every run. In most cases, negative
controls were performed by adding a matched IgG control
antibody (mouse IgG, Sigma, Poole, Dorset, UK; rabbit IgG,
Vector Laboratories, Peterborough, UK) of the same species
and at the same antibody concentration as the primary
antibody. Protocols were carried out either on the bench or
with the use of a Bond-X automated immunohistochemistry
staining machine (Vision Biosystems, Newcastle, UK).
All tissue sections were initially prepared in a similar
manner. Five-micron paraffin-embedded tissue sections
were dewaxed in Histoclear (National Diagnostics, Hessle,
UK) and rehydrated in descending grades of alcohol to
distilled water (dH20). Antigen retrieval was then carried
out by heating the sections either in a microwave oven
(setting: high) or in a Tefal Clipso pressure cooker (Setting
2/high, Tefal, Nottingham, UK). The buffer concentration
and duration of antigen retrieval varied depending on
protocol (Table 1). Sections were left to cool in both cases
for 20 min. Endogenous peroxidase activity was quenched
by immersion in 3% hydrogen peroxide (BDH, Poole, UK)
in methanol for 30 min at room temperature. For AR only,
sections were incubated in avidin for 15 min at room
temperature (Vector Laboratories), followed by incubation
in biotin (Vector Laboratories), also for 15 min at room
temperature. Nonspecific binding of the primary antibody
was blocked by incubating the sections for 20 min at room
temperature in a 1:5 dilution of nonimmune serum (Autogen
Bioclear, Holly Ditch Farm, Wilts, UK) in phosphate-
buffered saline containing 5% bovine serum albumin. All
immunostaining methods employed a detection system
dependent on visualization of the reaction using a horse¬
radish peroxidase enzyme and the chromagen 3' 3-diami-
nobenzidine (DAB). After the DAB step, the sections were
counterstained in hematoxylin before dehydrating them in
ascending grades of alcohol and mounting them from xylene
with Pertex (Cellpath pic., Hemel Hempstead, UK). Full
details of each individual protocol are given in Table 1.
2.7. IHC analysis
We used a descriptive methodology as there is no
quantitative or semiquantitative methodology established
for analysis of vaginal tissue samples in our laboratory. The
intensity and distribution of immunostaining for ERa, ERp,
PR, AR, PH3 and SLPI are described for vagina (epithelium
and stroma) and endometrium (glands, stroma and surface
epithelium), and differences between pre- and posttreatment
samples were analyzed.
2.8. RNA extraction
Tissue was minced using a standard sterile surgical scalpel
blade and immersed in 2 mL of Tris-buffered saline (Sigma-
Aldrich, St. Louis, MO, USA). The mixture was homoge¬
nized for 60 s and incubated overnight at 4°C. The following
day, tissue sample was wanned to room temperature and
200 pg of bromochloropropane was added. The mixture was
centrifuged at 14,000 rpm at 4°C for 15 min, and aqueous-
phase RNA (supernatant) was transferred to a fresh tube. Five
hundred microliters of isopropanol was added and incubated
at 4°C for 60 min. The mixture was centrifuged for 10 min;
the supernatantwas discarded, and the pelletwas washed with
1 mL of70% ethanol. The mixture was centrifuged for 5 min,
and the supernatant was discarded, allowing the pellet to dry
for 5 min. The pellet was resuspended in 20 pL of RNA
solution. To standardize measurements between the various
biopsy specimens, we assessed the same amount ofRNA in
each sample. The amount of specific amplicon is related to
ribosomal 18S, which is constant relative to the amount of
cDNA present and, subsequently, to an experimental internal
control. The RNA was reverse transcribed (TaqMan Reverse
Transcription Reagents Kit, Applied Biosystems, Foster City,
USA) and polymerase chain reaction (PCR) amplified (Taq¬
Man Universal Master Mix, No Amp Erase UNG, Applied
Biosystems) according to the manufacturer's instructions.
PCR amplification of cDNA was performed on an ABI Prism
7700 Sequence Detection System (Applied Biosystems).
Specific forward and reverse primers (300 nmol/L) and probe
(200 nmol/L, all synthesized by BioSource UK, Nivelles,
Belgium) for the natural antibiotic were also added. Ribo¬
somal 18S cDNA was measured using TaqMan Ribosomal
RNA Control Reagents (VIC dye, Applied Biosystems) in
each sample as an internal control following the manufactur¬
er's protocol. Samples were measured in triplicate, and no
template controls were included in all runs. Primers and
probes for quantitative PCR were designed using
the PRIMER EXPRESS program (Applied Biosystems;
Table 2
Sequences of quantitative PCR primers and probes for natural antimicrobials
Forward primer Reverse primer Probe
SLPI GCATCAAATGCCTGGATCCT GCATCAAACATTGGCCATAAGTC TGACACCCCAAACCCAACAAGGAGG
HBDI TCAGCAGTGGAGGGCAATG CCTCTGTAACAGGTGCCTTGAAT CTCTATTCTGCCTGCCCGATCTTTACCAA
HBD2 CTGATGCCTCTTCCAGGTGTTT CTGGATGACATATGGCTCCACTCT AAGGCAGGTAACAGGATCGCCTATACCACCA
HBD3 CAGAGGCGGCCGGTGT CGAGCACTTGCCGATCTGTT CTGTGCTCAGCTGCCTTCCAAAGGA
HBD4 GGCAGTCCCATAACCACATATTC TGCTGCTATTAGCCGTTTCTCTT TGTCCAATTCAAATTCGCTTCTCACTGGA
HBD5 ACCTCAGGTTCTCAGGCAAGAG AGAGGGACTCACGGGTAGCA CTGCTATTGCCGAACCGGCCGT
Granulysin CAGGGTGTGAAAGGCATCTCA GGAGCATGGCTGCAAGGA CGGCTGCCCCACCATGGC
Elafin TGGCTCCTGCCCCATTATC CAGTATCTTTCAAGCAGCGGTTAG ATCCGGTGCGCCATGTTGAATCC
All probes were labeled with 5' FAM and 3' TAMRA fluorophorcs.
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Table 2) [26-31], and probes were fluorescently labeled with
the proprietary dyes FAM (5') and TAMRA (3').
2.9. Pharmacokinetic study
A pharmacokinetic study of 5 mg of mifepristone was
earned out among the same cohort of women who had
previously participated in another pharmacokinetic study
[32], The study was approved by the Institutional Review
Board of the Helsinki Central Hospital and the Finnish
National Agency for Medicines; all subjects signed an
informed consent document. Subject characteristics, meth¬
odology, collection of sample, analysis of serum levels of
mifepristone and calculation of pharmacokinetic parameters
were as described previously [32], In brief, six healthy
women, with regular menstrual cycles (23-36 days), a mean
age of 32 years (range, 21—45) and a BMI that ranges from
19 to 26 kg/nr, volunteered for the study. The 10-mg
mifepristone tablets supplied by Hualian Pharmaceuticals
Co. Ltd. were halved, and a dose of 5 mg, po, was ingested
on Day 10 or 11 of the menstrual cycle. Blood samples were
collected at 0, 1, 2, 4 and 8 h and, thereafter, daily for the
next 6 days and on Day 10 following mifepristone ingestion.
Mifepristone was measured in serum by RIA after extraction
with /;-hexane:ethyl acetate and separation by column
chromatography using Chromosorb® [33]. The detection
limit is 0.36 nmol/L, and the intra-assay and interassay
coefficients of variation were 8.4% and between 10.3% and
13.6%, respectively.
2.10. Statistical analysis
Statistical analysis was performed using SPSS (SPSS,
Inc., Chicago, IL, USA) and Excel 2002 (Microsoft
Corporation, Reading, UK). Sex steroid, vaginal thickness
and pharmacokinetic data are expressed as mean with either
standard error of the mean or standard deviation. Menstrual
cycle data are expressed as mean and range. Nonparametric
tests (Friedman's test, Wilcoxon Signed Rank Test and
Mann-Whitney test) were used to compare sex steroid level,
menstrual data, vaginal thickness and natural antimicrobial
RNA content before and after treatment.
3. Results
3.1. Effects ofmifepristone on vagina
All eight subjects completed the study. The subjects
took mifepristone 5 mg/day, po, for an average of 33 days
(range, 28—40).
The average length of the control menstrual cycle was
27 days (range, 24—29), while that of the control menstrual
period was 5.7 days (range, 4-9). All eight women reported
amenorrhea during ingestion ofmifepristone. The time from
discontinuing the mifepristone treatment to the next
bleeding episode was 17 days (range, 10-23); thus, the
length of the mifepristone cycle was 50 days (range, 38-63).
Average length of the bleeding episode after discontinuation
of mifepristone was 5.1 days (range, 4—7).
During the treatment with mifepristone, seven of the
eight subjects experienced either complete suppression of
ovarian activity (3/8 women, Fig. 2A, Subject 8) or
persistent follicular activity but no ovulation (4/8 subjects,
Fig. 2B, Subject 4). In the remaining subject (Subject 7,
Fig. 2C), there was a threefold rise in the excretion of
pregnanediol in the first 10 days of treatment, suggesting the
formation of a corpus luteum. However, there was no
menstrual bleeding when the level of pregnanediol dropped
14 days after starting the mifepristone. In this subject, a
persistent ovarian cyst with a 42-mm diameter was detected
at completion of treatment (Day 40) when the level of
P (14 nmol/L) was slightly raised, which was consistent
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Fig. 2. Excretion of metabolites of ovarian steroids in women taking 5 mg
of mifepristone for 31-36 days. Estrone, E1G; prcgnancdiol, PdG; x-axis
shows timescale; Day 0. start of treatment. Pretreatment (negative values),
treatment (boxed) and follow-up cycles are shown. Black bars represent
menstrual episodes; arrow denotes vaginal biopsy. (A) Complete suppres¬
sion of ovarian activity. (B) Persistent follicular activity but no ovulation.
(C) Single ovulatory episode and no menstruation following fall in
prcgnancdiol levels.
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Fig. 3. IHC localization of ERa, ER[3, PR, AR and PH3 in the vagina [epithelium (cpth) and stroma (str)] and endometrium [gland (glnd) and stroma (str)]
before and after treatment with 5 mg mifepristone. Scale bar= 100 pm; inserts denote negative controls. Strong expression of ERa (A and B), ER|3 (D and E)
and AR (J and K) in the basal and parabasal layers of epithelium and a relative lack of PR (G and H) in the epithelium (there was no observed change following
treatment); PH3 expression in the basal layers (M and N; arrows) and endometrium [postmifepristone (O; arrows)]; strong expression of all steroid receptors in
the posttreatment endometrium (C, F, I and L); SLPI confined to superficial layers of vaginal epithelium (P and Q) and endometrial glands (R).
Multiple follicles were detected by transvaginal ultra¬
sound (diameter of the largest ranged from 10 to 29 mm) in
all eight subjects. The concentrations of E2 in blood
samples collected at Visit 2 on the last day of mifepristone
treatment were compatible with persistent follicular activity
(496±57 pmol/L). In seven of eight women, the concen¬
tration of P was < 10 nmol/L (3 ± 1 nmol/L), indicating lack
of ovulation.
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3.2. Endometrial histology
Endometrial biopsies obtained at the end of mifepristone
treatment displayed inactive or weakly proliferative endo¬
metrium in seven of the eight subjects. In one subject
(Subject 9), tortuous glands with evidence of intraluminal
secretion were seen. As expected, there was strong
immunostaining of ERa and ERp as well as of PR (A+B)
and AR in both glands and stroma. Histological evidence of
mitosis was absent or infrequent in all samples.
3.3. Vaginal histology and vaginal thiclaiess
Vaginal biopsy was obtained in all subjects without
complications both before and after mifepristone administra¬
tion. In seven of eight subjects the pretreatment vaginal
biopsy was performed between Day 6 and Day 16 of the
follicular phase prior to ovulation as confirmed by the
hormone levels (mean±SEM: E2, 659±141 pmol/L, P.
4.3±10 nmol/L). In the remaining subject (Subject 5),
ovulation had already occurred on the day of biopsy (Day
14 of menstrual cycle) as indicated by high circulating
concentration of P (44 nmol/L). Posttreatment vaginal biopsy
was performed on Day 33 (range, 28—40) of treatment.
The histology of the vagina showed the expected basal
layer of epithelium mounted by up to 20 layers of more
superficial desquamating cells (Fig. 1). Vaginal thickness
was not altered during administration of mifepristone
(342±40 gm vs. 303±69 pm; p=.2, NS).
3.4. Steroid receptor expression in the vagina
(ERx, ER[3, AR and PR)
There was nuclear staining of ERa, ERg and AR in
both vaginal stroma and in the epithelium. Immunoreactiv-
ity extended through the basal and intermediate layers but
not through the superficial layer of vaginal epithelium
(Fig. 3). Staining was far more evident in the epithelium as
compared with the stroma. There was no significant
difference in sex steroid receptor immunostaining after
mifepristone administration.
Apart from a few scattered nuclei in the stroma, the basal
layer of vaginal epithelium immunostaining for PR was
confined to stroma (Fig. 3). There was no significant
difference in PR immunoreactivity after administration
of mifepristone.
3.5. PH3 immunoreactivity
PH3 immunostaining was confined to scattered nuclei in
the basal layers of the vaginal epithelium (Fig. 3). There was
no significant change in immunoexpression following
treatment with mifepristone.
3.6. Natural antimicrobial mRNA and protein expression
SLPI mRNA was present in vagina, and this epitope was
localized to the superficial layer of the vaginal epithelium
both before and after mifepristone administration
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Fig. 4. Serum levels (mean±SD) of mifepristone following ingestion of
5 mg. The data are depicted on both linear (lower) and scmilogarithmic
(insert) scales.
the superficial layers of luminal and glandular epithelium of
the endometrium (Fig. 3). SLPI mRNA expression was
unchanged following treatment with mifepristone (p>.05,
Wilcoxon test). HBD1, HBD2, HBD3, HBD5, granulysin
and elafin mRNA were present in the vagina. The
expression was unchanged following treatment with mife¬
pristone (p>.05, Wilcoxon test).
3.7. Safety parameters
There was no derangement in heart rate, blood pressure
or in hematology and biochemistry parameters including
liver function tests during the study. Vaginal and cervical
bacteriology swab tests cultured negative for pathogenic
organisms in all subjects. Vaginal biopsy was well
tolerated by all women. One woman had possible low-
grade endometritis following endometrial biopsy and was
successfully treated with a 7-day course of antibiotics.
3.8. Pharmacokinetics of 5 mg mifepristone
Serum levels (mcan±SD) of mifepristone following
ingestion of 5 mg mifepristone are summarized in Fig. 4.
Mean Cmax measured at 1 h was 641.7 nmol/L (range, 502-
740 nmol/L). All subjects showed a similar pattern of
descending serum concentrations of mifepristone. The
elimination phase half-life was 18±5.1 h (mean±SD). The
mean (SD) areas-under-concentration-curves AUC0_S h and
AUCo_24 h were 2.4 (0.5) and 4.8 (1.3) pmol/L, respectively.
4. Discussion
The vagina is a key portal of entry for HIV and other
STIs. In this article, we report the effect of a potential new
contraceptive pill on different parameters involved in the
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natural defenses of the vagina to infection. Vaginal epithelial
thickness, steroid receptor and natural antimicrobial content
and distribution were unchanged following treatment with
mifepristone for 30—40 days. Vaginal epithelial thickness is
regulated by the levels of circulating estrogen. Epithelial
thickness is maximal at time of ovulation [34-37] and
decreases in the luteal phase and postmenopause [36], There
is a significant reduction in circulating estrogen levels
following long-term gestagen treatment [37]. Severe vaginal
atrophy has been demonstrated in primate studies, and this
clearly increases the risk of SIV transmission [4], However,
the response of human vaginal epithelium to gestagen-
induced hypoestrogenism is variable. A small but significant
decrease (10%) in thickness has been demonstrated in one
study [37], whereas most other studies have demonstrated
no change [38,39]. Paradoxically, vaginal epithelial hyper¬
plasia has been reported in users of depot medroxyproges¬
terone acetate (DMPA), oral contraceptive pill and P
implants [39-41]. E2 levels in all three treatment groups
were significantly lower compared with normal menstruat¬
ing women. The steroid receptor content and distribution
were similar except for PR, which was suppressed in the
DMPA group.
It is difficult to reconcile all available data into a working
hypothesis due to differences in study designs and
methodology. The vagina has diverse embryological origins
[42]; Ildgruben et al. used a cross-sectional study design and
sampled lateral vaginal fornices, whereas we used a
longitudinal study design and sampled lateral midvaginal
wall in keeping with other reports [41].
Although vaginal epithelium clearly responds to circu¬
lating estrogen, the underlying cellular and molecular
mechanisms are poorly understood. We localized PH3, a
marker for mitosis and cellular proliferation, to a few
scattered nuclei in the basal layers of the vaginal epithelium.
The strong nuclear expression of ER and AR in the basal
and parabasal layers suggests a role in the regulation of
epithelial proliferation. Estrogen treatment induces surface
keratinization and hyperplasia of primate vaginal epitheli¬
um, and we expected a similar change in mifepristone-
treated vaginal samples due to unopposed estrogen effect.
The observed epithelial thickness in control samples in the
present study (mean pretreatment thickness, 342 pm) is
comparable to other reports [38-40]. Thickness was
unchanged following mifepristone treatment, and this agrees
with similar work in cynomolgus monkeys [43], There are
several possible explanations for our findings. Firstly,
mifepristone treatment did not have any effect on level of
circulating steroid hormones. Secondly, PR was localized to
a few scattered nuclei in the basal layers of vaginal
epithelium and, hence, mifepristone, a high-affinity PR
ligand, did not have any direct epithelial effects.
Consistent with previous reports, we have demonstrated
a strong immunoexpression of ER and AR as well as a
relative lack of PR in the vaginal epithelium compared to
subepithelial stroma [44-51], The distribution of steroid
receptors has obvious implications for the development of
topical and parenteral steroid treatment. Available data,
including the present study, indicate that it is likely that
estrogen preparations will act via epithelial ER, whereas
P preparations are likely to have an endocrine and paracrine
effect after binding with the subepithelial PR. The role of
AR in the genital tract is unclear, but AR may play a role in
regulating endometrial proliferation [52-54] and in modu¬
lating vaginal blood flow [50] and female genital sexual
arousal [49],
The endometrium sampled at the end of mifepristone
treatment showed persistent proliferative histology and
strong ER, PR and AR expression, which is consistent with
our previous reports [54,55] and which demonstrates that
the mifepristone preparation used in this study is compara¬
ble to that we have used previously from another source
(Exelgyn, Paris).
The expression, regulation and role of natural antimicro¬
bial compounds in the female reproductive tract are
extensively reviewed elsewhere [29]. We have investigated
natural antimicrobials that regulate innate protection at
mucosal interfaces. SLPI has been shown to play an
important role in limiting transmission of HIV [20,56,57]
and other lower genital tract infection [19]. SLPI mRNA has
been demonstrated in vaginal fluid previously [19,20]. In
the present article, we demonstrate mRNA in vaginal tissue
and immunolocalize the protein to the superficial layers of
the vaginal epithelium. The expression in superficial layers
of surface and glandular endometrium is in keeping with
previous reports [26]. HBD1 [58] and elafin [59] rrrRNA
have been reported in human vagina. We show that HBD2,
HBD3, HBD5 and granulysin mRNA are present in vaginal
tissue. HBD4 mRNA was not previously demonstrated.
Natural antimicrobial expression is modulated by honnonal
treatment, and up-regulation of endometrial SLPI by P is
attenuated in the presence of mifepristone [31]. Reassur¬
ingly, expression and distribution of natural antimicrobials
were unchanged following mifepristone treatment.
Low-dose mifepristone suppressed menstruation and
ovulation in a majority of women in the present study. This
adds to similar observations in our previous reports [23,60]
and also demonstrates the biological activity ofmifepristone
supplied by Hualian Pharmaceuticals Co. Ltd. The pharma¬
cokinetic properties of the 5-mg dose from the above
supplier follow a first-order linear kinetic pattern [32,61].
The half-life of 18 h is shorter than the 20 h previously
reported for 10 mg mifepristone, whereas the AUC0_24 h was
half that of the 10-mg dose [32]. All women received
planned treatment for at least 5 days beyond the expected
date of menstruation (33 days) so that any posttreatment
vaginal bleeding was due to withdrawal of mifepristone
rather than to a spontaneous menstruation. Fortuitously,
Subject 7 was administered mifepristone for 40 days. She
did not bleed, although there was evidence of ovulation and
formation of corpus luteum followed by a significant
decrease in pregnanediol levels. This supports our previous
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reported findings that mifepristone-induced amenorrhea is a
result of direct endometrial effects that are possibly
mediated by a rise in glandular and luminal glucocorticoid
and AR [62],
In summary, we have shown that low-dose mifepristone
does not influence vaginal thickness and proliferation. We
have demonstrated that ER (ERa and ERp), PR, AR,
SLPI and other natural antimicrobials are present in the
human vagina. There is no change in epitope expression
following mifepristone treatment. The presence and distri¬
bution of vaginal steroid receptors have implications for
the development of topical and systemic preparations to
modulate this sex steroid responsive organ in health and
disease.
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